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EDITORIAL
Over the last 30 years signi!cant changes have been achieved in the 
management of epithelial ovarian cancer leading to a 2-year improve-
ment in median overall survival. According to International Federation 
of Gynecology and Obstetrics (FIGO) the 5-year survival has increased 
from 26.8% (1985) to 49.7% (2001) while according to the Surveil-
lance Epidemiology and End Results (SEER) program of the NCI it has 
improved from 36.6% (1975) to 44.6% (2010). However, still fewer 
than 25% of patients with ovarian cancer will survive long-term and 
will be cured, the gain in median survival being due to an extension 
of the survival time rather than an increase in the overall cure rate. In-
crease in overall survival is related to a variety of factors, ranging from 
more high-quality aggressive initial surgery to active new drugs and 
combinations, repeated treatments and rational planning of subsequent 
on /off therapy periods.
More recently, the understanding that ovarian cancer is not a single en-
tity but many diseases with different histologies and molecular features 
has led to the development of personalized medicine (1). Because of 
the rarity of the diagnosis, targeting histology-speci!c pathways, such 
as low grade serous/endometrioid with pathway speci!c agents (like 
MEK inhibitors in advanced low-grade disease), has been successfully 
pursued in histology speci!c trials, which are necessarily multicentric 
and international (2). The integrated genomic analyses of 316 high-
grade serous ovarian cancer (HGS-OvCa) in The Cancer Genome Atlas 
(TCGA) has con!rmed the high prevalence of TP53 mutations and of 
somatic mutations. Moreover, it has showed that BRCA1/2 mutated 
cases have better survival than wild-type patients and that homolo-
gous recombination defects may be present in approximately half of 
HGS-OvCa cases (3). These data further supported the development 
of the synthetic lethality approach and the broader clinical evaluation of 
PARP inhibitors, which are today the most signi!cant achievement 
of precision medicine in HGS-OvCa (4).
Can a biological process like angiogenesis be a target for treatment? So 
far, the lack of reproducible biomarkers to identify the patients most 
likely to respond to antiangiogenics has hindered the achievement of 
long-term signi!cant results. Recently the Scottish Group identi!ed, 
by a 63-gene signature in a subset of cases treated in the ICON 7 study, 
three major subgroups of patients, two with angiogenic gene upregula-
tion (the proangiogenic groups) and one with angiogenic gene repres-
sion and immune gene upregulation (the immune molecular subgroup) 
(5). The latter had a signi!cantly longer progression free survival (PFS) 
and overall survival possibly in relation to a more indolent disease with 
less blood supply and an active engagement of the tumor by the host 
immune system. When bevacizumab was added to the treatment, the 
immune subgroup showed a signi!cantly worse PFS suggesting that a 
gene signature for bevacizumab might become a strati!cation factor. 
Over the past decade it has become clear that also endometrial cancer, 
the most common gynecological malignancy, includes many biologi-
cally and genetically different diseases. Besides the traditional classi!-
cation of Type I and Type II cancers, based on clinical, endocrine and 
histopathological characteristics, today a newer genomic classi!cation 
on genetic and histopathological characteristics, based on the genomic 
Signi!cant  
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and transcriptomic analysis of the TCGA, is being discussed (6). A data 
set of 373 endometrial cancers (namely 307 endometrioid and 53 se-
rous) were analyzed by next-generation sequencing technologies lead-
ing to the identi!cation of four genomic classes: POLE (ultramutated 
with favorable outcome), microsatellite instable (MSI hypermutated) 
endometrioid, copy-number low (endometrioid) and copy-number 
high (serous like) with poor outcome.
Overall, it appears that endometrial cancer is a disease with many as-
pects and that the traditional histology-based classi!cation only partly 
encompasses this heterogeneity. The genomic classi!cation might be-
come a strati!cation factor and might identify poor-risk endometrioid 
patients more likely to respond to speci!c drugs (7). The prognostic 
and, above all, the predictive value of the genomic classi!cation can 
be assessed only through biomarker-driven clinical trials, which could 
become a priority considering that around 75% of patients are stages 
I-II and that, in this group, the outcome of women with serous and 
high-grade endometrioid type is still poor.
In cervical cancer, the introduction of the HPV vaccination as well as 
the new techniques of screening will likely eliminate the disease in 
vaccinated women while decreasing the mortality in the unvaccinated 
ones, if adequate infrastructures, information and !nancial resources 
are made available (8). Personalized medicine is still at its beginning. 
It is however remarkable that the only signi!cant results so far achieved 
with molecule targeted agents, namely the longer overall survival in 
locally advanced/recurrent disease observed when bevacizumab was 
added to combination chemotherapy, have a sound preclinical rationale, 
possibly related to the overexpression of oncogenic HPV subtypes and 
the accumulation of HIF-1  and VEGF expression (9).
Prof. Cristiana Sessa
Oncology Institute of Southern Switzerland, Bellinzona 
cristiana.sessa@eoc.ch
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Strained NHS misses target 
on cancer care for !rst time
Patients in need of urgent cancer treatment 
are being kept waiting for too long because 
of a «huge strain» on the NHS, charities have 
warned, as the health service missed one of its 
targets for the !rst time.
NHS guidelines say that when a GP makes an 
urgent referral for suspected cancer, 85 per 
cent of patients should wait no more than 62 
days before receiving their !rst treatment.
Figures released yesterday show that this 
dropped from 85.8 per cent to 84.4 per cent 
for the three months from January to March, the 
!rst time that the target has been missed since 
it was introduced !ve years ago.
Mike Hobday, a director at Macmillan cancer 
Support, said: «This is the !rst breach of any 
cancer waiting time in England since 2009 and 
is a clear warning sign that the NHS ist under 
huge strain.»
Sean Duffy, national clinical director for cancer 
at NHS England, said: «It is vital cancer patients 
are diagnosed and treated quickly so they have 
the best possible chance of recovery.»
«Latest !gures show nationally the NHS has 
met and exceeded seven out of eight cancer 
waiting-time standards. But there is variation 
in meeting the challenging standards, and na-
tional performance against one of the targets 
has dipped.»
Mr Hobday added: «It is of great concern that 
the number of trusts missing this target has 
doubled over the past year. Around one in four 
of the trusts that were hitting the target at the 
start of 2013-14 are now missing the target.»
The proportion of patients seen by a special-
ist within two weeks of an urgent GP referral 
has also dropped from 95,6 per cent to 95 per 
cent. ...
The Times, May 31, 2014
That’s where the money is
How to hand over $272 billion a year to criminals
Medical science is hazy about many things, but 
doctors agree that if a patient is losing pints 
of blood all over the carpet, it is a good idea 
to stanch his wounds. The same is true of a 
health-care system. If crooks are bleeding it of 
vast quantities of cash, it is time to tighten the 
safeguards.
In America the scale of medical embezzlement 
is extraordinary. According to Donald Berwick, 
the ex-boss of Medicare and Medicaid (the 
public health schemes for the old and poor), 
America lost between $82 billion and $272 bil-
lion in 2011 to medical fraud and abuse. The 
higher !gure is 10% of medical spending and 
a whopping 1.7% of GDP — as if robbers had 
made off with the entire output of Tennessee 
or nearly twice the budget of Britain’s National 
Health Service (NHS).
Crooks love American health care for two rea-
sons. First, as Willie Sutton said of banks, it’s 
where the money is — no other country spends 
nearly as much on pills and procedures. Sec-
ond, unlike a bank, it is barely guarded.
Some scams are simple. Patients claim ben-
e!ts to which they are not entitled; suppliers 
charge Medicaid for non-existent services. One 
doctor was recently accused of fraudulently 
billing for 1,000 powered wheelchairs, for ex-
ample. Fancier schemes involve syndicates of 
health workers and patients. Scammers scour 
nursing homes for old people willing, for a few 
hundred dollars, to let pharmacists supply their 
pills but bill Medicare for much costlier ones. 
Criminal gangs are switching from cocaine to 
prescription drugs — the rewards are as juicy, 
but with less risk of being shot or arrested. One 
clinic in New York allegedly wrote bogus pre-
scriptions for more than 5m painkillers, which 
were then sold on the street for $30-90 each. 
Identity thieves have realised that medical re-
cords are more valuable than credit-card num-
bers. Steal a credit card and the victim quickly 
notices; photocopy a Medicare card and you 
can bill Uncle Sam for ages, undetected.
It is hard to make such a vast system secure: 
Medicare’s contractors process 4.5m claims 
a day. But pointless complexity makes it even 
harder. Does Medicare really need 140,000 
billing codes, as it will have next year, includ-
ing ten for injuries that take place in mobile 
homes and nine for attacks by turtles? A toxic 
mix of incompetence and political gridlock has 
made matters worse. Medicare does not check 
new suppliers for links to !rms that have previ-
ously been caught embezzling (though a new 
bill aims to !x this). Fraud experts have long 
begged the government to remove Social Se-
curity numbers from Medicare cards to deter 
identity thieves — to no avail.
Start by closing the safe door
One piece of the solution is obvious: crack 
down on the criminals. Obamacare, for all its 
"aws, includes some useful measures. Suppli-
ers are better screened. And when Medicaid 
blackballs a dodgy provider, it now shares that 
information with Medicare — which previously 
it did not. For every dollar spent on probing 
health-care fraud, taxpayers recover eight. So 
the sleuths’ budgets should be boosted, not 
squeezed, as now.
But the broader point is that American health 
care needs to be simpli!ed. Whatever its de-
fects, Britain’s single-payer National Health 
Service is much simpler, much cheaper and 
relatively dif!cult to defraud. Doctors are paid 
to keep people well, not for every extra thing 
they do, so they don’t make more money by 
recommending unnecessary tests and opera-
tions—let alone billing for non-existent ones.
Too socialist for America? Then simplify what is 
left, scale back the health tax-perks for the rich 
and give people health accounts so they watch 
the dollars that are spent on their treatment. 
After all, Dr Berwick’s study found that admin-
istrative complexity and unnecessary treatment 
waste even more health dollars than fraud 
does. Perhaps that is the real crime.
Th1, 201Kommentar der Redaktion
Das interessante an der Studie ist vor al-
lem, dass die administrative Komplexität die 
Hauptursache der !nanziellen Verschwen-
dung im Gesundheitswesen ist. Bezüglich 
Komplexität: Wir bewegen uns in der Schweiz 
immer mehr in dieselbe Richtung…
Werden wir auch die gleichen Folgen wie in 
USA bei uns erleben?
Pharma opens new front in 
war on cancer
The industry now has a chance to develop a 
generation of bockbuster drugs
It is the Holy Grail of medical science. Ever 
since Hippocrates, the Greek physician, !rst 
described the disease more than 2,000 years 
ago, generation after generation of doctors 
have searched in vain for a cure for cancer.
This history of failure instils oncologists with a 
natural sense of caution, which makes it all the 
more striking when some say their profession 
is on the cusp of the biggest breakthrough in 
cancer therapy for decades.
«I’ve been an oncologist for a long time and 
I’ve never experienced as much excitement,» 
says Edward Bradley, head of Oncology Inno-
vative Medicines at Medimmune, part of Astra-
Zeneca, the UK drugmaker. This excitement will 
come to a head in Chicago [May 30-June 3] 
as thousands of scientists gather for the an-
nual meeting of the American Society of Clini-
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cal Oncology. Taking centre stage are a series of 
experimental drugs that promise to open a new 
front in the war on cancer.
Whereas traditional treatments such as chemo-
therapy and radiotherapy have been likened to 
«carpet bombing», the new class of immuno-
therapy drugs are more akin to precision-guid-
ed missiles that hunt and destroy cancer cells. 
Their potential is stirring optimism not only 
among scientists and patients but also among 
investors eyeing a multibillion-dollar windfall 
for the four main companies behind the medi-
cines: Merck & Co, Bristol-Myers Squibb, Roche 
and AstraZeneca.
Andrew Baum, an analyst at Citigroup, predicts 
that cancer immunotherapy will become the 
backbone of treatment for 60 per cent of can-
cers within 10 years, generating peak annual 
revenues of $35bn or more. This would exceed 
the value of past blockbuster drug categories 
such as cholesterol-busting statins and could 
go a long way towards reviving the fortunes of 
an industry struggling for growth.
Mr Baum has been championing the potential 
of immunotherapy since declaring in a report 
last year «the beginning of the end for cancer». 
Twelve months later, he says he is feeling even 
more bullish as fresh trial data emerge to sup-
port his belief that the new drugs will transform 
cancer into «something akin to a chronic dis-
ease».
Immunotherapy includes a range of techniques 
to harness the body’s immune system to attack 
cancer. Scientists have been experimenting 
with the concept since 1850, when German 
physicians noticed that tumours would some-
times shrink when they became infected - stim-
ulating an immune response. «It is not a new 
idea but we are !nally seeing that it is going to 
work,» says Paul Higham, chief executive of Im-
matics, a German biotech company that has an 
immunotherapy partnership with Roche. «The 
question now is what is the best way to do it.»
The leader so far has been US-based Bristol-
Myers Squibb, whose Yervoy treatment for ad-
vanced melanoma - the most deadly form of 
skin cancer - was the !rst product of its kind 
to reach market, with sales of almost $1bn last 
year. Without the drug, a patient with advanced 
melanoma would typically die within a year. 
When treated with Yervoy, 22 per cent were still 
alive three years later and 17 per cent survived 
for seven years.
Some of the next wave of drugs look still more 
promising. The focus at Asco will be on a cat-
egory known as anti-PD-1s and anti-PD-L1s, 
which aim to remove the «invisibility cloak» that 
cancer cells use to roam the body unchecked.
Programmed death receptor 1s (PD1s) are pro-
teins that act as a brake on the immune system 
to stop healthy cells from being attacked - but 
they are exploited by cancer cells to avoid de-
tection. When this process is blocked, cancer 
cells suddenly !nd themselves exposed to the 
body’s disease-busting killer T-cells.
«Tumours are damn smart,» Mr Baum says. 
«It’s like Whack a Mole. As soon as you block 
one pathway they !nd another. But, with a little 
help, the immune system is the one thing smart 
enough to keep up.»
Bristol-Myers Squibb is again at the forefront 
with nivolumab, a drug that has kept 43 per 
cent of advanced melanoma patients alive for 
two years in trials. But it is facing stiff competi-
tion from US rival Merck - which has jumped 
ahead in the race for regulatory approval - as 
well as Roche of Switzerland and AstraZeneca, 
which are scrambling to catch up. Analysts 
think all four could secure regulatory approval 
by the end of next year.
Having previously shown promise in treating 
lung cancer as well as melanoma, data re-
leased at Asco is expected to demonstrate the 
drugs’ potential to tackle several other forms 
of the disease, including cancers of the kidney, 
bladder, head and neck. Another focus will be 
on trials of combination therapies that twin the 
new drugs with other medicines in a bid to in-
crease response rates.
«It is an oversimpli!cation to see this as a horse 
race in which the winner is the !rst to market,» 
Mr Baum says. «Who ends up generating most 
economic value is going to be determined by a 
number of factors, including who has the right 
combinations.» This explains why Roche and 
AstraZeneca, which have broad portfolios of 
cancer drugs to mix and match, still feel they 
can be competitive even though they are cur-
rently trailing Bristol-Myers Squibb and Merck.
Novartis, another big oncology performer, is 
placing its bets on a different form of immuno-
therapy that involves removing patients’ T-cells 
from their bodies and re-engineering them to 
destroy cancer cells once reinjected. In early 
trials, 19 of 22 children suffering from acute 
lymphoblastic leukaemia went into complete 
remission after treatment.
Inevitably, scientists warn there will be set-
backs. There had been high hopes, for exam-
ple, that nivolumab and Yervoy would provide 
Bristol-Myers Squibb with a powerful combina-
tion therapy. However, trial results this month 
showed that nearly half the 46 participants 
suffered bad side effects and there were three 
«treatment-related» deaths – raising doubts 
over whether the bene!ts outweighed the risks.
Pricing is likely to be another challenge. Annual 
global spending on cancer drugs more than 
doubled in the past decade to $91bn in 2013. 
The !gure looks certain to rise further given that 
the World Health Organisation expects a 57 per 
cent increase in worldwide incidence of cancer 
in the next 20 years as western populations age 
and those in developing countries adopt less 
healthy lifestyles.
These trends should ensure strong demand for 
new cancer drugs but also put pressure on pric-
ing as countries from the US to China battle 
to contain rising healthcare costs. Mr Baum 
thinks society will reward industry for coming 
up with new ways to treat a disease responsible 
for a quarter of all developed-world deaths. He 
highlights Bristol-Myers Squibb’s success with 
Yervoy at a price of $120,000 a course. «These 
are not incremental drugs that add a couple of 
months’ of extra life,» Mr Baum says. «They are 
potentially transformational.»
Financial Times, May 31, 2014
GSK in $350m oncology deal
Glaxo Smith-Kline has struck a deal potentially 
worth more than $350m to develop new cancer 
drugs with a UK biotech company, less than six 
weeks after agreeing to sell its existing oncolo-
gy products to Novartis.
Under the agreement to be announced today, GSK 
will pay Adaptimmune as much as $350m over 
the next seven years, subject to development mi-
lestones being met. Further payments would be 
due in subsequent years if GSK exercises all its 
options and targets continue to be met. In additi-
on, Adaptimmune would receive sales royalties on 
any products that reach market.
Working with the Oxford-based biotech, GSK will 
develop cell-based cancer therapies that involve 
re-engineering patients’ white blood cells to im-
prove the body’s ability to !ght tumours.
The deal shows that GSK has not given up on 
cancer despite its $16bn disposal in April. At 
the time of that deal, GSK said it did not have 
enough scale in the oncology market to com-
pete effectively with its existing treatments for 
skin cancer, breast cancer and leukaemia.
However, Patrick Vallance, president of phar-
maceutical research and development for GSK, 
said it would be wrong to interpret the Novartis 
deal as a full-scale retreat from oncology.
«We won’t always be the best company to com-
mercialise products but we will continue to fo-
cus on [oncology] R&D,» he said.
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Once a new product was ready for market, GSK 
would decide whether it could generate most 
value by doing its own commercialisation or in-
stead seeking a partner or buyer.
James Noble, Adaptimmune chief executive, 
said the privately owned company had a choice 
of !ve potential partners, including three other 
top 10 drugmakers, but chose GSK because it 
promised the most collaborative approach.
The transaction will put GSK back in the race 
for a new generation of oncology treatments 
that harness the body’s immune system to hunt 
and destroy cancer cells.
Bristol-Myers Squibb, Merck & Co, Roche and 
AstraZeneca are leading the charge with a 
class of medicines called checkpoint inhibitors, 
which some analysts have likened to HIV drugs 
in their potential to extend life expectancy.
However, the Adaptimmune deal will put GSK 
alongside Novartis in pursuing an alternative 
form of immunotherapy that involves taking di-
sease-!ghting «T-cells» out of the body and mo-
difying them. Once reinjected, the cells bind on 
to cancer cells and destroy them. Once reinjec-
ted, the cells bind on to cancer cells and destroy 
them.
Analysts have cautioned that the !eld is sha-
ping up to be !ercely competitive.
Financial Times, June 2, 2014
Rethinking strategies for two 
cancers
Study cites advantages of early chemotherapy 
for treating prostate
Many men with prostate cancer put off using 
chemotherapy as long as possible, fearing its 
side effects.
But a new study has found that men given chemo-
therapy early in their treatment for advanced dis-
ease lived a median of nearly 14 months longer 
than those who did not get early chemotherapy. 
The result could upend the established treatment 
practice, researchers said here on Sunday.
«We haven’t seen survival bene!ts like that for 
any therapy in prostate cancer,» said Dr. Michael 
J. Morris, an associate professor at the Memo-
rial Sloan-Kettering Cancer Center, who was not 
involved in the study but was selected to pub-
licly comment on it at the annual meeting of the 
American Society of Clinical Oncology.
Another study being presented Sunday found 
that drugs called aromatase inhibitors might 
be better than the standard drug tamoxifen in 
preventing a recurrence of disease in premeno-
pausal women with early breast cancer.
Both studies were featured in the plenary ses-
sion on Sunday, meaning they were deemed 
among the most noteworthy of the more than 
5,000 studies being presented at the meeting.
Dr. Nicholas J. Vogelzang, an author of the study 
on prostate cancer, said the !ndings would 
change practice. The challenge, he said, is get-
ting men to agree.
«Not many of them want to do chemotherapy, 
even though the numbers are convincing,» said 
Dr. Vogelzang, who works at the Comprehensive 
Cancer Centers of Nevada.
The study’s !ndings apply to a fairly narrow 
group of patients — men whose cancer has al-
ready spread beyond the prostate gland at the 
time of diagnosis, or whose cancer has come 
back after surgery or radiation treatment and 
still remains susceptible to hormone therapy.
Only a small fraction of men have metastatic 
prostate cancer at the time of the initial diag-
nosis because prostate cancer screening using 
a blood test typically detects the disease be-
fore it has spread.
The study, sponsored by the National Cancer 
Institute, involved 790 men who received either 
only hormone therapy or hormone therapy in 
addition to at most six infusions of docetaxel 
spaced three weeks apart.
Those who received the chemotherapy lived 
a median of 57.6 months, compared with 44 
months in the control group, a difference of 
13.6 months. The difference in survival was 
even greater — 17 months — for the patients 
whose cancer had spread more extensively. Dr. 
Morris of Sloan-Kettering said those men were 
the best candidates for early chemotherapy.
Docetaxel is sold under the brand name Tax-
otere by Sano!, but generic versions are avail-
able. It was approved for metastatic prostate 
cancer in 2004. In the last few years, several 
other drugs have been approved, like Zytiga 
from Johnson & Johnson and Xtandi from Medi-
vation and Astellas Pharma.
But docetaxel and the newer drugs are typically 
used after hormone therapy has stopped work-
ing. In that setting, each of them has extended 
median survival by about two to !ve months in 
clinical trials.
Dr. Matthew R. Cooperberg, associate professor 
of urology at the University of California, San 
Francisco, said doctors were starting to use the 
newer agents before docetaxel, pushing che-
motherapy further back in the sequence.
So the new study «is, to an extent, bucking the 
tide,» he said.
In breast cancer, women with estrogen-respon-
sive disease typically take drugs for at least !ve 
years after their tumor has been removed surgi-
cally, to prevent cancer from recurring.
Aromatase inhibitors are generally considered 
a better choice than tamoxifen for postmeno-
pausal women. But aromatase inhibitors work 
only when women have low estrogen levels, 
which usually rules them out for premenopaus-
al women.
The new study — actually two studies being 
analyzed together to accumulate nearly 4,700 
patients — involved suppressing the functioning 
of the ovaries so that the younger women could 
take an aromatase inhibitor.
Five years of an aromatase inhibitor in addition 
to ovarian suppression proved superior to !ve 
years of tamoxifen in addition to ovarian suppres-
sion. After !ve years, 91.1 percent of those who 
received the aromatase inhibitor, exemestane, 
were free of cancer, compared with 87.3 percent 
of those who received tamoxifen with ovarian sup-
pression. (In the United States, tamoxifen is typi-
cally used without ovarian suppression.)
International New York Times, June 3, 2014 
Bund verzögert Zugang zu 
lebensrettenden Medis  
Schweizer Patienten müssen auf neue Medi-
kamente warten, die anderswo längst von der 
Grundversicherung bezahlt werden. Der Grund: 
Das Bundesamt für Gesundheit hintertreibt die 
vom Bundesrat versprochene Beschleunigung. 
Seit dem 1. Juni 2013 ist eine Verordnung des 
Bundesrates in Kraft, die das Bundesamt für 
Gesundheit (BAG) verp"ichtet, in der Regel in-
nert 60 Tagen nach der Zulassung eines neuen 
Medikaments durch die Arzneimittelbehörde 
Swissmedic zu entscheiden, ob das Arzneimittel 
von der Grundversicherung vergütet wird. Ge-
sundheitsminister Alain Berset reagierte damit 
auf scharfe Kritik von Novartis und Roche. Sie 
hatten das BAG als «innovationsfeindlich» ange-
prangert, weil es im Schnitt 200 Tage für den Ent-
scheid brauchte. Es schade damit sowohl den 
Patienten als auch der Pharmaindustrie. 
Ein Jahr nach Inkrafttreten zeigt sich, dass die 
Verordnung toter Buchstabe geblieben ist. Bei 
mehr als der Hälfte der 37 neu zugelassenen 
Originalpräparate hat das BAG die 60-Ta-
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ge-Frist zur Aufnahme in die Spezialitätenliste 
der Grundversicherung nicht eingehalten. In 13 
Fällen hat es noch gar keinen Entscheid gefällt, 
obwohl die Frist schon längst überschritten ist. 
 
Zum Beispiel beim Blutkrebsmedikament Folo-
tyn: Es wurde von Swissmedic am 11.  Oktober 
2013 zugelassen. Ärzte dürfen es also seit 238 
Tagen verschreiben. Aber die Grundversicherung 
bezahlt es nicht, weil das BAG seinen Entscheid 
hinauszögert. Für schwer kranke Patienten, die 
das Medikament nicht selber zahlen können, 
kann das fatale Folgen haben. 
 
Besonders stossend ist, dass lebensrettende 
Medikamente in anderen Ländern längst von 
der Grundversicherung erstattet werden, wäh-
rend sich die Schweizer Patienten gedulden 
müssen. Beispielsweise beim Blutkrebsmittel 
Jakavi von Novartis. Es wurde in der Europäi-
schen Union am 23.  August 2012 zugelassen. 
In Deutschland, Österreich, Grossbritannien 
und Dänemark erfolgte die Erstattung inner-
halb von zwei Monaten nach der Zulassung. Die 
Schweiz hinkte Europa klar hinterher: Am 27. 
Dezember 2012 wurde Jakavi von Swissmedic 
zugelassen. Geschlagene 370 Tage später, am 
1. Januar 2014, nahm es das BAG in die Spe-
 zia litätenliste der Grundversicherung auf. 
 
Die Pharmaindustrie kritisiert das Bundesamt für 
Gesundheit scharf. «Der Wille, die Beschleunigung 
umzusetzen, fehlt bei den zuständigen Beamten 
im BAG», sagt Sara Käch, Sprecherin des Bran-
chenverbandes Interpharma. «Die von Bundesrat 
Berset versprochene, seit einem Jahr in der Ver-
ordnung vorgeschriebene Beschleunigung hat 
nichts bewirkt. Die Verordnung wird in der Praxis 
nicht umgesetzt.» Interpharma hat deshalb kürz-
lich bei Bundesrat Alain Berset und BAG-Chef 
Pascal Strupler interveniert und sie aufgefordert, 
bei ihren Untergegebenen einzuschreiten. 
 
Das BAG sieht jedoch kein Problem und sagt, 
es habe die 60-Tage-Frist in 80 Prozent der Fäl-
le eingehalten. «Das BAG setzt die Verordnung 
mehrheitlich innerhalb der vorgegebenen Zeit 
um», sagt Sprecher Daniel Dauwalder. Zu diesem 
Ergebnis kommt das Bundesamt allerdings nur, 
weil es entgegen der Verordnung nach eigenen 
Arbeits- und nicht nach Kalendertagen rechnet. 
Zudem hat es alle Gesuche aus dem Jahr 2014 
und alle hängigen Gesuche, die tendenziell be-
sonders lange dauern, herausgerechnet, um auf 
das gewünschte Ergebnis zu kommen. 
 
Interpharma wirft dem BAG vor, es verschulde 
die Zeitverzögerung, indem es den Preis unter 
jenen der sechs Vergleichsländer drücke. Das 
löse lange Preisverhandlungen aus. «Innovati-
ve Medikamente werden in der Schweiz syste-
matisch unter dem europäischen Auslandpreis 
eingestuft», sagt Manfred Heinzer, der Leiter 
von Roche Pharma Schweiz. «Diese für uns 
nicht akzeptablen Preisvorstellungen führen zu 
Verzögerungen im Zugang zu hoch innovativen, 
neuen Produkten, welche von den Patienten 
dringend benötigt werden.» Beispielsweise 
habe das BAG beim Brustkrebsmedikament 
Kadcyla über einen langen Zeitraum an einem 
Preis festgehalten, der rund 30  Prozent tiefer 
als derjenige in Deutschland, Frankreich und 
weiteren Referenzländern gelegen wäre. 
 
Dabei kosten neue Medikamente in der Schweiz 
schon heute weniger als in den sechs Ver-
gleichsländern. Im Schnitt sind sie 13 Prozent 
billiger, wie ein von Interpharma durchgeführter 
Preisvergleich bei den seit 2011 kassenp"ichti-
gen Medikamenten mit neuen Wirkstoffen zeigt. 
Noch grösser ist der Preisunterschied bei jenen 
Medikamenten, wo der Zusatznutzen nach den 
strengen deutschen Regeln klar belegt ist. Hier 
liegt er bei 15 Prozent. Gegenüber Deutschland 
sind es sogar 29  Prozent. 
 
«Diese Praxis des BAG führt zu einem innova-
tionsfeindlichen Umfeld in der Schweiz», sagt 
Interpharma-Sprecherin Sara Käch. «Und dies 
ausgerechnet in dem Land, das über Investi-
tionen in Forschung und Entwicklung, Arbeits-
plätze und Exporte wie kein anderes weltweit 
von der Pharmaindustrie pro!tiert. Das ist ein 
schlechtes Signal gegenüber den hier ansäs-
sigen Firmen.» Zudem widerspreche es dem 
Willen des Parlaments. Dieses hatte vor einem 
Jahr verlangt, dass bei der Preisfestsetzung die 
Innovation berücksichtigt wird.
Schweiz am Sonntag, 8. Juni 2014
Die vergessenen Asbestopfer
Das Urteil des Gerichtshofs für Menschenrech-
te im März 2014 war für Asbestgeschädigte 
eine grosse Genugtuung. Endlich hat ein Ge-
richt gesagt, dass es nicht in Ordnung ist, wenn 
Ansprüche auf Schadenersatz verjähren, bevor 
die Betroffenen vom Schaden wissen. Doch die 
Freude währte nur kurz. Einen Monat später 
hat das Bundesgericht eine weitere pendente 
Asbestklage sistiert, und zwar bis die eidge-
nössischen Räte die Verjährungsrechtsrevision 
abschliessen.
 
Das Gericht will dem gesetzgeberischen Prozess 
nicht vorgreifen und keine Präjudizien schaffen, 
die dem künftigen Recht widersprechen könn-
ten. Dabei missachtet das Bundesgericht aber 
die Tatsache, dass schon das heutige Obligatio-
nenrecht bei einem Teil der Klagen eine geschä-
digtenfreundlichere Rechtsprechung zuliesse – 
dann nämlich, wenn der Geschädigte bei der 
Asbestverarbeiterin angestellt war. Weniger 
Spielraum haben die Gerichte, wenn es keinen 
Vertrag gab und der Betroffene beispielsweise 
als Anwohner geschädigt wurde.
Ungeachtet dieser möglichen Differenzierung 
weist das Bundesgericht seit 1980 alle Asbest-
klagen als verjährt ab. Immerhin betrifft die Sis-
tierung einen sogenannten ausservertraglichen 
Fall. Für die andern Fälle, zu denen auch der 
im März in Strassburg beurteilte gehört, besteht 
also Hoffnung auf eine Behandlung.
So oder so schafft das Bundesgericht eine wei-
tere Unsicherheit für Rechtsuchende. Sie müssen 
möglicherweise warten, bis das Parlament die 
Gesetzesrevision zu Ende beraten hat, was noch 
Jahre dauern wird. Im schlimmsten und gleich-
zeitig wahrscheinlichsten Fall resultieren daraus 
keine substanziellen Verbesserungen für Opfer 
von Langzeitschäden. Darauf deutet das Gezerre 
um die künftige Verjährungsfrist hin, die schon 
begonnen hat: Die Wirtschaft wehrt sich gegen 
die geplante Verlängerung von 10 auf 30 Jahre; 
Opfervertretern hingegen genügen 30 Jahre nicht.
Abgesehen davon vergisst die Politik Tausende 
Asbestopfer: Bereits verjährte Fälle bleiben es 
voraussichtlich auch mit einem neuen Gesetz – 
und sie machen den grössten Teil der mehreren 
Tausend Betroffenen aus. Es ist ein Fehler von 
Justizministerin Simonetta Sommaruga, einen 
runden Tisch zur Klärung der Asbestfrage abzu-
lehnen. Der Bund sollte parallel zur Gesetzesre-
vision einen Entschädigungsfonds für die ver-
gessenen Fälle initiieren. So würde das Leid der 
Betroffenen gelindert, wodurch die juristische 
Aufarbeitung an Bedeutung verlieren würde.
Tages-Anzeiger, 11. Juni 2014
Alain Berset will 
Medikamentenpreise 
nochmals deutlich senken
Die Vorstellungen des SP-Bundesrats dürften in der 
Pharmaindustrie auf heftigen Widerstand stossen. 
Betroffen sind auch die Hersteller von Generika
Noch bevor die letzte Preissenkungsrunde ab-
geschlossen ist, steht bereits die nächste ins 
Haus. Gesundheits minister Alain Berset wird 
in Kürze einen Entwurf vorlegen, wie die Medi-
kamentenpreise in der Schweiz neu festgelegt 
werden sollen. Die Vorstellungen des SP-Bun-
desrats dürften der  Pharmaindustrie missfal-
len, da sie bereits bei der laufenden Runde 
zwischen 2012 und 2015 Einbussen von über 
700 Millionen Franken hinnehmen muss. Laut 
Informationen des TA will Berset zusätzlich fol-
gende Änderungen vornehmen:
Auslandpreisvergleich: Bisher  werden die hie-
sigen Preise mit jenen von Deutschland, den 
Niederlanden, Frankreich, Österreich, Dänemark 
und Grossbritannien verglichen. Nun sollen bis zu 
drei weitere Länder hinzukommen. Es ist davon 
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auszugehen, dass dies Nationen mit tieferen Me-
dikamentenpreisen sein werden, was sich kos-
tendämpfend auf die Schweiz auswirken würde.
Toleranzmarge: Bei der laufenden Runde kam 
der Bundesrat der Pharmaindustrie entgegen, 
indem er die Umrechnung der ausländischen 
Preise in Franken mit einer Marge von 5 Pro-
zent abfederte. So wurde den Herstellern ein 
Wechselkurs von 1.29 Franken pro Euro zuge-
standen, obwohl der vom Bundesamt für Ge-
sundheit (BAG) festgelegte Durchschnittskurs 
1.23 Franken beträgt. Nun soll diese Toleranz-
marge von 5 auf 3 Prozent gesenkt werden.
Nutzen eines Medikaments: In der letzten 
Preissenkungsrunde wurde fast ausschliesslich 
auf die ausländischen Preise abgestellt. Nun 
soll wie früher wieder der Nutzen des Medi-
kaments im Vergleich zu ähnlichen Präparaten 
einbezogen werden. Allerdings soll der Ausland-
preisvergleich ein höheres Gewicht erhalten.
Kurzfristige Kehrtwende
Diese und andere Änderungen kann Berset 
über die entsprechende Verordnung regeln. Die 
Vernehmlassung soll dem Vernehmen nach in-
nert 30 Tagen durchgeführt werden. Es ist gut 
möglich, dass einige Details noch geändert 
werden, die Richtung ist jedoch eindeutig.
Innerhalb der Pharmaindustrie zeigen sich di-
verse Vertreter denn auch irritiert und fürchten 
sich vor einem weiteren markanten Einschnitt. 
Viel von dem, was an den runden Tischen mit 
dem BAG in den letzten Monaten besprochen 
wurde, sei nicht mehr übrig. Der Widerstand der 
Pharma branche wird heftig ausfallen. Bevor der 
Entwurf nicht vorliegt, will sich jedoch niemand 
of!ziell dazu  äussern. Laut Beobachtern habe 
vieles auf einen Kompromiss hingedeutet, mit 
der die Pharmaindustrie hätte leben können. Der 
Kurswechsel Bersets sei offenbar relativ kurzfris-
tig  erfolgt.
Eine Änderung fasst der Gesundheitsminister 
auch bei den Generika ins Auge. Berset favorisiert 
das von Preisüberwacher Stefan Meierhans vorge-
schlagene Festbetragssystem. Dabei müssen die 
Patienten den Aufpreis gegenüber dem billigsten 
Generikum selber berappen. Beim bisherigen 
Mechanismus müssen Nachahmerpräparate eine 
bestimmte Preisdifferenz zum Originalmedika-
ment aufweisen. Laut Meierhans könnten mit dem 
Systemwechsel jährlich 380 Millionen Franken 
gespart werden. Die Generikaindustrie fürchtet 
happige Einbussen und sieht die Wahlfreiheit der 
Patienten in Gefahr. Für eine solch weitgehende 
Anpassung muss das Gesetz geändert werden. 
Damit liegt die Hürde höher als bei den Preissen-
kungen der Originalpräparate, da das Parlament 
darüber be!nden muss.
Tages-Anzeiger, 11. Juni 2014
Ein Boykott verletzt den 
Forschergeist
Diesen Erfolg kann dem Hirnforscher Henry 
Markram keiner mehr nehmen: Das Human 
Brain Project ist wohl das seit Jahrzehnten um-
strittenste Forschungsprojekt der Schweiz. Es 
hat somit die Neuroforschung auf die Landkar-
te der öffentlichen Aufmerksamkeit gesetzt.
Was bisher geschah: Der schillernde, dandy-
hafte südafrikanisch-israelisch-schweizerische 
Neuroforscher war 2002 mit einer Vision an 
die ETH Lausanne gekommen: Wenn es gelingt, 
alles Wissen über das Gehirn in einen vernünf-
tigen Computer einzuspeisen, wird man dieses 
dereinst simulieren können. Und dann werde 
uns wie Schuppen von den Augen fallen, was 
das Gehirn ausmacht und wie es funktioniert. 
Aber nicht nur das: Weil ein solcher Super-Su-
percomputer erst noch gebaut werden muss, 
werden auf dem Weg dahin reichlich neue Ein-
sichten fruchten, vor allem auch im Bereich der 
Informationstechnologie.
Eine derart allumfassende Vision braucht na-
türlich, das war Markram von Beginn weg klar, 
eine den Rahmen sprengende Finanzierung. 
Aus neu geschaffenen EU-Töpfen, die er selber 
vorgeschlagen hat, hat er prompt den Zuschlag 
für rund eine Milliarde Euro für einen Zeitraum 
von zehn Jahren erhalten. Das Human Brain 
Project wurde im Januar 2013 gegen harte 
Konkurrenz zum EU-Flaggschiff-Projekt erklärt. 
Im vergangenen Oktober dann startete die erste 
rund dreijährige Phase des Projektes mit rund 
200 Forschern aus 112 Institutionen.
Doch nun haben rund 150 Neurowissenschaft-
ler aus ganz Europa einen offenen Brief an die 
EU-Kommission veröffentlicht, in dem sie die wis-
senschaftlichen Ziele und auch die Führung des 
Megaprojektes hart kritisieren. Das Projekt sei zu 
computerlastig und die Vergabe von Unterprojek-
ten zu wenig transparent. Internationale Stan-
dards würden nicht eingehalten. Anlass ist eine 
Eingabe der dreiköp!gen Führungscrew um Henry 
Markram an die EU-Kommission, in der für die 
zweite Phase ein Unterprojekt über die kognitive 
Neuroforschung aus dem Kernprojekt gestrichen 
wurde. Die Initianten des Briefes kommen aus 
den Reihen dieser kognitiven Neuroforscher und 
fordern von der EU-Kommission eine minutiöse 
und peinlich genaue Prüfung des ganzen Projek-
tes, bevor die Gelder der zweiten Phase bewilligt 
würden, für die ab 2016 rund 100 Millionen Euro 
pro Jahr vorgesehen sind. Andernfalls rufen die 
Unterzeichnenden dazu auf, fortan auf eine Be-
teiligung am Projekt zu verzichten – die Forscher 
sollen das Human Brain Project also boykottieren.
Guruhafte Art
Erstaunlich ist der grosse Anklang, den der 
Protestbrief gefunden hat. Bis gestern Nach-
mittag waren es bereits mehr als 500 Wis-
senschaftler, darunter bekannte Namen wie 
der Zürcher Neuroökonom Ernst Fehr oder die 
Philosophin Ursula Pia Jauch. Viele davon sind 
nicht direkt in das Vorhaben involviert, son-
dern wurden von einem generellen Unbehagen 
gegenüber dem Megaprojekt motiviert – aber 
auch die guruhafte Art von Projektleiter Mar-
kram ist umstritten.
Die wissenschaftliche Kritik ist nicht neu: Einige 
Neuroforscher haben von Beginn weg bezwei-
felt, dass allein aus der massiven Anhäufung 
von Daten die realen Abläufe im Gehirn ver-
ständlich würden und so Wege für die Behand-
lung von Krankheiten wie Alzheimer, Depression 
zu !nden seien. Nicht weniger als das steht auf 
dem Banner des Human Brain Project. Mar-
kram und seine Leute wollen sich jedoch nicht 
daran messen lassen und antworten, dass es 
eigentlich um Forschung im Bereich der Infor-
mationstechnologie handle, welche die Neuro-
forschung als Ganzes voranbringe.
Die Auseinandersetzung hat mittlerweile Cha-
rakterzüge eines Glaubenskrieges angenom-
men: Jeder glaubt, sich sofort und laut dazu 
äussern zu müssen. Die Forderung, das Ma-
nagement kritisch, genau und unabhängig zu 
überprüfen, ist sicher richtig. Der Boykott-Aufruf 
jedoch widerspricht dem Geist der freien For-
schung zutiefst, die vom freien Gedankenaus-
tausch und dem ständigen Streit der Ideen lebt. 
Dies auch im Interesse des gemeinsamen Ziels, 
nämlich dem Verständnis des so wundersam 
komplexen Gehirns.
Tages-Anzeiger, 11. Juli 2014
 
Joint Venture zwischen der 
Pharma und Hasch-Gegnern
US-Pharmakonzerne !nanzieren die Gegner 
der Cannabis-Liberalisierung. Sie befürchten, 
dass ihre opiathaltigen Schmerzmittel vom 
Markt verdrängt werden.
Polizeigewerkschaften, Gefängnisunternehmen, 
Bierbrauer und Familienverbände haben im 
Kampf gegen die Can na bis frei gabe in den USA 
einen !nanzkräftigen Verbündeten gefunden: 
Auch etliche Hersteller von starken opiat haltigen 
Schmerz mitteln widersetzen sich der Liberalisie-
rung oder fordern  rigide Regeln für den priva-
ten Konsum. Der ist seit dieser Woche auch im 
Bundes staat Washington problemlos möglich: 
Nach Colorado hat der Staat im Nordwesten der 
USA den Verkauf von Cannabis ebenfalls lega-
lisiert.
Angeführt wird die Opposition von Patrick 
Kennedy, Sohn des verstorbenen Senators Ted 
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Kennedy. Patrick Kennedy litt an Alkohol- und 
Drogenproblemen und setzte 2006 seinen Ford 
Mustang in die Sicherheitsschranken vor dem 
Capitol in der US-Hauptstadt Washington. Er 
gab zu, ein rezeptp"ichtiges Schmerzmittel mit 
opiathaltigen Wirkstoffen konsumiert zu haben.
Heute ist der 46-Jährige wieder suchtfrei. 2013 
gründete er die Bewegung Smart Approaches 
to Marijuana (SAM) als Antwort auf den Ent-
scheid der Stimmbürger in Colorado und Was-
hington, den Handel und Konsum mit Canna-
bis produkten freizugeben.
Eine tödliche Suchtwelle
SAM und anderen Oppositionsgruppen geht es 
nicht allein um Aufklärung von Jugendlichen. Ein 
vertrauliches Dokument der Partnership for Drug-
Free Kids zeigt, dass mehrere Pharma!rmen die 
Kampagnen gegen die Haschfreigabe mit!nan-
zieren. Das Magazin «The Nation» berichtet ge-
stützt auf das Dokument, dass Purdue Pharma 
und Abbott Laboratories zu den grössten Spen-
dern der Partnership gehören. Bekannt ist auch, 
dass Pharma!rmen und Polizei gewerkschaften 
in Kalifornien bis zur Hälfte der Spenden an An-
ti-Hasch-Abstimmungskomitees beisteuerten.
Purdue zählt zusammen mit der Pharma!rma 
Alkermes auch zu den Geldgebern der Commu-
nity Anti-Drug Coalition of America (CADCA). 
Weitere Financiers der Anti-Hasch-Bewegung 
sind gemäss «The Nation» P!zer sowie die 
Johnson-&-Johnson-Tochter Janssen.
All diesen Unternehmen ist gemeinsam, dass 
sie starke Schmerzmittel herstellen, die aus 
Opium gewonnen werden oder synthetisches 
Opium enthalten. Die Präparate sind entspre-
chend suchtgefährlich. Patrick Kennedy sel-
ber hatte das Purdue-Präparat Oxycontin ge-
schnupft, als er den Autounfall in Wa shing ton 
verursachte. Alkermes sorgte dieses Frühjahr 
für einen stürmischen Protest, als es das an-
geblich zehnmal stärkere Schmerzmittel Zohy-
dro auf den Markt warf.
Diese Opiate in Form von Schmerzmitteln sind 
in den USA für eine enorme Suchtwelle ver-
antwortlich. Die staat lichen Center for Disease 
Control und Prevention sind höchst besorgt: 
Jährlich sterben über 16‘000 Abhängige an 
einer Überdosis solcher Schmerzmittel. Das 
sind mehr Menschen, als jedes Jahr  wegen 
Heroin und Kokain den Tod !nden. Zwar ver-
suchen die Hersteller, den Missbrauch zu ver-
hindern, indem sie die Pillen mit einer Schutz-
schicht versehen, die es unmöglich machen 
soll, sie zu  einem schnupftauglichen Pulver 
zu zerreiben. Doch insbesondere in den ärm-
lichen Regionen des Südens ist die Oxycont-
in-Suchtwelle akut.
Für die Hersteller sind die Schmerzmittel ein 
grosses Geschäft. Purdue machte seit 1996 
mehr als 27 Milliarden Umsatz mit Oxycontin. 
Im Strassen handel erzielen opiathaltige Prä-
parate Höchstpreise. Diese Woche wurde der 
Chefapotheker eines New Yorker Spitals des 
Drogenhandels angeklagt, weil er 200‘000 Oxy-
contin-Pillen mit einem Schwarzmarktwert von 
5,6 Millionen Dollar entwendet hatte.
Cannabis ist ein Schmerzmittel
Von der Schmerzmittelgefahr ist in den Aufklä-
rungsbroschüren der Anti-Marihuana-Gruppen 
wenig zu sehen. In  ihren Kampagnen richten sie 
sich einzig gegen die Freigabe und fordern stark 
einschränkende Konsumvorschriften. Dies, ob-
wohl Marihuana für Chronischkranke als Alter-
native zu den Opiat- Schmerzmitteln verschrie-
ben wird. Es sei heuchlerisch, sich nicht zu den 
 Risiken der suchterzeugenden Schmerzmittel 
zu äussern und dabei Marihuana auf der Liste 
der gefährlichsten Drogen behalten zu wollen, 
kritisieren Ärztegruppen wie die Physicians for 
Responsible Opioid Prescribing. Es stelle sich 
somit die Frage, ob diese Gruppen von ihren 
Geldgebern aus der Pharma branche beein-
"usst würden.
Eine Antwort lässt sich vom Widerstand gegen 
die Zulassung des Schmerzmittels Zohydro 
ableiten. 42 Drogen aufklärungs gruppen unter-
schrieben im Frühjahr den Protestbrief an die Zu-
lassungs behörde. Doch die Partnership for Drug-
Free Kids und die Anti Drug Coalition (CADCA) 
fehlten auf der Liste der Unterzeichner.
Tages-Anzeiger, 11. Juli 2014 
Vor der Operation zum 
Gentest
Die Klinik Hirslanden bietet neu genetische Ab-
klärungen an, um unerwünschten Medikamen-
tenwirkungen vorzubeugen. Am Unispital Zürich 
wird die Methode bisher nur zurückhaltend 
eingesetzt.
Noch ist es erst eine Praxis, doch diese soll 
sich mit der Zeit zu einem Zentrum entwickeln. 
So, wie es in der Vergangenheit an der Klinik 
Hirslanden mit vielen Fachgebieten passiert ist: 
Ein Spezialist fängt an, und um ihn gruppieren 
sich immer mehr Kollegen. Die «personalisier-
te Medizin», die jetzt neu angeboten wird, ist 
für Klinikdirektor Daniel Liedtke eine «wichtige 
Innovation». Dabei geht es grob gesagt darum, 
dank Gentests Medikamente so einzusetzen, 
dass sie bestmöglich wirken beziehungsweise 
keine unerwünschte Wirkung haben. 
Die Idee für das neue Angebot stammt von 
Thomas Szucs, hauptberu"ich Direktor des Eu-
ropäischen Zentrums für Pharmazeutische Me-
dizin an der Universität Basel. Szucs’ Karriere 
ist vielfältig. Er ist ausserordentlicher Professor, 
hat zwei Facharzttitel (Pharmazeutische Medi-
zin und Präventivmedizin) und je einen Master 
in Public Health, in Unternehmensführung und 
in internationalem Wirtschaftsrecht. Er arbeite-
te an diversen Kliniken im In- und Ausland als 
Arzt, Ökonom oder Manager, war in der Phar-
maindustrie tätig, und aktuell präsidiert er auch 
noch den Verwaltungsrat der Krankenversiche-
rung Helsana. Wie kommt dieser «Hansdampf 
in allen Gassen», wie er in der Gesundheitss-
zene genannt wird, dazu, eine Praxis an einer 
Zürcher Privatklinik zu eröffnen? …
…
Der Test inklusive Beratung kostet 950 Franken 
und wird von der Krankenkasse nicht übernom-
men. Klinikdirektor Liedtke erwartet vorerst kei-
nen Ansturm. Aus seiner Sicht ist die Untersu-
chung vor allem für mehrfach kranke Personen 
sinnvoll: «Bei Risikopatienten kann ein gutes 
Arzneimittelmanagement über Erfolg oder Miss-
erfolg einer Operation entscheiden.»
Am Universitätsspital Zürich wird die Pharma-
kogenetik bisher nur gezielt dort eingesetzt, wo 
ein Nutzen in Studien gezeigt werden konnte, wie 
Oberärztin Natascia Corti erklärt. Die Forschung 
habe erst bei wenigen Genen einen klaren Zu-
sammenhang mit der Wirkung oder Nebenwir-
kung bestimmter Medikamente nachweisen kön-
nen. Gentests ohne konkrete Problemstellung zu 
machen, hält die klinische Pharmakologin für 
verfrüht. Hingegen seien sie sinnvoll, wenn ein 
Problem vorliegt. «Wenn zum Beispiel ein Patient 
eine Unverträglichkeit mit einem Medikament 
aufweist, wird er zu uns geschickt. Wir klären 
dann ab und ordnen möglicherweise einen Gen-
test an.» Sehr wichtig sei danach, dass ein Spe-
zialist die Testresultate bewertet und sie dem Pa-
tienten erklärt, damit dieser nicht beunruhigt ist. 
«Dafür braucht es pharmakologisches Wissen 
auf dem neusten Stand und eine entsprechende 
klinische Erfahrung.» …
Tages-Anzeiger, 25. Juli 2014
Kommentar der Redaktion
In einem Expertenbericht, den das schwei-
zerische Zentrum für Technologiefolgen-Ab-
schätzung TA-Swiss im März dieses Jahres 
erstellt hat, warnen die Fachleute vor einer 
unkontrollierten breiten Anwendung. Viele 
Ergebnisse sind zudem alles andere als 
eindeutig. Nach zehn Jahren intensiver Ge-
nomforschung ist vor allem klar geworden, 
dass die Beziehung zwischen dem Erbgut 
und einer Krankheit äusserst komplex ist.
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Der Tabakmulti Philip Morris mit Sitz in der 
Schweiz verklagt den Staat Uruguay wegen 
Gesundheitsvorschriften. Der Bund will nicht 
intervenieren.
Am 5. und 6. Februar 2013 fand hinter den ver-
schlossenen Türen der Internationalen Handels-
kammer in Paris ein Treffen hochrangiger Wirt-
schaftsanwälte statt. Der italienische Richter 
Piero Bernardini und seine Kollegen Gary Born 
aus den USA und James Crawford aus Austra-
lien hatten knapp zwei Dutzend AnwältInnen, 
Regierungsvertreter und KonzernmanagerInnen 
zu einer Anhörung geladen. 
Was an diesem Treffen gesagt wurde, blieb un-
ter Verschluss. Kein Reporter war anwesend, 
keine Medienmitteilung wurde verschickt. Die 
Öffentlichkeit war ausgeschlossen. Dabei ver-
handelten die 26 anwesenden Herren und Da-
men während zweier Tage nichts weniger als die 
Souveranität eines Staates. 
Der Fall trägt das Aktenzeichen ARB/10/7. Es 
geht um eine Klage von Philip Morris gegen die 
Republik Uruguay. Der Tabakkonzern beschäftigt 
weltweit über 87000 Angestellte, seit 2003 be-
!ndet sich seine Betriebszentrale in Lausanne. 
Viel ist nicht über das Verfahren bekannt, denn 
die Klage wird nicht vor einem ordentlichen Ge-
richt in Uruguay, in der Schweiz oder in den USA 
verhandelt, sondern an einem fast unbekannten 
Schiedsgericht bei der Weltbank in Washington, 
dem ICSID, dem Internationalen Zentrum zur 
Beilegung von Investitionsstreitigkeiten.
Postkoloniales Vermächtnis
Diese Geschichte nahm ihren Anfang im März 
2006, als Uruguay unter Präsident Tabaré Vas-
quez, einem Onkologen, das Rauchen in ge-
schlossenen Räumen untersagte. Es war der ers-
te Schritt der uruguayischen Regierung im Kampf 
gegen die Nikotinsucht, an der weltweit jedes 
Jahr über fünf Millionen Menschen sterben.
2008 und 2009 folgten weitere Gesetze: Ziga-
rettenpackungen müssen seither beidseitig zu 
achtzig Prozent mit Hinweisen und Piktogram-
men versehen werden, die vor den Gefahren 
des Rauchens warnen, und die Verkaufsstellen 
dürfen von jeder Marke jeweils nur eine Variante 
anbieten (zum Beispiel nur Marlboro Rot, nicht 
aber zusätzlich Marlboro Gold).
Die Tabakindustrie sieht dadurch ihr Geschäft 
gefährdet. Der Konzern Philipp Morris liess 
2010 verlauten, dass er wegen der «extremen 
und uneffektiven Regulierungen» sieben von 
zwölf Markenvariationen vom uruguayischen 
Markt nehmen musste, unter anderem auch 
Marlboro-Varianten, die vierzig Prozent der Marl - 
boro-Verkäufe ausmachten. Da der Tabakkrieg 
seine Investitionen bedroht sah, reichte er am 
Schiedsgericht des ICSID Klage gegen den 
Staat Uruguay ein. Lange wurde über die Höhe 
der Klagesumme spekuliert, der Konzern aber 
schwieg eisern dazu. Anfang Mai allerdings sah 
sich Philipp Morris genötigt, einen Beitrag der 
«Financial Times» zu korrigieren, die die Summe 
von zwei Milliarden US-Dollar genannt hatte. 
Seither ist klar: Es geht um 25 Millionen Dollar, 
wie Philipp Morris auf Anfrage bestätigt.
Die rechtliche Grundlage für die Klage am ICSID 
geht zurück auf ein sogenanntes Investitions-
schutzabkommen, das die Schweiz 1991 mit 
Uruguay abschloss. Das Abkommen wurde zum 
Schutz von Auslandsinvestitionen geschaffen. 
Weltweit bestehen über 3000 solcher bilatera-
ler und multilateraler Abkommen. Die Schweiz 
hat insgesamt 130 Abkommen unterzeichnet, 
den Grossteil mit Entwicklungsländern. ...
...
Das Hauptproblem bei diesem System der In-
vestitionsabkommen liegt jedoch in dessen 
Gerichtsbarkeit. Über die Streitigkeiten be!n-
det ein höchst intransparentes Schiedsgericht 
in Washington. Bei jedem Fall werden drei 
handverlesene Wirtschaftsanwälte zu Schieds-
richtern ernannt, je einer vom Kläger und vom 
Beklagten, und der Präsident von den beiden 
ernannten Richtern. Zu 96 Prozent sind diese 
Richter Männer, wie «Le Monde diplomatique» 
in seiner Juniausgabe berechnete. Ihre Stun-
denansätze betragen zwischen 300 und 650 
Franken, wobei die Verfahren pro Richter 500 
Stunden und mehr in Anspruch nehmen. Ist ein 
Urteil gefällt, kann dagegen keine Berufung ein-
gelegt werden. Die Entscheide sind endgültig. ...
...
Bis zum Urteil dürfte noch ein weiteres Jahr 
vergehen. Eine Niederlage Uruguays könnte ein 
«entscheidender Schlag gegen die Weltgesund-
heitsorganisation WHO und die Länder des Sü-
dens in ihrem Kampf gegen die Folgen des Ta-
bakmissbrauchs» sein, befürchtet Alliance Sud. 
Letzte Woche forderte sie deshalb die Schweiz 
zum Handeln auf. In einer diplomatischen Note, 
einer sogenannten Auslegungsnote, soll sich 
die Schweiz für Uruguay einsetzen. Das Land 
verfolgte schliesslich eine Antitabakgesund-
heitspolitik, die in Einklang mit den Empfehlun-
gen der WHO stehe.
PRESSESPIEGEL – REVUE DE PRESSE
Philip Morris versus Uruguay
In den Fängen der Schattenjustiz
Kommentar der Redaktion
Wir verweisen auf drei vorausgegange ne 
Artikel im Schweizer Krebsbulletin: 
1/2011: 42-44, 2/2012: 124-125, 
1/2014: 28-29.
Im ersten Artikel hatte Sergio Ferrari den 
früheren (und wahrscheinlich auch nächs-
ten: die Präsidentenwahl erfolgt im Oktober 
2014) Präsidenten von Urugay, Dr. Tabaré 
Vasquez, einen bekannten Onkologen, in-
terviewt.
Seit langem und trotz einiger Anfragen im 
Parlament versucht die Schweizer Regie-
rung, sich aus der Affäre zu ziehen, indem 
sie sagt, «es ist nicht our business». Das 
Problem ist eher, dass auch unsere Regie-
rung vor Philipp Morris kuscht.
In der Tat hat die Schweiz auch die Frame-
work Convention on Tobacco Control (FCTC) 
unterschrieben und rati!ziert. Das ist ein 
internationaler Vertrag, an den die Schweiz 
gebunden ist. Und was Uruguay getan hat, 
ist nur die Klauseln dieses internationalen 
Vertrages in die Praxis umzusetzen. Wahr-
scheinlich müssten die KLS und im Grunde 
genommen auch die anderen onkologi-
schen Vereine in der Schweiz Druck auf un-
seren Bundesrat ausüben. Der Kampf gegen 
die Tabakmultis kann nicht nur ein Lippen-
bekenntnis bleiben.
Beim zuständigen Staatssekretariat für Wirt-
schaft (Seco) will man davon nichts wissen. 
Die Schweiz sei nicht Partei. Zudem sei es nach 
den Regeln des ICSID gehalten, «nicht in das 
rechtshängige Verfahren einzugreifen».
WOZ, 17. Juli 2014 
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LESERBRIEFE
Stellungnahme zum Leserbrief von 
M. Fey im Schweizer Krebsbulletin 
Nr. 2/2014, S. 101
Audiatur et altera pars
Jürg Nadig, Präsident SGMO
In seinem Leserbrief1 kommentiert Marin Fey meinem 
Artikel zu Choosing wisely2 im Schweizer Krebsbulletin 
vom März 2014.
Martin Feys Annahme, ich hätte mich ohne Rückspra-
che mit dem Vorstand oder den SGMO Mitgliedern im 
Namen der Fachgesellschaft gegen die Screening-Mam-
mographie ausgesprochen und den Verzicht auf diese Lei-
stung mit politischer Weisheit gleichgesetzt, kann nicht 
unwidersprochen bleiben. Liesse sich zeigen, dass M. Feys 
Annahme falsch ist, wäre es auch seine Schlussfolgerung.
Der Artikel gibt meine Grussadresse zur Eröffnung des 
DGHO Kongresses in Wien 2013 wieder. Ich beleuch-
tete Möglichkeiten und Grenzen von Choosing wisely. 
Eine solche Orientierung braucht keine Zustimmung des 
Vorstandes. Ich fragte nach der politischen Umsetzbarkeit 
solcher Empfehlungen am Beispiel der Mammographie: 
Könnte die Screening-Mammographie überhaupt aus dem 
P#ichtleistungskatalog gestrichen werden, wenn im Rah-
men von Choosing wisely die Datenlage ergäbe, dass der 
Schaden den Nutzen überwiegt? Auf Grund früherer Er-
fahrungen sind Zweifel an der politischen Umsetzbarkeit 
evidenzbasierter Entscheide berechtigt: Die Versuche, in 
der Schwangerschaft die Ultraschall-Untersuchungen von 
drei auf zwei zu reduzieren löste in der Bevölkerung einen 
konzertierten medialen Entrüstungssturm aus. Die Ver-
ordnung wurde deshalb wieder aufgehoben. Andererseits 
wurde der Anspruch auf alternativmedizinische Leistun-
gen zu Lasten der Sozialversicherung mit einer Volksini-
tiative in der Verfassung verankert, ohne dass für einzelne 
Methoden die Evidenz nachgewiesen wurde. 
Mein Artikel erschien, als der Medical Board-Entscheid 
zum Mammographie-Screening diskutiert wurde. Ich 
hatte den Artikel der Redaktion des Krebsbulletins aber 
eingereicht, bevor der Medical Board Entscheid vorlag. 
Allein schon auf Grund der zeitlichen Verhältnisse kann 
mein Artikel also gar keine Stellungnahme zum Medical 
Board Entscheid sein. M. Feys Annahme trifft also nicht 
zu. Ein Kommentar zu seinen Schlussfolgerungen erübrigt 
sich damit. 
Ich schrieb, Weisheit leuchte erst in der Retrospektive 
nach umfassender Würdigung aller Umstände auf. Ent-
scheide am Krankenbett oder in der Sprechstunde müss-
ten aber prospektiv hier und jetzt und naturgemäss ohne 
Kenntnis aller Umstände gefällt werden. Das ist eine täg-
liche Erfahrung. Sie illustriert eine gewisse Widersprüch-
lichkeit des Begriffes «Choosing wisely«. Da mich M. Fey 
in diesem Zusammenhang aber falsch zitiert, erübrigt 
sich auch hier ein Kommentar.  
 
Einen Kommentar verlangt aber die Art und Weise sei-
ner Kon#iktaustragung:  Interessenskon#ikte unter den 
Onkologen sollten primär innerhalb der Fachgesellschaft 
einvernehmlich gelöst werden. Die dazu notwendigen Or-
gane wären vorhanden. Wer sich aber aus der Fachgesell-
schaft verabschiedet, verbaut sich diese Möglichkeit und 
sucht den Weg an die Öffentlichkeit.    
Hätte mir die Redaktion des Krebsbulletins vor dessen 
Publikation M. Fey’s Artikel zur Stellung vorgelegt, hät-
te sich rasch gezeigt, dass er auf falschen Annahmen und 
Zitaten beruht. Eine Veröffentlichung hätte sich damit 
erübrigt. Nun haben die Mitglieder der SGMO erst re-
trospektive, dafür aber in Würdigung aller Umstände, die 
Möglichkeit, sich eine Meinung zu bilden, «whether they 
have chosen their chairman wisely».
Audiatur et altera pars: Gehört werde auch der andere 
Teil.
1. Fey M.  Kommentar zum Artikel in der Sektion SGMO «Choosing 
wisely» von Jürg Nadig Schweizer Krebsbulletin 2014; 2:101
2. Nadig J. Choosing wisely, Schweizer Krebsbulletin 2014; 1:74
Dr. Jürg Nadig, Präsident SGMO
juerg.nadig@hin.ch
Wir drucken hier die Antwort von Dr. Jürg Na-
dig auf die Stellungnahme von Prof. M. Fey, die in 
der letzten Ausgabe des Krebsbulletins erschienen 
war (S. 101). Journalistische Sorgfalt hätte schon 
damals verlangt, dass wir dem Kollegen Nadig 
die Möglichkeit gegeben hätten, auf die Stellung-
nahme von Prof. Fey in derselben Ausgabe zu ant-
worten. Aus verschiedenen, vor allem zeitlichen 
Umständen, haben wir dies unterlassen. Dafür ent-
schuldigen wir uns.
Die Redaktion
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HPV and cancer: 
a unique opportunity for 
cancer prevention
Silvia Franceschi, International Agency for Research on 
Cancer, Lyon, France
Approximately 610,000 of the 13 million new cancer 
cases worldwide are attributable to human papillomavirus 
(HPV).1 The global attributable fraction (AF) of HPV is 
4.8% with 570,000 new cancer cases diagnosed among 
women (AF: 9.4%) and 39,000 cases among men (AF: 
0.6%). HPV is believed to be responsible for 100% of cer-
vical cancers, 88% of anal cancers, 70% of vaginal cancers, 
50% of penile cancers, and 43% of vulvar cancers with 
the majority caused by HPV16 or 18. The corresponding 
percentage for oro-pharyngeal cancer is less well-de!ned 
than for the other anatomic sites due to the still predomi-
nant role of tobacco and alcohol use in many populations. 
The AF of HPV in oro-pharyngeal cancer is estimated to 
be 26% globally, but the corresponding HPV prevalence 
rises to ≥50% in Northern Europe, North America, Japan, 
and Australia.1
The AF of HPV in women is much greater in in countries 
in which cervical screening is inadequate. It ranges from 
≤2.5% in North America and Australia to 4.5% in Europe 
and 25% in sub-Saharan Africa and India. In men, the 
PAF is highest in India (1.8%) and <1.0% in all other 
countries or regions. 
Cervical cancer is the most important cancer in women 
in several countries in sub-Saharan Africa and a few ones 
in Latin America and Asia. Of notice, cervical cancer in-
cidence rates are also very high (>20 per 100,000 wom-
en) in many countries, including a few Eastern European 
countries, in which breast cancer has become more com-
mon than cervical cancer. 
The knowledge on the carcinogenicity of HPV has rap-
idly grown in the last three decades and HPV infection 
with thirteen high-risk HPV types is now recognized to 
be the necessary cause of cervical cancer and precancerous 
lesions.2 This knowledge has paved the way to unique op-
portunities of prevention through a combination of HPV 
vaccination and HPV test-based screening.
Currently available (bivalent or quadrivalent) HPV vac-
cines against HPV16 and 18 can certainly prevent ap-
proximately 70% of cervical cancer in every world region.2 
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However, cross-protection of current vaccines from other 
similar types (HPV31, 33, and 45) has been reported and 
a new vaccine against HPV6/11/16/18/31/33/45/52/58 
will soon be marketed raising expectations that a larger 
fraction of cervical cancers will be eventually prevented.3 
The HPV vaccine has the greatest ef!cacy in individuals 
not yet exposed to the virus. The World Health Organiza-
tion (WHO) therefore recommends including HPV im-
munization of girls at age 9-to-12 years into comprehen-
sive cervical cancer prevention and control programmes. 
Major challenges for the introduction of HPV vaccination 
were the high cost of the vaccine and the need to target 
adolescent girls, for whom no ef!cient vaccination plat-
forms were in place. Fortunately, the cost of the vaccine 
for the public sector is steadily declining. The price of 
HPV vaccine was, for instance, more than 100 Euro per 
dose in Europe and North America in 2007 but few years 
later it has dropped to 30 Euro in Italy, 20 in Sweden, 
and 13 in Latin America. The vaccine can be currently 
purchased by the Global Alliance for Vaccines and Im-
munisation (GAVI) at less than 5 US Dollars per dose: 
still too expensive compared to other widely used vaccines 
but approaching the price (approximately 2 Dollars per 
dose) that would make it very cost-effective in most of the 
poorest countries.4 Twenty-one GAVI-eligible countries 
are expected to bene!t from the introduction of the HPV 
vaccine in 2013-14 (http://www.gavialliance.org). Two 
pioneer countries, Bhutan and Rwanda, have shown that 
low-income countries can implement school-based HPV 
vaccination programmes and achieve even higher coverage 
(>90%) than high-income countries. HPV vaccination in 
the two countries is currently monitored by the Interna-
tional Agency for Research on Cancer, Lyon, France.5 
HPV vaccination with fewer doses has been shown to 
be non-inferior to vaccination with three doses and the 
WHO Strategic Advisory Group of Experts on immuni-
zation (SAGE) endorsed dose reduction to two doses in 
April 2014.6 This change will substantially simplify the 
logistics and further reduce the costs associated with HPV 
vaccination.
New opportunities have also become available for second-
ary prevention of cervical cancer. The disease, the most 
widely screened cancer worldwide, has a long natural his-
tory with slow-progressing precancerous lesions such as 
cervical intraepithelial neoplasia grade 2 and 3 (CIN2 and 
3) and adenocarcinoma in-situ. Contrary to breast cancer 
screening, cervical cancer screening’s aim is to detect pre-
cancerous lesions instead of cancer and, therefore, screen-
ing reduces not only mortality rates but also incidence 
rates in screened populations. Currently, four main types 
of tests can be used, mainly depending upon the income 
level of a country: conventional cytology (Pap smear), 
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liquid-based cytology, visual inspection with acetic acid 
(VIA), and HPV testing. They can all identify women 
with CIN as well as early invasive cancer, if provided with 
quality assurance and by well-trained providers.
 
Pap smear screening has been largely responsible for the 
substantial decline in cervical cancer incidence and mor-
tality in developed countries of Europe, North America, 
Japan, Australia, and New Zealand in the last !ve de-
cades. However, quality assurance of cytology is dif!cult 
and the test has to be repeated every few years to remedy 
to a relatively low sensitivity. Four large randomised con-
trolled trials of HPV testing versus cytology have been car-
ried out in Italy, the Netherlands, Sweden, and the United 
Kingdom.7 A lower CIN3 incidence was recorded after 
HPV testing compared with cytology. Despite different 
screening protocols, the relative incidence of CIN3 or 
worse histological !ndings after the !rst screening round 
was approximately halved in the HPV arm versus the cy-
tology arm in all trials. These results show that HPV-
based screening detects persistent CIN3 better and earlier 
than cytology, thus increasing the probability of treat-
ment before invasion. HPV-based screening also provides 
60–70% greater protection against invasive cervical carci-
nomas compared with cytology.7 Data of the randomised 
trials supported initiation of HPV-based screening from 
age 30 years and extension of screening intervals to at least 
!ve years. 
Cervical screening using HPV testing and, to a lesser ex-
tent, VIA has been found to be effective in preventing 
cervical neoplasia and deaths caused by cervical cancer in 
clinical trials in Asia8 and Africa.9 Recently, the WHO 
issued new recommendations for cervical cancer screening 
in women age 30 years or older in low/middle- income 
countries.  Where resources permit, a strategy of screen 
with HPV tests and treat with cryotherapy (or loop elec-
trosurgical excision procedure, LEEP, when not eligible 
for cryotherapy) or a strategy of screen with HPV test-
ing followed by VIA and treat with cryotherapy (or LEEP 
when not eligible for cryotherapy) are preferable compared 
to a strategy of screen-and-treat with VIA.10
In conclusion, HPV vaccination and HPV-based screen-
ing have the potential to attain a nearly complete elimi-
nation of cervical cancer in the new generations of vacci-
nated women and to avoid of the vast majority of cervical 
cancer deaths in unvaccinated women. HPV vaccination 
will allow a gradual reduction of screening frequency and 
the cost and anxiety related to the detection and treat-
ment of precancerous lesions. Priorities in low/middle-
income countries include access to cheaper HPV vaccines 
and HPV tests and the establishment of adequate infra-
structures for screening and vaccination. In many high-
income countries major challenges include overcoming 
socio-cultural inequalities in screening and improving 
the coverage of HPV vaccination that is at present sub-
optimal (≤50% in France, Germany, and Switzerland) due 
to organizational problems, complicated reimbursement 
schemes, and unfortunate misperception of the risk/ben-
e!t ratio of vaccination. 
Con!ict of interest: No potential con#ict of interest is 
disclosed by the author.
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PARP inhibitors – the next 
standard of care in ovarian 
cancer?
Daria Glaessgen1,2 and Susana Banerjee1
1 The Royal Marsden NHS Foundation Trust, London, UK
2 Karolinska University Hospital, Stockholm, Sweden
PARP inhibitors – the next standard of care 
in ovarian cancer?
These are exciting times for the treatment of ovarian can-
cer as strategies incorporating molecular targeted thera-
pies are proving successful (1). The majority of women 
continue to be diagnosed with advanced disease and the 
overall 5-year survival rate is around 40-50%. The inter-
national standard of care for newly diagnosed ovarian can-
cer is a combination of optimal cytoreductive surgery and 
platinum-based chemotherapy. However, there remains a 
signi!cant risk of recurrence and drug resistance at which 
stage, the condition is not curable. 
There has been an explosion in our understanding of the 
biology of ovarian cancer and drug development in recent 
years. Molecularly targeted agents hold the promise of 
greater selectivity and hence increased ef!cacy associated 
with lower toxicity than traditional chemotherapy. Tar-
geting angiogenesis and DNA repair pathways are two 
intensively exploited areas. Here, we summarise the key 
results and concepts of PARP inhibitors. 
There are distinct DNA repair pathways that exist to 
repair DNA lesions which are essential for cell viability 
(2). BRCA1 and BRCA2 are critical for the maintenance 
of genome integrity.  They are important for the DNA 
repair of double-strand breaks (DSBs) using the homolo-
gous recombination (HR) pathway. Cancer cells that are 
de!cient in BRCA1 or BRCA2 function utilise alternative 
pathways for the repair of DSBs, such as non-homologous 
end-joining (NHEJ) which leads to chromosome instabil-
ity. This is increased by DNA-damaging agents such as 
platinum that induce DSBs leading to chemosensitivity. 
PARP (Poly ADP ribose polymerase) inhibitors have 
shown exceptional activity in women with BRCA muta-
tion–associated ovarian cancer and represent a therapeutic 
approach that exploits the concept of «synthetic lethality» 
- the situation where two defects acting individually have 
little effect, but when combined become lethal. PARP 
inhibitors block PARP proteins which facilitate the re-
pair of single-strand DNA breaks (SSBs). This leads to 
accumulation of SSBs and can generate DSBs that require 
repair by HR.  Therefore, when PARP inhibitors are used 
in a HR de!cient background (such as BRCA1 or BRCA2 
mutation), this results in the generation of DNA lesions 
that cannot be effectively repaired, leading to cell cycle 
arrest and/or cell death. 
In addition to germline BRCA1 and BRCA2 mutations, 
there are other causes of HR de!ciency that can result in 
cancers having BRCA-like behaviour - a phenomenon 
termed ‘BRCAness’ (3). These include somatically ac-
quired BRCA1/2 mutations, BRCA methylation (epigen-
etic silencing) and dysfunction of other genes involved 
in HR. Up to 50% of patients with high grade serous 
ovarian carcinoma (HGSOC) show HR de!ciency (4). The 
majority of ovarian cancer cases are sporadic with approxi-
mately 10% considered familial. Up to 90% of hereditary 
ovarian cancer cases are caused by mutations in BRCA1 
or BRCA2. Furthermore, over 15% of sporadic cases of 
HGSOC (without a family history) are associated with a 
germline BRCA mutation (5). 
Evidence to support the treatment of BRCA-de!cient tu-
mours with PARP inhibitors was demonstrated in land-
mark preclinical studies (6) which led to the concept be-
ing developed into clinical trials.
In 2009 Fong et al (7) reported results from a phase 1 
study for the PARP inhibitor, olaparib in a group of pa-
tients with advanced solid tumours enriched for the pres-
ence of a BRCA1/2 mutation. The drug was generally 
well tolerated with minimal adverse effects (mostly gas-
troinstestinal and fatigue) and encouraging single-agent 
anticancer activity in BRCA1/2 mutation carriers; 9/19 
(47%) partial responses, including 8 patients with ovarian 
cancer; 63% (12/19) derived clinical bene!t from olapa-
rib, providing proof of concept in the clinic for synthetic 
lethality.  The study was expanded to include 50 patients 
with BRCA1/2 ovarian cancer (8). Of note, the results sug-
gested that responses to PARP inhibition decreased with 
platinum resistance, with clinical bene!t rate of 69% for 
platinum-sensitive, 45% for platinum-resistant and 23% 
for platinum-refractory disease.
These encouraging results led to the development of phase 
II studies in ovarian cancer. Audeh et al demonstrated ef-
!cacy (33% RECIST response at 400 mg bd) and toler-
ability of olaparib in germline BRCA-mutated recurrent 
ovarian cancer which included platinum-resistant patients 
(9).  Gelmon and colleagues provided evidence for a wider 
use of PARP inhibitors based on the fact that up to 50% 
of high-grade serous, sporadic ovarian cancers have defec-
tive HR.  In this study patients with high-grade serous 
ovarian cancer without germline BRCA1/2 mutations also 
achieved clinical responses (50% in platinum-sensitive 
group (10).
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Given the encouraging tolerability and ef!cacy, the next 
step was to pursue PARP inhibitors as maintenance therapy. 
In a randomised, double-blind, placebo-controlled phase 2 
trial in which patients with platinum-sensitive, recurrent, 
high-grade serous ovarian cancer were randomised to ei-
ther olaparib or placebo maintenance therapy (following a 
response from their most recent platinum-based regimen), 
olaparib maintenance treatment signi!cantly improved pro-
gression-free survival (median 8.4 months vs. 4.8 months 
(HR 0.35, p<0.0001)). An interim analysis has shown no 
overall survival bene!t so far (11). Amongst BRCA mu-
tated patients, the median PFS was signi!cantly longer in 
the olaparib group than in the placebo group (11.2 months 
vs 4.3 months HR 0.18, p<.0001). Bene!t was also seen 
in the BRCA non-mutated group although the magnitude 
of PFS prolongation was less (7.4 vs 5.5 months; HR 0.54, 
p=0.008).  The lack of overall survival bene!t so far (data 
immature) may be in part due to the fact that a signi!cant 
proportion of patients in placebo group received a PARP 
inhibitor post-progression. 
Several phase III studies  (eg. SOLO1, SOLO2, ARIEL3 
and NOVA) are currently addressing maintenance PARP 
inhibitors in BRCA and non-BRCA mutated ovarian 
cancer.
Combination strategies of PARP inhibitors with chemo-
therapy, radiotherapy or other targeted agents are under 
evaluation.  A potential limitation is increased myelosup-
pression with chemotherapy. The preliminary results of the 
!rst randomised study of a PARP inhibitor (olaparib) in 
combination with an antiangiogenic agent (cediranib) in 
platinum-sensitive ovarian cancer were presented at ASCO 
2014 (12). There was a signi!cant improvement in the me-
dian PFS (17.7 months vs 9.0 months HR 0.42, p=0.005) 
and response rate (80% vs 48%, p=0.002) for the olaparib/
cediranib arm compared to olaparib alone. Grade 3/4 toxic-
ity was sign!cantly higher for patients in the combination 
arm (70% vs 7%) (12). Studies evalating PARP inhibitors 
with PI3kinase pathway agents are underway.
There are approximately 40 clinical trials of PARP in-
hibitors ongoing. Table 1 lists the phase II/III trials in 
ovarian cancer. Important issues for the development of 
PARP inhibitors are patient selection (BRCA mutated 
only or wider population?) and drug resistance. Key 
questions include: Single agent PARP inhibitors versus 
combination strategies? When is the best time to use 
PARP inhibitors?- maintenance vs treatment, !rst line 
vs recurrent disease, platinum-sensitive vs role in plati-
num-resistant disease?




Olaparib III SOLO-2: Maintenance treatment in relapsed platinum-sensitive disease NCT01874353
Olaparib III SOLO-1: Maintenance monotherapy following !rst line platinum-based chemotherapy. NCT01844986
E7449 I/II Single agent treatment in platinum sensitive/resistant ovarian cancer NCT01618136
BMN 673 I/II Single agent treatment in platinum –sensitive disease NCT01989546
Niraparib III NOVA: Maintenance monotherapy following chemotherapy in platinum-sensitive relapsed disease NCT01847274
Veliparib I/II Single agent treatment in platinum-resistant or partially platinum-sensitive relapse NCT01472783
Rucaparib I/II Single agent treatment in platinum-sensitive disease NCT01482715
Rucaparib II ARIEL-2: Single agent treatment in platinum-sensitive relapsed disease NCT01891344
Rucaparib III ARIEL-3: Maintenance monotherapy following chemotherapy in platinum-sensitive relapsed disease NCT01968213
Chemotherapy 
combination Veliparib I/II




Combination treatment with Cediranib Maleate (VEGFR 
inhibitor) in recurrent/metastatic diesease NCT01116648
Table 1: Phase II/III clinical trials of PARP inhibitors in ovarian cancer.
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An application for the use of olaparib in BRCA mutated 
platinum-sensitive ovarian cancer has already been sub-
mitted to the European Medicines Agency (based on the 
phase II results). Hopefully, PARP inhibitors will be stan-
dard of care for BRCA mutated ovarian cancer in 2015.
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The working group 
Gynecological tumors of 
the SAKK: so far so good!
Cristiana Sessa, Co President of the WG  
Gynecological tumors
There has always been a remarkable interest for gyneco-
logical tumors in the Swiss Group for Clinical Cancer Re-
search (SAKK). The !rst successful results, which were 
published in Cancer, were achieved already in the 45/81 
study (Melphalan IV and cisplatin in stage III-IV ovarian 
cancer) chaired by A. Goldhirsh. Despite this success, and 
because of a variety of reasons ranging from changes in the 
membership to lack of interesting studies, from low pa-
tients’ accrual to competition with the private sector, the 
activity and the interest for the group steadily decreased 
until its end in 2003. 
Since 2009, however, a lively discussion was carried out in 
the SAKK board in order to explore the possibility of res-
urrecting the group. The result was the proposal of a new 
structure which could re#ect the multimodal approach of 
gynecological cancers and the well established clinical sit-
uation of a joint clinical management with gynecologists 
and gyneco-oncologists.
The development of a working group composed by medi-
cal oncologists and gyneco-oncologists was proposed by the 
President of the SAKK Prof. B. Thürlimann to Prof. D. 
Fink, President of the Swiss AGO Group, who accepted it.
The start
On the 26th November 2011, during the semiannual 
meeting of the SAKK in Basel, the new working group, 
called Gynecological Tumors Group, was founded. The !rst 
meeting of the new group was attended by many new par-
ticipants and the discussion was intense. Prof. B. Thür-
limann presented the Gynecological Tumors Group to the 
audience and Prof. C. Sessa introduced its aims.
Prof. C. Sessa (SAKK) and PD M. Fehr (AGO) were ap-
pointed representatives of the Group. They were respon-
sible for the organization of the next steps, namely the 
preparation of new proposals for the SAKK Board, the 
organization of future meetings, and so on. Moreover, 
they were the contact persons between the SAKK and the 
Group.
The Group discussed the INOVATYON trial (a trial con-
cerning ovarian cancer sponsored by the group Mango 
in Italy), which was presented to the SAKK board for 
!nal assessment in January 2012; moreover three other 
trials of the ENGOT group were discussed. The Group 
wished that SAKK joined an international group such as 
ENGOT* or ICON.
Current situation (June 2014)
Fourteen (out of 22) SAKK centers are today participat-
ing in the Group: for each center a team of   one dedicated 
medical oncologist and one gynecologist has been identi-
!ed and is of reference to the Group.
The application for membership to ENGOT was accepted 
in January 2014. The Gynecogroup is participating to 
two studies, the ENGOT-ov17 Mito 16/Mango and the 
ENGOT-ov 5 Inovatyon in ovarian cancer:
• The MITO-16/MANGO-ENGOT-ov17 study is an 
academic phase III study promoted by the Univer-
sity of Naples to evaluate, in patients with platinum 
sensitive ovarian cancer, whether the continuation of 
Bevacizumab, which was part of the initial treatment, 
is of bene!t at the time of the !rst recurrence. The 
study commitment is of 400 patients over 24 months. 
The SAKK declared an accrual of 30 patients.
• The Inovatyon ENGOT-ov5 study is an academic 
phase III study promoted by the Italian MANGO 
group to compare the ef!cacy of a combination with 
platinum versus a combination without platinum in 
the 2nd-3rd treatment of partially platinum sensitive 
ovarian cancer patients. The study commitment is of 
588 patients over 3.5 years, the SAKK declared an 
accrual of 40 patients.
In addition, the group is participating to the AGO proj-
ect for a registry on quality of surgery in ovarian cancer.
Future plans include the active participation to the trans-
lational working group of ENGOT, the development of 
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phase II studies with new antitumor drugs, the participa-
tion to !rst line international phase III studies in ovar-
ian cancer and the implementation of other new ENGOT 
studies, in particular in endometrial and cervical cancer.
Collaboration with international groups is essential for 
keeping alive the group and for making members aware 
of the most recent achievements in gyneco-oncology.
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ENGOT (European Network of Gynecological 
Oncological Trial Groups) is a network of national 
and regional clinical trial units that coordinates 
and promotes clinical trials in Europe in patients 
with gynecological cancers. This coordination is 
relevant for academic clinical trials, translational 
research and research on rare diseases and for com-
pany-sponsored clinical trials to perform multina-
tional studies in Europe. The ultimate goal is to 
bring the best treatment to gyneco cancer patients 
through the best science, and enabling every pa-
tient in every European country to access a clinical 
trial. Currently 20 European cooperative groups 
are participating to ENGOT studies.
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Brustkrebs und Sexualität: 
Eine Übersicht
Eliane Sarasin Ricklin, Gynäkologie und Geburtshilfe, 
Brust-Zentrum, Zürich
Brustkrebs ist die häu!gste Krebserkrankung der Frau, 
und weiterhin nehmen die Krankheitsfälle zu. Erfreuli-
cherweise haben Früherkennung und innovative Behand-
lungsmöglichkeiten die Prognose in den letzten Jahr-
zehnten deutlich verbessert, so dass die psychosozialen 
Konsequenzen der Erkrankung und somit die Lebensqua-
lität der sogenannten «Survivors» in den Fokus rücken. 
Dazu gehört auch die zunehmende Beachtung des Ein-
#uss von Brustkrebs und dessen Behandlung auf die Se-
xualität der betroffenen Frau. Die Brust gilt in unserer 
Gesellschaft seit jeher als ein Symbol der Weiblichkeit, 
sexuellen Attraktivität und Fruchtbarkeit. So erleben die 
Frauen nebst der Erschütterung durch die potentiell le-
bensbedrohliche Erkrankung den Brustkrebs als direkten 
Angriff auf die eigene Erotik. Dass sich dies folglich auch 
störend in der individuell gelebten Sexualität und Part-
nerschaft auswirken kann, erstaunt nicht.
Wie beein!usst die Brustkrebserkrankung sowie  
deren Behandlung die weibliche Sexualität?
Im Vordergrund stehen häu!g sexuelle Funktionsstö-
rungen durch die adjuvanten Therapiemassnahmen. 
Ebenso fühlt sich die Frau durch den schmerzlich emp-
fundenem Verlust an weiblicher Attraktivität und Erotik 
in ihrer sexuellen Identität getroffen. Das Gefühl «keine 
vollwertige Frau mehr zu sein» begründet sich durch den 
Verlust der Körperintegrität nach Operation sowie die 
oft vorzeitig herbeigeführte Menopause mit Sistieren der 
Blutungen und Unfruchtbarkeit. Hinzu kommen gegebe-
nenfalls passagere Veränderungen des Erscheinungsbildes 
wie Alopezie, Verlust der Wimpern und Schamhaare 
sowie Gewichtsveränderungen unter Chemotherapie. 
Nachweislich haben alle diese Faktoren einen negativen 
Ein#uss auf das sexuelle Erleben wie auch die sexuelle Zu-
friedenheit der Frau. Die Krankheit trifft immer auch das 
Umfeld und insbesondere den Partner der von Brustkrebs 
betroffenen Frau. Dieser spielt nicht nur eine bedeutende 
Rolle in der Unterstützung der erkrankten Partnerin, son-
dern erfährt selbst eine emotionale Belastung. Die Angst 
durch die ungewisse Prognose der Krankheit sowie neue 
Verp#ichtungen im Rahmen der Fürsorge stehen im Vor-
dergrund und verdrängen das Verlangen nach Intimität. 
Diese rücksichtsvoll intendierte Zurückhaltung des Part-
ners wird oft von der Frau als Abweisung erlebt, die sie 
als Bestätigung, nicht mehr begehrenswert zu sein, inter-
pretiert. Die Spontaneität und Leichtigkeit im Umgang 
des Paares miteinander geht verloren und führt dazu, dass 
nicht nur jede Form von Sexualität, sondern auch Zärt-
lichkeit und Körperkontakt vermieden werden und die 
Distanz auch emotional erlebt wird.
Eine spezielle Risikokonstellation: die junge 
Brustkrebspatientin
Es gilt zu beachten, dass insbesondere die junge Brust-
krebspatientin ein erhöhtes Risiko für sexuelle Störungen 
aufweist. Obwohl glücklicherweise in der Minderzahl, 
müssen sich diese Frauen mit zusätzlichen Schwierigkeiten 
auseinandersetzen. Das junge Erkrankungsalter bedingt 
häu!ger eine intensive Chemotherapie, eventuell in Kom-
bination mit einer zunehmend längerdauernden Antihor-
montherapie und dem Risiko der konsekutiven Ovarialin-
suf!zienz. Oft ist die Familienplanung zum Zeitpunkt der 
Diagnose nicht abgeschlossen, oder es besteht gar keine 
feste Partnerschaft. Die Partnersuche für die Single-Frau 
mit einer Brustkrebsdiagnose in der Biographie wird noch 
schwieriger, als sie schon war. Dazu haben junge Frauen 
noch keine Erfahrungen mit körperlichen Altersverände-
rungen und akzeptieren ihren durch die chirurgische The-
rapie versehrten Körper mit grösserer Mühe. Nicht selten 
müssen sich diese Frauen noch zusätzlich der Frage nach 
einer genetischen Mutation stellen mit der emotionalen 
Belastung einer Testung und deren Konsequenzen.
Was sind die häu"gsten sexuellen Störungen bei 
Brustkrebs?
Die hohe Störanfälligkeit der Sexualität in der bereits ge-
sunden Bevölkerung erstaunt nicht, dass sich diese durch 
die schwere Erkrankung noch deutlicher zeigt. Bis zu 70% 
der betroffenen Frauen geben eine Verschlechterung ihres 
sexuellen Lebens an. Am häu!gsten wird eine Abnahme 
des sexuellen Verlangens beklagt, Erregungsstörungen 
und Schmerzen beim Verkehr schliessen sich an und sel-
tener kommt es auch zu Schwierigkeiten, einen Orgasmus 
zu erlangen oder dessen komplettem Ausbleiben. Der Lei-
densdruck der Frauen ist unterschiedlich ausgeprägt in 
Abhängigkeit vom Beziehungsstatus, der Partnerschaft-
dauer und nicht zuletzt dem Alter der Patientin.
Den grössten Ein#uss auf die Frequenz und Intensität 
von sexuellen Funktionsstörungen hat der Einsatz der 
Chemotherapie in der Brustkrebsbehandlung. Nebst 
der transienten oder permanenten iatrogenen Meno-
pause mit lokaler Atrophie, leiden die Frauen häu!g 
zusätzlich unter Erschöpfung, Nausea und rezidivie-
renden Vaginalinfektionen bei Immunsuppression. 
Nicht zu unterschätzen sind ebenso Alopezie, Verlust 
der Wimpern und Brauen sowie die häu!ge Gewichts-
zunahme, welche die Krankheit sichtbar und öffentlich 
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machen, während sich die Narben nach Operation bes-
ser verdecken lassen.
Die alleinige antihormonelle Therapie wird meist als we-
niger belastend erlebt, insbesondere bei bereits vor der Er-
krankung erreichter Menopause. Im Vordergrund stehen 
Schmerzen beim Geschlechtsverkehr durch den lokalen 
Hormonentzug und eine verminderte Lubrikation, wel-
che als direkte Konsequenz einen Verlust des sexuellen 
Verlangen nach sich ziehen. Es erstaunt nicht, dass Aro-
matasehemmer deutlich mehr sexuelle Probleme verursa-
chen als Tamoxifen, welches zumindest durch den parti-
ellen Oestrogen-Effekt weniger lokal atrophierend wirkt.
Der Ein#uss der chirurgischen Brustkrebsbehandlung 
ist weniger eindeutig. Entgegen der gängigen Vorstel-
lung werden sexuelle Funktionsstörungen weniger durch 
den Operationsmodus, sondern deutlicher durch die me-
dikamentöse Therapie (insbesondere Chemotherapie) 
beein#usst. Unbestritten hat die Wahl des operativen 
Vorgehens jedoch einen wesentlichen Ein#uss auf das 
Körperbild und auf die emotionale Verarbeitung der ia-
trogenen Veränderung sowie auf das Sexualverhalten und 
die Lebensqualität der betroffenen Frau. Gerade in un-
serer Gesellschaft, die den Wert einer Frau an Jugend und 
Schönheit misst, leiden insbesondere die jüngeren Patien-
tinnen an der verlorenen Unversehrtheit ihres Körpers. Ei-
nige Studien konnten eine grössere Beeinträchtigung der 
Sexualität bei Mastektomie gegenüber der Brusterhaltung 
zeigen, insbesondere bei Frauen, welche ihr Selbstbild in 
hohem Mass auf ihre äusserliche Erscheinung abstützen. 
Der Ein#uss der Brustrekonstruktion wird trotz des deut-
lichen Vorteils durch Verzicht auf eine externe Prothese 
und #exiblere Kleiderwahl eher überschätzt. Die Frauen 
emp!nden die rekonstruierte Brust zwar als «Silhouetten-
Korrektur», eine «Ich-Zugehörigkeit» fehlt hingegen 
häu!g, nicht zuletzt auch durch den Sensibilitätsverlust 
der einst erogenen Zone. Objektiver Befund und subjek-
tive Be!ndlichkeit können postoperativ deutlich ausei-
nander klaffen, was manchmal von ärztlicher Seite schwer 
zu verstehen ist. Ein wichtiger protektiver Faktor für die 
Anpassung an ein verändertes Körperbild ist der Mitein-
bezug der Patientin in den Entscheidungsprozess über das 
operative Vorgehen.
Zur vorherrschenden Praxis der Sexualberatung bei 
Brustkrebs
Obwohl Sexualität in unserer Gesellschaft heute sehr 
präsent ist, bleibt das eigene Sexualleben ein sehr per-
sönliches Thema. Insbesondere sexuelles Versagen wird 
tabuisiert. Auch in der Beziehung zwischen Arzt und 
Patientin !ndet das Gespräch über sexuelle Folgen der 
Brustkrebsdiagnose wenig Platz, obwohl von Seiten der 
Frauen ein grosses Bedürfnis besteht. Nicht nur in der 
frühen Phase der Diagnose und Primärbehandlung, wo 
das Thema vielleicht vernachlässigbar erscheinen mag, 
sondern auch in der Nachsorge wird die Patientin häu-
!g nicht auf eine mögliche Veränderung der Sexualität 
angesprochen. Als Gründe dafür geben Ärzte ungenü-
gende sexualmedizinische Kenntnisse, Zeitmangel aber 
auch Hemmungen, dieses heikle Thema anzusprechen, 
an. Es wäre jedoch wünschenswert, dass das behandelnde 
Team über mögliche Auswirkungen der Erkrankung und 
deren Behandlung auf das Sexualleben aufklärt wie über 
jede andere Nebenwirkung auch. Wenn Patientinnen die 
Gesprächsbereitschaft ihres behandelnden Arztes für se-
xuelle Anliegen erleben, fühlen sie sich entlastet und ha-
ben auch zu einem späteren Zeitpunkt die Möglichkeit 
darauf zurückzukommen. Selbstverständlich gehört die 
Aufklärung über mögliche supportive Massnahmen, ins-
besondere in Bezug auf die genitale Atrophie, dazu. Be-
sonders wichtig ist das Angebot, auf Wunsch den Partner 
in die Beratungsgespräche einzubeziehen. Die häu!g ein-
geschränkte Kommunikation über sexuelle Probleme und 
Wünsche kann so in einem sicheren Rahmen in Richtung 
einer grösseren Offenheit gefördert werden. Manchmal 
reicht ein stützendes ärztliches Gespräch nicht aus, insbe-
sondere bei bereits vor der Brustkrebsdiagnose bestehen-
der sexueller Unzufriedenheit oder Paarproblematik. Hier 
ist eine Überweisung an einen sexual- und paartherapeu-
tisch erfahrenen Psychotherapeuten oder Sexualmediziner 
sinnvoll.
Ich danke Herrn Prof. Dr. phil. U. Clement, Leiter des 
Instituts für Sexualtherapie Heidelberg für das sorgfältige 
Durchlesen des Artikels und seine konstruktiven Anre-
gungen.
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University Professional Sexual Medicine/Therapy
Brust-Zentrum, CH-8008 Zürich
e.sarasin@brust-zentrum.ch
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Frauen mit vulvären Neoplasien 
können mit diesem Instrument 
erstmals ihre Erfahrungen nach 
einem chirurgischen Eingriff stan-
dardisiert einschätzen. Zusätzlich 
kann es im klinischen Assessment 
zur systematischen Erfassung von 
zentralen Symptomen und Infor-
mationsbedürfnissen unterstützend 
zum Einsatz kommen. Das Instru-
ment verfügt über eine hervorra-
gende Inhaltsvalidität (CVI=1.0) 
und lässt eine reliable Messung 
der Symptom erfahrung (wund-
bedingte Symp tome:  = 0.81, 
Schwierigkeiten im täglichen Le-
ben:  = 0.74 und psychosoziale 
Symptome:  = 0.90) zu (Senn et 
al., 2012).
Darüber hinaus kann das Assess-
ment-Tool in Studien als Messin-
strument der Symptomprävalenz 
und -erfahrungen eingesetzt wer-
den. Hierzu wurde es erstmals 
im Rahmen eines Mixes-Methods 
Projektes mit 65 Frauen mit vul-
vären Neoplasien aus jeweils vier 
Kliniken in der Schweiz (Zürich, 
Basel, Bern, St. Gallen) und in 
Deutschland (Berlin, Düsseldorf, 
Freiburg, München), welche dort 
zwischen Oktober 2010 und Ok-
tober 2011 behandelt wurden, ge-
nutzt. Die durchschnittliche An-
zahl der Symptome lag bei 20,2 
(Standardabweichung 5.77), pro 
Patientin wurden 5 bis 31 Symp-
tome angegeben. Die drei häu-
!gsten wundbedingten Symp tome waren «Schwellung» 
(n=56), «Flüssigkeitsaustritt» (n=54) und «Schmerz» 
(n=52), während bei den Schwierigkeiten im Alltag «Sit-
zen» (n=63), «Kleider tragen» (n=56) sowie «Ausführen 
der Alltagstätigkeiten» (n=51) und bei den psychosozi-
alen Problemen «Müdigkeit» (n=62), «Unsicherheit» 
(n=54) und «Gefühl, dass sich der Körper verändert hat» 
(n=50) am häu!gsten auftraten (Senn et al., 2013). 
Zukunftsoptionen für Frauen mit vulvären Neoplasien
Die hohe Anzahl an belastenden postoperativen Symp-
tomen unterstreicht die Wichtigkeit eines strukturierten 
Assessments im Rahmen regelmässig statt!ndender 
SCHWERPUNKTTHEMA
Symptomassessment und 
-management bei Frauen 
mit vulvären Neoplasien
Status quo und künftige 
Entwicklungen
Andrea Kobleder, Silvia Raphaelis, Beate Senn
Ein systematisches Symptomassessment bildet bei Frauen 
mit vulvären Neoplasien die Basis für ein optimales Symp-
 tommanagement. Der Einbezug der Patientinnensichtweise 
ist die Bedingung für einen effektiven Betreuungsprozess. 
Frauen mit vulvären Neoplasien stellen unter den Pati-
entinnen mit gynäkologischen Tumoren eine vergleichs-
weise kleine Gruppe dar. Die Inzidenzrate von Vulvären 
Neoplasien, welche vulväre intraepitheliale Neoplasien 
(VIN) und das Vulvakarzinom beinhalten, beträgt  in 
Deutschland und der Schweiz ungefähr 2-7 pro 100.000 
Frauen pro Jahr (Deutsche Gesellschaft für Gynäkologie 
und Geburtshilfe, 2010). In der Therapie dieser Erkran-
kung konnten in den vergangenen Jahren große Fort-
schritte erzielt werden (Gray, 2010). Da die minimal in-
vasive Chirurgie jedoch ebenfalls vielfältige postoperative 
Symptome verursachen kann (Kaushik, Pepas & Nordin, 
2011) und zu vergleichsweise kurzen Krankenhausaufent-
halten führt (Oncosuisse, 2011), müssen die Patientinnen 
über die Entlassung hinaus bestehende oder später auf-
tretende Symptome selbst beobachten, einschätzen und 
behandeln sowie hierfür notwendige Symptommanage-
ment-Kompetenzen innerhalb kurzer Zeit erlernen. 
Der erste wesentliche Schritt für ein optimales Sym-
ptommanagement ist eine systematische Symptomer-
fassung. Diese kann grundsätzlich aus einem klinischen 
Assessment durch Fachpersonen und/oder den Berichten 
der Patientinnen selbst über ihre Gesundheit bzw. Sym-
ptome (patient reported outcomes = PRO) bestehen. Da 
Frauen mit vulvären Neoplasien ihre postoperativen Sym-
ptome nach der Entlassung überwiegend selbst behandeln 
müssen und Symptome in der klinischen Praxis häu!g 
unterschätzt werden, ist hier vor allem eine selbstein-
schätzende Symptomerfassung relevant. Denn diese kann 
grundlegende Informationen aus der Perspektive der Pa-
tientinnen über die Wirksamkeit und die Konsequenzen 
der Symptombehandlung liefern. Bislang stand jedoch 
kein entsprechendes Assessmentinstrument für diese Pa-
tientinnen zur Verfügung. Deshalb wurde im Jahr 2010 
mit 20 Betroffenen und 9 Fachexpertinnen und -exper-
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Follow-Up Termine zwischen den Patientinnen und dem 
interprofessionellen Team. Eine Kombination aus PRO- 
und klinischem Assessment kann massgeblich zur Ver-
besserung der Situation betroffener Frauen beitragen und 
Hinweise zu Massnahmen, die das Selbstmanagement un-
terstützen liefern. Um das Wissen, die Motivation und die 
Handlungen der Patientinnen zu unterstützen, empfehlen 
wir eine Beratung durch eine/n P#egeexpertin bzw. -ex-
perten. Diese Beratungen sollten komplementär zu den 
ärztlichen Konsultationen statt!nden und können einen 
wichtigen Beitrag zur optimierten Symptombehandlung 
und Früherkennung von Komplikationen liefern. Zurzeit 
wird in einem internationalen Projekt der Fachhochschu-
le St.Gallen, der WOMAN PRO II Studie (Clinical Trial 
ID: NCT01986725) ein komplexes Beratungsprogramm 
durch eine P#egende mit erweiterte bzw. spezieller Ex-
pertise, einer sogenannten Advanced Practice Nurse 
(APN) getestet. Die Studie wird von 2013 bis 2016 in 
der Schweiz, in Österreich und Australien durchgeführt. 
Um die Qualität der p#egerischen Beratung zu de!nieren, 
wurden clinical pathways für die Patientinnen beschrieben 
und eine evidenzbasierte Leitlinie mit 44 Empfehlungen 
entwickelt. Die Empfehlungen fokussieren die Themen-
bereiche Symptom Selbst-Assessment, Operationswunde 
und Vulvap#ege, postoperativer Schmerz, postoperative 
Müdigkeit, postoperative Miktionsprobleme, Schwierig-
keiten beim Sitzen, Kleider tragen sowie beim Ausführen 
alltäglicher Handlungen, Lymphödem, Unsicherheit und 
Körperbild. 
Nebst der Überprüfung der Wirkung der Beratung soll 
eine Kosten-Nutzen-Analyse erfolgen. Ziel dieser Analyse 
ist, relevante wirtschaftliche Fragestellungen im Rahmen 
der WOMAN PRO II Studie zu beantworten. Es soll dar-
gelegt werden, welche Kosten für unterschiedliche Be-
treuungsansätze aufgewendet werden müssen und welche 
Betreuungsart zu weniger postoperativen Beschwerden 
führt.
Ferner wird insbesondere für jüngere Patientinnen eine 
Web-Applikation (App) entwickelt. Sie soll den Patien-
tinnen zusätzlich zum persönlichen Kontakt mit den Ge-
sundheitsfachpersonen aktuelles und verlässliches Wissen 
zur Erkrankung rund um die Uhr niederschwellig und 
unabhängig zur Verfügung stellen. Die App könnte die 
Patientinnen hierdurch nicht nur in ihrem Selbstmanage-
ment und ihrer Lebensqualität unterstützen, sondern auch 
die Hürde über eine zumeist tabuisierte Erkrankung zu 
sprechen, minimieren. Durch eine Social Network Funk-
tion haben die Patientinnen ausserdem die Möglichkeit, 
mit anderen Betroffenen in Kontakt zu treten und Erfah-
rungen auszutauschen. 
Die genannten Projekte unterstützen Frauen mit vulvären 
Neoplasien in ihrem Symptommanagement und tragen 
zur Enttabuisierung der Erkrankung bei. 
Die Autorinnen bedanken sich bei allen Beteiligten, die 
für das Gelingen des Projektes wesentlich waren und sind. 
Besonderer Dank gilt den Patientinnen für ihre Offenheit, 
den Fachpersonen und Kliniken für die Unterstützung bei 
der Datensammlung, den IT Expertinnen und -experten 
für die Weiterentwicklung des Symptom-Assessment-
Tools, und den Gesundheitsökonomen für die Planung 
der Kosten-Nutzen-Analyse. 
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Introduction 
Bone metastases represent a frequent and challenging 
clinical problem in the !eld of advanced cancer disease and 
the most common cause of cancer-related pain. According 
to the tumour type, their incidence may rank from 40% 
(lung, kidney) up to 70% (prostate and breast cancer) but 
major concerns also exist for many other cancer types [1]. 
Pathophysiologically three different types of bone metas-
tases can be characterized, resulting in different radio-
logical features: osteoblastic (high bone tissue density), 
osteolytic (low bone tissue density) and «mixed type» 
metastases. Over their prognostic signi!cance inside the 
disease course, bone metastases usually generate problems 
and complications that may produce a signi!cant impact 
on quality of life (pain, fractures) or even be life threaten-
ing under some circumstances (hypercalcemia, fractures, 
spinal cord compression). Furthermore they still repre-
sent a signi!cant cause of increased medical consultations, 
emergency room and hospital admissions. Their onset may 
interfere with or even delay the timing of an appropriate 
administration of cancer therapies. 
Following these and other reasons, an early, proper and 
unavoidably multidisciplinary management of this onco-
logical challenge and of its related complications, should 
be considered mandatory in the modern cancer medicine. 
Pathophysiology 
Osteolytic metastases are characterized by the release 
of osteoclastogenic agents by tumor cells in the bone 
microenvironment and the osteoblastic metastases are a 
direct consequence of the release of factors that stimu-
late osteoblast proliferation, differentiation and sub-
sequently uncontrolled bone formation by metastatic 
cancer cells [2]. More recent studies have highlighted 
the importance of the bone microenvironment and the 
interactions with tumor cells. To generate bone metas-
tases, cancer cells must intravasate and survive into cir-
culation, attach to the vascular endothelium, extrava-
sate and proceed with colonization into the bone. The 
bidirectional interaction of bone cells with cancer cells 
in the production of bone metastases is characterized 
by a complex release of osteolytic mediators, such as 
TGF- , parathyroid hormone related peptide (PTHrP), 
RANKL, proteases like cathepsins and matrix metal-
loproteinases, and osteoblastic mediators with a large 
variety of growth factors. Fibroblast-, platelet- and in-
sulin-like growth factors, are important actors known in 
the metastasizing process [3, 4, 5].
Diagnosis and imaging
Diagnostic imaging has a primary role in the detection, 
diagnosis, treatment planning and, later, follow-up of 
bone metastatic disease. Secondary bone lesions can be 
found at every site, but more often, in decrescent percent-
age, in vertebrae, pelvis, proximal femur and proximal 
humerus and skull. Other diagnostic modalities are in 
the !eld of Nuclear Medicine: Technetium-99m (99m Tc) 
scintigraphy and #uorodeoxyglucose (FDG) positron 
emission tomography (PET) scanning.
Plain X-ray !lm is an easy and low cost imaging meth-
od, with good speci!city but low sensibility to bone le-
sions [6]. Lesions can appear as osteolytic, osteosclerotic or 
mixed lesions, often suggesting the nature of the primary 
tumor. While plain !lm is of low utility in the detection 
of new lesions, it remains a good instrument in the follow-
up of known lesions especially in peripheral sites.
Computed Tomography (CT) is far much superior to plain 
!lm in the detection of bone lesions but has low sensi-
tivity to early lesions, that only involve bone marrow. 
The use of contrast media can give some more informa-
tion, especially on associated masses, in particular about 
the relationships with adjacent vessels and nerves, but in 
any case sensitivity remains low. Metser et al. [7] made 
a retrospective review to compare CT and FDG-PET in 
the assessment of secondary malignant involvement of the 
spinal column. Of 242 lesions detected on PET/CT, PET 
identi!ed 220 lesions and CT identi!ed 159. For both 
PET alone and CT alone speci!city was 56%. On a pa-
tient-based analysis, the sensitivity of PET and of PET/CT 
for the detection of spinal metastasis was 98% and 74%, 
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respectively (P<0.01). FDG-PET was more sensitive than 
CT in detecting spinal metastases in patients with known 
spinal metastases. One major drawback of CT is the rela-
tively high radiation dose; on the other hand neoplastic 
patients undergo staging CT examinations that usually 
covers the greatest part of the axial skeleton. Moreover CT 
is the best imaging modality for a guided biopsy of bone 
lesions and it is always needed when planning some inter-
ventional procedures as cementoplasty (see later).
Magnetic Resonance (MRI) has very high sensitivity to 
bone lesions: the routinary use of T1w, T2w and STIR 
images gives high sensitivity and high speci!city to 
MRI examinations in which bone lesions are usually 
hypointense in T1w images and hyperintense in T2w; 
results are better if Gadolinium (Gd) enhanced T1 Fat 
Suppressed images are taken with variable but usually 
high degree of contrast enhancement. MRI depicts early 
hematogenous dissemination of the tumor to the bone 
marrow before reactions in the adjacent bone are detect-
able even on 99m Tc scintiscans (sensitivities of 91.4% for 
MRI and 84.8% for bone scintiscanning) [8]. Flickinger 
and Sanal [9] reported sensitivities of 100% for MRI and 
62% for scintiscanning while speci!cities was of 62% 
for MRI and 100% for scintiscanning. Eustace et al. [10] 
reported for MRI and scintiscans, respectively, sensitivi-
ties of 96.5% and 72%, speci!cities of 100% and 98%, 
and positive predictive values of 100% and 95%. Lauen-
stein et al. [11] compared the results of whole-body MRI 
in patients with tumors, with staging based on results 
of CT, dedicated MRI, and nuclear scintigraphy as stan-
dards of reference. Whole-body MRI revealed sensitiv-
ity and speci!city values of 100%. It was more sensitive 
in the detection of hepatic and osseous metastases than 
were the reference techniques. 
In Nuclear Medicine, 99m Tc bone scintigraphy and FDG-
PET CT scanning are both effective methods in the 
research of occult secondary bone lesions. In case of an 
aspeci!c !nding an imaging procedure is needed (plain 
!lm, CT or MRI depending on site and dimensions of 
the suspected bone lesion) to con!rm and characterize 
the lesions. Both procedures have great sensitivity (high-
er for FDG PET-CT) but often low speci!city and poor 
spatial resolution so that complementary CT or, better, 
MRI examinations are required to localize and qualify 
areas of increased uptake. In a comparative study of 
MRI, FDG PET and 99m Tc bone scintigraphy Daldrup-
Link et al. [12] found sensitivities of 90% for FDG-PET 
scanning, 82% for whole-body MRI, and 71% for99m Tc 
bone scintiscanning. FDG-PET scanning shows a high 
number of false-positive lesions, which require follow-up 
imaging with other modalities. The use of semi-quanti-
tative criteria for tumor FDG uptake in the qualitative 
evaluation of images may increase the speci!city. In skull 
metastases, the high rate of glucose metabolism in the 
normal areas of brain may obscure metastases.
Management
The management of bone metastases evolved dramatically 
in the last decades, becoming a !eld where the applica-
tion of multidisciplinary competences represent a model 
for other !elds of oncology. In the following text we will 
focus on some aspects of the multimodal approach and re-
view the current status of scienti!c evidence.
Radiotherapy 
Radiotherapy and in particular External Beam Radio-
therapy (EBRT) is a widely accepted and effective way to 
palliate pain caused by bone metastases. It has few side 
effects and can provide signi!cant palliation of painful 
bone metastases in up to 60-70% of cases. Its underlying 
mechanism can be explained not just by a direct antitu-
mor effect which is particularly important if the tumour 
is radiosensitive, but also by radiation-induced inhibi-
tion of osteoclast activity and stimulation of osteoblast 
activity. It follows that its role in skeletal metastases is 
not only limited to the palliation of pain but it is also 
oriented to prevent impending fractures and/or cord de-
compression in cases where vertebral metastatic lesions 
extend into the spinal canal or the nerve root exits. The 
initial antalgic effect can be reached in 24 hours and the 
maximum effect in 3-4 weeks after EBRT. A transitional 
increase of pain is possible in a sub-acute phase (Flare 
effect). In the case of cord compression, results of radio-
therapy are closely linked to neurological status at time 
of treatment and patients who are already paraplegic, es-
pecially for over 48 hours, with loss of bladder control 
are unlikely to have neurological recovery with radiation 
[13]. All cases have to be urgently discussed within a 
multidisciplinary board in order to select those patients 
who will pro!t of an urgent surgical management. The 
Patchell’s randomised phase III trial demonstrated that 
surgery plus postoperative radiotherapy was superior to 
radiotherapy alone in patients with metastatic spinal 
cord compression. Nevertheless, those cases need to be 
carefully selected according to well de!ned prognosti-
cators, as histology, systemic disease extension and spi-
nal metastasis extension are [14]. As far as fractionation 
schemes/doses for pain relief are concerned, international 
practice guidelines now support the assertion that Single 
Fraction (SF) radiation therapy is the standard of care for 
the relief of pain due to uncomplicated bone metastases 
[15]. Trials that have compared different SF doses showed 
that higher doses indeed produce superior response rates. 
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The most commonly administered SF dose is by far 8 Gy. 
This dose should be the standard due to its reproducible 
pain response and retreatment rates, and its safety pro!le. 
However, if the aim of radiotherapy also contemplates 
prevention of impending fractures via recalci!cation, a 
30Gy/10fr scheme has been shown to have a signi!cantly 
higher effect, especially in patients with breast or pros-
tate histology. Prolonged fractionation is also associated 
with a longer duration of pain relief and should be con-
sidered in patients with a life expectancy (LE) above 6 
months [16]. A growing problem, as metastatic patients 
live longer, is pain due to recurrence even in previously 
irradiated bone. A recent review of 70 full-text articles 
has shown an overall response to retreatment «aequo 
loco» of 68 % [17]. This is comparable to the overall 
response for !rst radiation. The authors found that a re-
sponse to therapy is possible, even if the !rst irradiation 
failed. Data about an increased toxicity after a second 
irradiation couldn’t be detected in this review in one 
part due to the fact that adverse events and toxicity are 
poorly reported due to the decreased ability to properly 
assess acute toxicity of re-irradiation. The international 
Bone Metastases Consensus Working Party recommends 
a 4-week waiting time before considering re-irradiation. 
In conclusion, the results of this meta-analysis allow to 
answer «YES» to the question of the effectiveness of 
re-irradiation on interdisciplinary tumorboards. Fur-
thermore, the emergence of Stereotactic Body Radio-
therapy (SBRT), essentially an extracranial extension of 
radiosurgery, has greatly enhanced the safety pro!le and 
effectiveness re-irradiation of bony metastases [18]. We 
therefore recommend SF 8 Gy to uncomplicated pain-
ful bone lesions in patients with unfavourable prognostic 
factors or LE < 6 months and longer schemes (30Gy/10fr 
or similar) in cases with LE ≥ 6 months. Re-irradiation 
should be considered in case of recurrence in previously 
irradiated volumes. Radiometabolic treatment with Ra-
dium 223 dichlorid  has nowadays also an indication in 
the treatment  in prostate cancer castration resistant pa-
tients with diffuse asintomatic bone metastases in absence 
of visceral involvement. In fact there has been a fase III 
study who has demonstrated an improvement of time to 
!rst symptomatic skeletal event in comparison to placebo 
and an improvement on overall survival [19].
Bisphosphonates and Denosumab
Patients with bone metastases have increased osteoclastic 
activity resulting in local bone destruction, this leads to 
pain, hypercalcaemia and skeletal related events (SRE) as 
pathological fractures and spinal compression, which sig-
ni!cantly impact quality of life. Bone modifying agents, 
such as Bisphosphonates and Denosumab, inhibit the ac-
tion of the osteoclasts and this leads to less bone loss and 
decrease of the risk of fractures. 
Denosumab, an inhibitor of receptor activator of nuclear fac-
tor kappa-B (RANK) ligand, was superior to Zoledronic 
acid in many trials for bone metastases from solid tumors 
and it is generally well tolerated [20]. This fully human 
monoclonal IgG2 antibody is one of the best potential 
treatments for patients with bone metastases with the con-
venience of a subcutaneous injection and no requirement 
for renal monitoring (improved the time to the !rst and 
subsequent SREs when compared to Zoledronic acid) [20]. 
The recommended dose and schedule for Denosumab for 
the prevention of SREs is 120 mg every four weeks. Limita-
tions are cost and/or reimbursement. The use of Denosum-
ab is not approved  in Multiple Myeloma at the moment. 
The Bisphosphonates are analogs of pyrophosphate with af-
!nity for hydroxyapatite, the principal bone mineral, and 
that prevent the dissolution of mineral bone and conse-
quently prevent SREs. Particularly Zoledronic acid, given 
by 4 weekly intravenous infusion, seems to be the most 
ef!cacious Bisphosphonate, compared to Clodronate, 
Pamidronate, and Ibandronate (i.v. and oral), for reduc-
ing the risk of SREs in patients with breast or prostate 
cancer and with multiple myeloma [21]. A recent large 
randomized phase 3 trial showed that daily oral medica-
tion with Ibandronic acid 50 mg was inferior to monthly 
Zoledronic acid 4 mg in reducing SRE in patients with 
breast cancer but with the same acceptable side effects 
and less frequent renal toxic effects is another option in 
patients for whom the oral administration is preferable 
[22]. In a recent retrospective observational study in the 
USA Bisphophonates are reported as underutilized, espe-
cially in metastatic Prostate and Lung Cancer [23]. Previ-
ous analyses have shown that premature discontinuation 
of Zoledronic acid use was associated with higher monthly 
rates of skeletal complications [24]. 
Hypercalcemia is a common !nding in metastatic malignan-
cies. The local osteolysis due to metastases invasion of bone 
causes hypercalcemia (patients can have also hypercalcemia 
due to secreted factors, such as Parathyroid-related Hormone, 
or due to an excess of Vitamin D produced by malignancies). 
The mainstays of therapy are adequate intravenous saline in-
fusion and Bisphosphonates administration [25].
Cementoplasty
Percutaneous procedures as Cementoplasty/Osteoplasty 
and Ablation techniques as Coblation, Cryoablation, Ra-
diofrequency (RF), MicroWaves (MW), are possible alter-
natives, often used in association. 
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Vertebroplasty/Kyphoplasty (VP/KP) is a percutaneous inter-
ventional procedure established in early eighties by Galib-
ert, Deramond et al. [26] for the radiological percutaneous 
treatment of aggressive vertebral hemangiomas. VP is a 
radiological procedure in which a needle is inserted into 
a vertebra under radiological guidance (CT and/or #uoro-
scopic); through this access coaxial devices can be used in 
order to obtain bioptic specimens and/or insert cement, 
usually Poly-Methyl MethAcrylate (PMMA), or speci!c 
instruments inside the vertebral lesion. The whole proce-
dure is usually made in outpatients, in local anesthesia and 
intravenous sedation.
In selected Patients a ballon Kyphoplasty (KP) can be 
performed in order to obtain a non-surgical vertebral 
augmentation. Indications to VP and KP include: diag-
nosis (biopsy), pain palliation, stabilization, fracture ar-
rest and/or prevention, debulking and local control. The 
prevalent goals are anyway pain control and bone stabi-
lization. In patients with impending vertebral body col-
lapse VP/KP may improve patient outcomes over simply 
waiting for the vertebral body to fracture [27]; the pro-
cedure is effective in reducing pain, add stability, and 
can be combined with radiotherapy or chemotherapy. 
VP/KP improve function and quality of life, decreases 
morbidity and mortality [28, 29] and can be considered 
«as a !rst-line treatment for painful myelomatous verte-
bral disease. More easily than surgery, VP and KP can be 
combined with radiotherapy» [30]. Many authors agree 
that a multimodality approach for the management of 
metastatic bone disease includes VP/KP procedures and 
the majority of patients will have excellent palliation 
with this approach [31]. The complication rate is low 
and usually little or with no importance; the most com-
mon are linked to some cement extravasation that can be 
paravertebral, inside the disc, epidural, intraforaminal, 
in adjacent veins. Very rare complications include: hem-
orrhage, infection, fracture (pedicle, ribs), pneumotho-
rax, spinal cord or nerve root injury. Although the great-
est number of bone lesions is extra-spinal (about 66%) 
osteoplasty beyond the spine (Extra-Spinal Cementoplasty) 
is not a very used procedure. Up to February 2013 the 
literature reported only 543 articles on this topic vs over 
3000 about VP/KP. The procedure is very similar to VP/
KP and has the same indications. As in VP/KP its com-
plexity varies from very simple to complex depending 
on the site, shape and size of the lesions. The procedure 
can be associated to radiotherapy and to ablation proce-
dures [32, 33, 34]. On the contrary of VP/KP extraspinal 
cementoplasty is less effective in consolidation in long 
bone since the lower resistance of cement to torsional 
stress (as in the diaphysis of long bones) in respect to 
pure axial stress (as in vertebrae and in #at bones) due 
to lower young module of PMMA in respect to normal 
bone [35]. De!nitively, VP/KP and extra-spinal cemen-
toplasty are safe and effective procedures in the palliative 
treatment of localized painful bone metastatic lesions, 
whose range of technical complexity is extremely wide.
Pain management 
Pain is the most common symptom in patients with bone 
metastases. Metastatic extent does not directly correlate 
with the global pain burden perceived by the patients. 
According with daily clinical observations, some of them 
with advanced bone destruction do not report signi!cant 
or only minimal pain. The gap between the radiologic 
bone architecture destruction and the effective clinical 
manifestations may be very surprising. Both osteolytic 
and osteoblastic metastases usually generate signi!cant 
pain through different pathophysiological mechanisms 
including mechanical (loss of substance) and/or functional 
(loss of structure) pathways [1, 36]. Different pain clus-
ters or syndromes can be produced by a sequential or con-
comitant arise of basis/background pain, spontaneous and 
movement-induced (incidental) pain. Episodical acute 
exacerbations of pain (breakthrough) represent a frequent 
constatation in clinical practice.
Available analgesic drugs can be considered as very ef!ca-
cious in the management of cancer-related bone pain. In 
most cases, the right answer is a combination of different 
drugs targeting different pain mechanisms and pathways, 
like non-opioids, opioids and, very important in some par-
ticular settings, adjuvant analgesics [1, 37, 38]. According 
to the WHO-Guidelines [39] analgesic drugs should be 
administered «by the mouth», «by the clock» (follow-
ing well-de!ned time intervals) and «by the ladder» (that 
means according to the levels of analgesic potency). 
Non-opioid analgesic drugs like Paracetamol, Metamizol 
and anti-in!ammatory drugs (like Diclofenac, Ibuprofen, 
Ketorolac, Celecoxib and others) may represent a good 
pharmacological basis but they are usually not enough if 
taken as a monotherapy [1, 36]. Anti-in#ammatory drugs 
may rise some concerns in patients with a fragile condi-
tion, gastrointestinal and/or renal situation. Corticosteroids 
may have some indications (vertebral fracture, spinal cord 
compression), particularly for the pain management on 
the short term [40]. 
Opioids still represent the drugs of choice in moderate to 
severe malignant bone pain. According to the recent evi-
dence, Morphine, Oxycodon or Hydromorphone can be 
alternatively used as !rst line-opioids [41]. The oral way 
should always be preferred whenever possible and the sub-
cutaneous way should represent the !rst choice in patients 
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requiring parenteral drug administration where a venous 
access is not yet or no more available. Fears of long-term 
side effects or toxicities and/or addiction-related concerns 
are de!nitely not an issue of discussion in patients with 
short prognosis and should not prevent patients from re-
ceiving an adequate drug medication.
Endocrine- and chemotherapy
Palliative endocrine and chemotherapy may offer a con-
tribution in the management of progressive metastatic 
bone involvement. In selected patients with advanced 
systemic disease, even though displaying rapidly de-
clining performance status, a proper assessment of the 
potential risk-bene!t of systemic therapies may help to 
identify patients who could potentially bene!t from ac-
tive treatments. 
Surgery
Palliative surgery and osteosynthesis procedures may pro-
vide long-term or at least transient solutions in patients 
with pathological bone fracture. In many clinical situa-
tions surgery may help to restore mobility, functionality 
and to reduce or to control local or irradiating pain. 
The indication for surgery in this setting should consider 
the general conditions of the patient, the estimated prog-
nosis and, de!nitely, be a part of a multidisciplinary ap-
proach. 
Conclusions
As we enter an era of outstanding progresses in cancer 
medicine, metastases-related bone problems and compli-
cations are and will remain complex clinical challenges. 
Their great prevalence forces medical oncologists and the 
whole medical community dealing with cancer patients 
to be alert and updated on this topic. Since the «multi-
disciplinary approach way» should be considered the cur-
rently best one if we look at the outcomes, an intensive 
collaboration is required from all the specialists to treat 
patients according to the evolving scienti!c knowledge. 
Some issues like proper assessment, accurate diagnostic 
procedures and adequate management still represent con-
solidated priorities.
Integrating active oncologic treatments, palliative sur-
gery, supportive and palliative care concepts into the daily 
practice seems to be the way of the present and possibly 
even more, the way of the future.
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SAKK News
Annik Steiner, SAKK Coordinating Center, Bern
BOARD DECISIONS
At its annual board meeting and retreat on May 15 and 
16, 2014, in Konol!ngen, the SAKK Board accepted to 
conduct the following trials:
ETOP SPLENDOUR, coordinating investigator R. 
von Moos, Kantonsspital Graubünden. Survival im-
Provement in Lung cancEr iNduced by DenOsUmab theRapy 
(SPLENDOUR). An ETOP sponsored / EORTC coordinated 
phase III trial in advanced NSCLC. 
The board agreed to participate in this international trial. 
SAKK 06/14, coordinating investigator C. Rentsch, 
Universitätsspital Basel. A phase I/II open label clinical 
trial assessing safety and ef"cacy of intravesical instillation 
of the recombinant BCG VPM1002 in patients with recur-
rent non-muscle invasive bladder cancer after standard BCG 
therapy. 
Notably, the use of BCG as a means of initiating anti-
tumor immunity represents one of the most successful im-
munotherapies used in clinical practice. While successful, 
tumor recurrence and disease progression are seen often in 
these patients. VPM1002 is a genetically modi!ed BCG 
vaccine for which preclinical studies have con!rmed lower 
toxicity compared to conventional BCG. VPM1002 will 
be tested for safety, ef!cacy, tolerability and immunoge-
nicity in a phase I/II clinical trial, respectively, in patients 
with tumor recurrence after a !rst BCG therapy. Of note, 
this will (to the best of knowledge) be the !rst in human 
trial with recombinant intravesical bacteria and the !rst 
in human intra-bladder application of VPM1002. 
SAKK 09/14, coordinating investigator A. dal Pra, 
Inselspital Bern. Dose intensi"ed Salvage radiotherapy in 
combination with short-term enzalutamide after biochemical fai-
lure post-prostatectomy: a Phase I/II study. 
Enzalutamide is a promising agent to be employed in the 
management of earlier stages of prostate cancer. By ad-
dressing occult metastases and optimizing local control in 
patients with biochemical failure post-prostatectomy (~ 
30 % of all surgical patients). The trial could substantially 
impact the treatment of this type of cancer which is the 
most common among men in Switzerland. It is hypoth-
esized that dose intensi!ed RT combined with a short-
course of the second-generation anti-androgen, enzalu-
tamide, is clinically bene!cial in terms of progression-free 
survival and low toxicity pro!le in patients presenting 
biochemical failure post-RP. The board agreed to conduct 
this trial under the condition that the company supports 
the trial.
SAKK 96/12, coordinating investigators M. Joerger, 
Kantonsspital St.Gallen / L. Albiges, Institut Gustave 
Roussy, Villejuif (FRA). Bone Turnover Markers in Patients 
Receiving 4-Weekly versus 12-Weekly Denosumab in the SAKK 
96/12 Randomized-Non-Inferiority Phase III Trial. A Pros-
pective Kinetic-Pharmacodynamic (K-PD) Population Modeling 
Analysis. 
This translational research sub-study of the trial SAKK 
96/12 aims at investigating the prospective and pre-
dictive value of speci!c bone turnover markers and it 
enables an early !rst analysis of the safety and ef!cacy 
of the reduced treatment with denosumab in the main 
trial. The board agreed to conduct this translational re-
search project.
SAKK 36/13, coordinating investigators U. Novak, 
Inselspital Bern / C. Renner, Onkozentrum Zürich 
Combination of Ibrutinib and Bortezomib to treat mantle cell 
lymphomas patients – a multicenter phase I/II trial.
The trial aims at investigating the combination of ibruti-
nib and bortezomib in mantle cell lymphoma. Both drugs 
are active in MCL and investigating the combination is 
very attractive. It is planned to perform the trial in coop-
eration with Italian and German organizations. The board 
agreed to conduct this trial under the condition that the 
company supports the trial.
SAKK 35/14, coordinating investigators E. Zucca, 
IOSI Bellinzona / E. Kimby, Karolinska University 
Hospital, Stockholm (SWE) / B. Ostenstad, Ullevål 
universitetssykehus, Oslo (NOR). Extended Rituximab 
with or without Ibrutinib. A randomized blinded Phase II trial.
SAKK has a long tradition in treatment of follicular lym-
phoma patients with «soft» treatment (i.e. without chemo 
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petences and signatures. The revision mainly gives the 
project managers more competences. The Board members 
approved of the changes.
Approval of the president of the project group lung 
cancer
In their last meeting, the project group lung cancer ap-
pointed Oliver Gautschi for a second term as president. The 
Board members approved of this election.
AWARDS AND PROMOTIONS
Florian Strasser, senior physi-
cian oncology and palliative 
medicine at the Kantons-
spital St.Gallen, is new chair 
of the Working Group Pal-
liative Care of the European 
Society of Medical Oncology 
(ESMO) since the beginning 
of this year.
Matthias Guckenberger was 
appointed full professor and 
director of radio-oncology 
at the University Hospital 
Zürich. He joined the SAKK 
Project Group Lung Cancer.
GENERAL ASSEMBLY
During the General Assem-
bly, which took place on 
June 26, the participants 
reelected Walter Marti from 
the Kantonsspital Aarau 
and Arnaud Roth from the University Hospital Geneva 
as Board members.
The members of the General Assembly were informed about 
the implementation of the new Human Research Act. The 
implementation of the new law without a transition phase 
was very challenging for all stakeholders and resulted in 
signi!cant delays for trial/amendment authorization.
Furthermore, the General Assembly discussed the pos-
sibilities of involving the voices of patients and patient 
organizations in the research of SAKK in the future. 
Additionally, the General Assembly approved to accept 
the renewed mandate from the scienti!c committee HSM 
and to keep playing an active part in elaborating recom-
mendations how the treatment of rare cancers should be 
organized in the future.
SAKK 
or radiation) based on rituximab solely or mainly. The aim 
of the trial is to study the activity and the safety of the 1st 
line treatment with ibrutinib in combination with RTX 
for patients with advanced follicular lymphoma in need 
of therapy. Furthermore, this trial would allow the search 
of new prognostic factors in gene expression and immu-
nophenotyping. SAKK will collaborate with the Nordic 
Lymphoma Group in this trial. The board agreed to con-
duct this trial under the condition that the company sup-
ports the trial.
TRIANGLE, coordinating investigator U. Mey, 
Kantonsspital Graubünden. Ef"cacy of Ibrutinib during 
R-CHOP/R-DHAP induction and after or in comparison to 
autologous stem cell transplantation (ASCT) in previously un-
treated patients with mantle cell lymphoma.
This trial was designed by the European Mantle Cell Lym-
phoma Network. It is an important trial in this disease 
and would allow Switzerland to be integrated in the Euro-
pean setting. The board agreed to participate in the trial.
SAKK 16/14, coordinating investigator S. Roth - 
schild, Universitätsspital Basel. Perioperative anti-PD-L1 
antibody MPDL3280A in addition to standard neoadjuvant 
chemotherapy in non-small cell lung cancer (NSCLC) patients 
with mediastinal lymph node metastases (stage IIIA, N2).
The hypothesis of the trial is that the addition of preop-
erative immunotherapy (anti-PD-L1 antibody) to stan-
dard chemotherapy (cisplatin/docetaxel) could improve 
local control, event-free survival and overall survival in 
stage IIIA (N2) NSCLC. The addition of the anti-PD-
L1 antibody offers a novel approach as the outcome of 
patients with stage IIIA NSCLC is poor. The task is to 
substantially decrease the number of patients who die in 
spite of intensive multimodality treatment. The addi-
tion of this novel treatment modality (immunotherapy) 
has the potential to improve the outcome without add-
ing additional substantial toxicity. The board agreed to 
conduct this trial under the condition that the company 
supports the trial.
BIG 6-13, coordinating investigator U. Novak, In-
selspital Bern. A randomised, double-blind, parallel group, 
placebo-controlled multi-centre Phase III study to assess the ef"-
cacy and safety of olaparib vs placebo as adjuvant treatment in 
patients with high risk germline BRCA mutated HER2 negative 
breast cancer who have completed de"nitive local and systemic 
neoadjuvant/adjuvant treatment.
This is an international trial in a niche indication by the 
Breast International Group. The board agreed to partici-
pate in the trial.
Revised regulations on competences and signatures
The executive board has revised the regulation on com-
Florian Strasser
Matthias Guckenberger
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SEMI-ANNUAL MEETING
On June 26 and 27, SAKK held its summer semi-annual 
meeting in Bern, which was attended by more than 250 
specialists.
Gateway/RTF-CCR/SAKK Research Grant: 
Winning trial awarded
Shawn Stephenson, Chair-
man and Eveline Mu-
menthaler, Director Ri-
sing Tide Foundation, 
along with Teresa Hall 
Bartels, President of 
Gateway for Cancer 
Research, awarded the 
winner of the Gate-
way/RTF-CCR/SAKK 
Research Grant 2014, 
Prof. Dr. Radek Skoda 
from the University 
Hospital Basel, for a 
novel «Phase II study to 
test the effects of beta-
3-sympathicomimetic 
agonists on the disease 
course and mutant al-
lele burden in patients 
with myeloproliferative neoplasms (MPN)». The winning 
proposal was chosen out of 10 initial grant applications and 
stood out for its high potential for patient bene!t, signi!-
cance, innovation and feasibility.
With no current cure available, MPN are a group of 
chronic leukemias (blood cancers) in which patients pro-
duce too many blood cells. These increased blood cell 
numbers cause problems to the patient such as bleedings 
or thrombosis and some patients may progress to acute 
leukemia, a life threatening condition. Most MPN pa-
tients (>80% overall) have a gene mutation called JAK2-
V617F. The disease is maintained by mutant MPN stem 
cells that reside in the bone marrow in specialized loca-
tions called «niches». These niches need connections to 
the nervous system. New !ndings show that these con-
nections are destroyed by the presence of the mutated 
MPN stem cells. The research teams around the co-ap-
plicant Prof. Simon Mendez-Ferrer and Prof. Radek Skoda 
found that some drugs (beta3-sympathicomimetics) can 
restore these damaged niches and at the same time re-
duce the MPN disease manifestation in a mouse model 
of MPN. Such sympathicomimetic drugs are already be-
ing used to treat patients with asthma or hyperactive 
bladder. These drugs have shown to have only few side 
effects.
The research team is to test the effects of the beta-3-sym-
pathicomimetic drug Mirabegron (Betmiga®) in 36 pa-
tients with MPN that carry a JAK2-V617F mutation. 
Betmiga® is currently approved for the treatment of hy-
peractive bladder. The researchers expect that Mirabegron 
will have a bene!cial effect on bone marrow niche cells 
and will thereby improve the disease manifestation in 
MPN patients. This study should provide a rapid answer 
whether targeting the nervous system of the niche cells 
could be useful for patients with MPN and warrants to be 
tested in larger and more long-term studies.
There is currently no cure for MPN. The approach pro-
posed by Prof. Skoda and his team is novel and fundamen-
tally different from the current strategies, since the pri-
mary target of therapy is the correction of the stem cell 
niche damage, rather than the malignant clone itself. 
The Gateway/RTF-CCR/SAKK Research Grant for out-
standing and novel clinical cancer research is endowed for 
450 000 U.S. dollars and is jointly awarded by Gateway 
for Cancer Research, a U.S.-based non-pro!t organization, 
the Rising Tide Foundation for Clinical Cancer Research, a 
Swiss-based foundation, and SAKK. As a joint front, Gate-
way, RTF-CCR and SAKK decided in 2011 to create a stra-
tegic partnership with the aim to stimulate innovative and 
practice relevant oncology research that may lead to more 
potent, less toxic and potentially life-saving treatment op-
tions for cancer patients. The Call for Proposals was now 
Award winner Radek Skoda 
(right) with Shawn Stephenson, 
President Rising Tide 
Foundation.
Shawn Stephenson, RTF Chairman; Morgan Stephenson, RTF; 
Eveline Mumenthaler, RTF, Director; Beat Thürlimann, SAKK 
President; Jakob Passweg, University Hospital Basel; 
Teresa Hall Bartels, Gateway for Cancer Research, President; 
Radek Skoda, University Hospital Basel; Wendelin Zellmayer, 
Rising Tide, CEO; Hermann Schulin, RTF, Board Member; 
Peter Brauchli, SAKK CEO (f.l.t.r.)
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conducted for the second time. All submitted proposals 
were reviewed by an international review committee com-
prising of Gateway, RTF-CCR and SAKK scientists in a 
two-step procedure, with a !nal decision in May 2014.
Additional to the Gateway/RTF-CCR/SAKK Research 
Grant 2014, Gateway for Cancer Research stepped up and 
agreed to fund also the runner-up of the proposals, the 
grant application by Christoph Mamot from the Kantons-
spital Aarau with the title «multi-center, investigator-ini-
tiated single arm phase II trial to evaluate the ef!cacy of 
anti-EGFR immunoliposomes in patients with pretreat-
ed triple-negative breast cancer». The Scienti!c Review 
Committee was impressed with this proposal and the high 
potential for patient impact.
SAKK/Dr. Paul Janssen Fellowship for 
Benjamin Kasenda
Benjamin Kasenda from the University Hospital Basel ob-
tained the SAKK/Dr. Paul Janssen Fellowship, which is 
jointly awarded by SAKK and Janssen-Cilag. The educa-
tional grant is endowed with CHF 50 000.- and is aimed 
at offering young doctors the opportunity to spend four 
months at a renowned research center abroad to gain ex-
perience and acquire the necessary know-how and tools to 
develop and conduct top-quality clinical trials. 
Kasenda spends his fellowship at the Royal Marsden Hos-
pital in London where he manages a project in the !eld of 
kidney cancer. For this rare entity, new agents have been 
developed over the last years, however research on prog-
nostic factors or side effects is still rare. In Kasenda’s view 
this opportunity to work and conduct clinical research 
at this large UK oncology centre offers a great chance to 




ASCO Annual Meeting 2014
Poster
Templeton A. et al. Prevention of symptomatic skeletal 
events with denosumab administered every 4 weeks 
versus every 12 weeks – a non-inferiority phase III 
trial (SAKK 96/12, REDUSE).
Koeberle D. et al. Sorafenib with or without everoli-
mus in patients with unresectable hepatocellular car-
cinoma (HCC): A randomized multicenter phase II 
trial (SAKK 77/08 and SASL 29).
Poster discussion
Von Moos R. et al. Neoadjuvant radiotherapy (RT) 
combined with capecitabine (Cape) and sorafenib 
(Sor) in patients (pts) with locally advanced, k-ras-
mutated rectal cancer (LARC): A phase I/II trial 
SAKK 41/08.
Rochlitz C. et al. SAKK 24/09: Safety and tolerability 
of bevacizumab plus Paclitaxel vs. bevacizumab plus 
metronomic cyclophosphamide and capecitabine as 
"rst-line therapy in patients with HER2-negative ad-
vanced stage breast cancer. A multicenter, random-
ized phase III trial.
Oral presentation
Sargent DJ. et al. Prognostic impact of de"cient mis-
match repair (dMMR) in 7,803 stage II/III colon can-
cer (CC) patients (pts): A pooled individual pt data 





Joerger M, Baty F, Früh M, Droege C, Stahel RA, Bettich-
er DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, 
Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche 
M. Circulating microRNA pro"ling in patients with 
advanced non-squamous NSCLC receiving bevaci-
zumab/erlotinib followed by platinum-based che-
motherapy at progression (SAKK 19/05). Lung Cancer. 
2014 May 29.
SAKK President Beat Thürlimann, Award winner Benjamin 
Kasenda and Sabine Albrecht, Janssen-Cilag




Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz 
SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller 
A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos 
R, Zaman K, Thürlimann BJ, Ruhstaller T; Swiss Group 
for Clinical Cancer Research (SAKK) Coordinating Cen-
ter. Prevention of palmar-plantar erythrodysesthesia 
with an antiperspirant in breast cancer patients treat-
ed with pegylated liposomal doxorubicin (SAKK 
92/08). Breast. 2014 Mar 19.
EORTC 10994
Bonnefoi H, Litière S, Piccart M, Macgrogan G, Fumo-
leau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan 
C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, 
Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron 
DA; on behalf of the EORTC 10994/BIG 1-00 Study in-
vestigators. Pathological complete response after neo-
adjuvant chemotherapy is an independent predictive 
factor irrespective of simpli"ed breast cancer in-
trinsic subtypes: a landmark and two-step approach 
analyses from the EORTC 10994/BIG 1-00 phase III 
trial. Ann Oncol. 2014 Mar 11.
IBCSG 24-02/25-02
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni 
M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, 
Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE 
Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer 
EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-
Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale 
G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; 
the TEXT and SOFT Investigators and the International 
Breast Cancer Study Group. Adjuvant Exemestane with 
Ovarian Suppression in Premenopausal Breast Can-
cer. N Engl J Med. 2014 Jun 1. 
IBIS-II
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Caw-
thorn S, Saunders C, Roche N, Mansel RE, von Minckwitz 
G, Bonanni B, Palva T, Howell A; IBIS-II investigators. 
Anastrozole for prevention of breast cancer in high-
risk postmenopausal women (IBIS-II): an interna-
tional, double-blind, randomised placebo-controlled 
trial. Lancet. 2014 Mar 22.
Leukemia
CML III
P!rrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, 
Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer 
J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, 
Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel 
H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; for the 
Schweizerische Arbeitsgemeinschaft für Klinische Forsc-
hung (SAKK) and the German CML Study Group. Ex-
plaining survival differences between two consecu-
tive studies with allogeneic stem cell transplantation 
in patients with chronic myeloid leukemia. J Cancer 
Res Clin Oncol. 2014 Apr 10. 
CML IV
Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Sau-
ssele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger 
S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler 
J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, 
Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher 
GM, P!rrmann M, Hasford J, Hofmann WK, Hochhaus 
A, Müller MC; for the SAKK and the German CML Study 
Group. Velocity of early BCR-ABL transcript elimina-
tion as an optimized predictor of outcome in chronic 
myeloid leukemia (CML) patients in chronic phase on 
treatment with imatinib. Leukemia. 2014 May 6. 
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanf - 
stein B, Krause SW, Kalmanti L, Schreiber A, Heim D, 
Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wer-
nli M, Kremers S, Schlag R, Müller L, Hänel M, Link 
H, Hertenstein B, P!rrmann M, Hochhaus A, Hasford 
J, Hehlmann R, Saußele S; for the German Chronic My-
eloid Leukemia Study Group, and the Schweizerische Ar-
beitsgemeinschaft für Klinische Krebsforschung (SAKK). 
Older patients with chronic myeloid leukemia (≥65 
years) pro"t more from higher imatinib doses than 
younger patients: a subanalysis of the randomized 
CML-Study IV. Ann Hematol. 2014 Mar 22. 
Gastrointestinal Cancer
SAKK 44/00
Bernhard J, Dietrich D, Glimelius B, Bodoky G, 
Scheithauer W, Herrmann R. Clinical bene"t response 




Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koe-
berle D, Strasser F. Development and Validation of a 
Medical Chart Review Checklist for Symptom Man-
agement Performance of Oncologists in the Routine 
Care of Patients With Advanced Cancer. J Pain Symp-
tom Manage. 2014 May 23. 
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Law for cancer registration
Every year in Switzerland, 37 000 people are diagnosed 
with cancer and nearly 16 000 affected individuals die. 
In March 2013, the federal government launched the ini-
tiative for a law for cancer registration with the aim to im-
prove the overall minimal data on cancer in Switzerland. 
Main emphasis of the registration is to obtain profound 
evidence on cancer prevention programs, better proofs of 
the effectiveness of cancer diagnosis and treatments and an 
improved planning for the infrastructure of medical care. 
Moreover, the enhanced data sets may hopefully allow a 
faster evaluation of Swiss-wide data with higher quality. It 
is also intended that anonymized data shall be accessible 
for researchers and governmental administration as well 
as for statistics and extended investigations. This may also 
foster research in areas like epidemiology, quality of life, 
rare cancers, long-time implications of treatments and 
others.
The new law shall determine which minimal data on the 
diagnosis, treatment and follow-up must be collected 
nationwide, and what data may be gathered for speci!c 
research questions such as treatment success, further de-
velopment of the disease or quality of life. Furthermore, 
a suitable process to access collected data for researchers 
Outcomes research
Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, 
Schwenkglenks M. Using the EuroQol EQ-5D in Swiss 
Cancer Patients, Which Value Set Should be Ap-
plied? Pharmacoeconomics. 2014 Mar 27. 
SAKK 89/09
Matter-Walstra KW, Achermann R, Rapold R, Klingbiel 
D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-
Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC. De-
livery of health care at the end of life in cancer pa-
tients of four swiss cantons a retrospective database 
study (SAKK 89/09). BMC Cancer. 2014 May 1. 
Consultancy
Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, 
Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr 
M. Relevant risk of Carboplatin underdosing in can-
cer patients with normal renal function using esti-
mated GFR: Lessons from a stage I Seminoma cohort. 
Ann Oncol. 2014 Mar 25. 
Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, 
Scherrer E, Holzmann D, Dummer R. Clinical implica-
has to be de!ned. For both questions, national institu-
tions like the National Institute for Cancer Epidemi-
ology and Registration (NICER), the Swiss Paediatric 
Oncology Group (SPOG), Children’s Cancer Registry 
and SAKK have been involved in this process. While 
NICER was actively involved in the determination of 
the minimal data set, SAKK was asked for advice how to 
regulate access to patient data for recruitment into clini-
cal trials and research through the cancer registration. 
SAKK gave, in alignment with SPOG, the Children’s 
Cancer Registry and a cantonal cancer registry an ex-
tended answer to this question. Also NICER is prepar-
ing a profound report by the end of June, de!ning the 
minimal data set that is necessary to give the answers 
to the asked questions and questions that may be asked 
in the future. NICER will include also the experiences 
from other European countries that have introduced such 
registrations a decade ago. The Federal Of!ce of Public 
Health (FOPH) has now to !nalize a law that balances 
well the practicability and research on one hand and the 
sensitivity of patient data and patient integrity on the 
other hand. The draft of the law is likely to be presented 
to the parliament this fall.
Claudia Weiss
SAKK Politics & Development
claudia.weiss@sakk.ch
tions of distinct metastasizing preferences of different 
melanoma subtypes. Eur J Dermatol. 2014 Apr 11. 
Fehr M, Geldart T, Klingbiel D, Cathomas R. Measure-
ment or estimation of glomerular !ltration rate in 
seminoma patients: Quite another cup of tea. Eur J 









October 21 Board Meeting
October 23&30 Investigators’ Education
November 19 General Assembly
November 20&21 Semi-Annual Meeting
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J. R. Rischewski, Head of the Structural Development 
Working Group (SDWG) of the Swiss Paediatric 
Oncology Group (SPOG)
Introduction
The Swiss Paediatric Oncology Group (SPOG), one of 16 
national paediatric haematology and oncology societies in 
Europe (11), decided in 2013 to formalize already existing 
and functional efforts of the group to ensure, maintain and 
improve the quality of paediatric oncologic health care in 
Switzerland. SPOG therefor established a Structural De-
velopment Working Group (SDWG) to analyse structural 
and quality aspects of paediatric oncological supply in 
Switzerland. In a !rst step towards quality measurement, 
a survey of the infrastructure of the 9 SPOG Paediatric 
Cancer Centres (PCC) (Aarau (A), Basel (B), Bellinzona 
(Bel), Berne (Be), Geneva (G), Lausanne (L), Lucerne (Lu), 
St. Gallen (S) and Zurich (Z)) was initiated.
We also compared published overall survival data (OS) of 
paediatric cancer patients in Switzerland and other Euro-
pean Countries, in order to document what could so far be 
gained by the existing structures.
Method
The American Society of Pediatrics has published in-
frastructural requirements for paediatric oncologic 
units in the USA (1). Despite the fact that health care 
structures are different, we used these requirements as a 
template to record the resources of the 9 SPOG centres. 
The centres self-reported within the templates between 
October and December 2013, and sent it to the SPOG 
for summary.
The centres also self-reported patient load as sum of three 
years (2010-2012), and the available number of special-
ists (paediatric haemato-oncologists) who took care of the 
patients. A ratio of diagnoses per specialist per year was 
calculated.
All patients with a !rst diagnosis of a malignant disease 
according to ICCR-3 (13), relapse or secondary tumor 
were counted, patients with Langerhans cell histiocytosis 
and aplastic anemia were also included.
To describe OS of malignant diseases in children in Swit-
zerland the actual numbers as published by the Swiss 
Childhood Cancer Registry Annual report were used (2).
To compare OS in Switzerland to other European coun-
tries, the recent !gures published by Gatta (3) were used, 
which assessed regional and national cancer and death 
registries in Switzerland and in Europe to produce their 
!ndings.






 Time since diagnosis (years) 
Figure 1: Survival of patients in the SCCR, by period of 
diagnosis. Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1976-2011; all diagnoses (ICCC-3 or 
Langerhans cell histiocytosis); N=5913; adjusted for sex, age 
at diagnosis and ICCC-3 groups. The graph shows an actuarial 
curve presenting overall survival up to 35 years after diagnosis 
for patients diagnosed between 1976 and 2011, grouped in 
four periods. In total, 1503 (25%) children have died. Ten-year 
survival increased from 60.5% in children diagnosed between 
1976 and 1981, 70.3% in children diagnosed between 
1982-1991, to 77.3% in children diagnosed between 1992 
and 2001, and reached 82.7% in children diagnosed within 
the last decade. Graph taken with permission from (2).
Paediatric Oncology in Switzerland: 
Infrastructure and Results
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Results
All 9 SPOG centres replied to the questionnaire. Infra-
structural details correspond to the state at the end of 
2013. The results are summarized in table 1 and 2.
None of the Swiss centers ful!ll all the requirements 
from the American Society of Paediatrics. Seven of the 
nine SPOG centres reported only minor infrastructural 
differences, apart from the restriction of allogenic stem 
cell transplantation to three centres. Transition times for 
requirements not available in a PCC on the children’s hos-
pital compound are between !ve and 150 minutes. The 
actual patient load for all centers together was 345 pa-
tients per year. The smallest center cared for 4% of the 
patients, the largest for 27%, the remaining for 5-19% 
each of the patients. The specialist/patient per year ratio 
varied between 5.2 and 22. 
OS in Switzerland as reported by the SCCR are displayed 
in !gure 1 and 2, and in italics in table 3. OS in other Eu-
ropean countries as reported by Gatta (3) are summarized 
in table 3. The table displays !gures generated by differ-
ing epidemiological methods, please refer to the original 
publication for full details.
Discussion
15% of the Swiss population are below 15 years of age, 
corresponding in 2012 roughly to 1.200.000 children 
(10). Around 11% of the patients reported to the Swiss 
Childhood Cancer Registry (SCCR) are non Swiss resi-
dents (2). The nine SPOG centers cared for 345 new pa-
tients/year between 2010 and 2012. 
Published 5yOS rates for all paediatric cancers in Swit-
zerland are at least at the level of the Central European 
EUROCARE-5 data (table 3). The European and Central 
European rates have been reported by Gatta (3) to be sig-
ni!cantly above Eastern European rates. The Swiss 5yOS 
!gures for the disease subgroups do also !t well into the 
range of the Central European EUROCARE-5 data. EU-
ROCARE-5 evaluated the OS in 28 European countries. 
5yOS in Switzerland was in the upper 25% for acute lym-
phoblastic leukemia, and second for 5yOS for all cancers 
combined (CNS tumors excluded in Gatta’s analysis). 
Disparities between countries and regions in 5yOS ranged 
from 70% to 82%. For neuroblastoma a further evalua-
tion of the Swiss 5yOS data is necessary, the published 
data do not allow for an interpretation of the apparent 
worse outcome in Switzerland in comparison to the Cen-
tral European !gures. It may be a result of an underre-
porting of surgically only managed patients with excel-
lent prognosis, however, this remains to be proven. For 
leukemia, lymphoma, osteosarcoma, Ewing sarcoma and 
Time since diagnosis (years) 
% alive
Figure 2: Survival of patients by diagnostic groups according 
to ICCC-3. Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1992-2011; all diagnoses (ICCC-3 
or Langerhans cell histiocytosis); N=3822; adjusted for 
sex and age at diagnosis. The graph presents survival by 
diagnostic group according to ICCC-3 in cases diagnosed 
between 1992 and 2011. Of these, 756 (19.8%) have died. 
The following numbers describe !ve-year survival for each 
main diagnostic group: 82.6% for cases with leukaemias; 
92.4% for those with lymphomas; 71.7% for central 
nervous system neoplasms; 63.4% for neuroblastoma; 
96.1% for retinoblastoma; 91.3% for renal tumours; 
65.7% for hepatic tumours; 85.6% for malignant bone 
tumours; 74.0% for soft tissue sarcomas; 96.4% for germ 
cell tumours; and 100.0% in Langerhans cell histiocytosis. 
Graph taken with permission from (2). 
The International Classi!cation of Childhood Cancer (ICCC-3) 
distinguishes 12 groups of cancers. The most common 
are leukaemias (33% of all cancers), followed by tumours 
of the central nervous system (20%; especially brain 
tumours); and lymphomas (13%). Other cancers arise from 
embryonic tissue. These include neuroblastoma (7%) from 
primitive neural tissue, nephroblastoma (5%) from renal 
tissue, hepatoblastoma (1%) in the liver, retinoblastoma 
(3%) from cells of the retina, as well as germ cell tumours 
(3%). The latter may arise in the gonads (ovaries and testes), 
or in other sites, for example in the brain (intracranial germ 
cell tumours). In older children, malignant bone tumours 
(4%) and soft tissue sarcomas (7%), which arise from 
abnormal connective tissue, are occurring with increasing 
frequency. Sometimes children also develop melanomas 
and other rare tumours (3%). Langerhans cell histiocytosis 
(3%) is not encoded as malignant disease according to 
ICCR-3, but is also reported to Swiss Childhood Cancer 
Registry (SCCR). (2)
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Table 1. Infrastructure of the 9 SPOG Paediatric Cancer Centres (PCC) (Aarau (A), Basel (B), Bellinzona (Bel), Bern (Be), Geneva (G), 
Lausanne (L), Lucerne (Lu), St. Gallen (S) and Zurich (Z)). Base of the questionnaire are the infrastructural requirements for 
pediatric oncologic units in the US. As published from the American Society of Pediatrics (1). Available off site means not 
available in the hospital compound containing the children’s hospital. Transition times are transport times in an ambulance car. 
If a centre is not named in a line, the requirement is ful!lled.
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1. 24/7 staff with pediatric diagnostic experience present
2. Position !lled in 2014
3. Adult unit on site
4. Paul Scherrer Institut, CH-5232 Villigen 
5. Autologous available on site
6. A, Bel and Lu are also regular members of specialized Tumorboards in B and/or Z
soft tissue tumours, further subgroup analyses of the Swiss 
data are needed to allow for more exact comparisons. The 
total patient numbers are too small for single center 5yOS 
comparisons within Switzerland.
In summary, published !gures show that 5yOS in Swit-
zerland is within the highest range reported in Europe.
The reported physician staf!ng for oncological needs is 
within the recommended range as reported by Halton 
(12) for the Canadian healthcare system, proposing an 
oncologist ratio of 1/15 patients. As the Swiss paediat-
ric hemato-oncologists also cover the hematological needs 
of the patients, and Halton recommended 1 hematolo-
gist per 2.5 oncologists, at least half of the centres would 
have a need for more physicians. However, whether these 
!gures apply to the Swiss healthcare system remains to 
be proven. Individual infrastructural differences of the 
PCC’s, like the number of assigned non specialists to the 
care of the patients as well as non hemato-oncological du-
ties of the specialists may explain in part the differences in 
staf!ng in the PCC’s.
None of the Swiss PCC’s ful!lled all the requirements 
from the American Society of Paediatrics. Seven of the 
nine SPOG centers reported only minor infrastructur-
al differences, apart from the restriction of allogenic 
stem cell transplantation to three centres. Transition 
times for requirements not available in a PCC on the 
children’s hospital compound are between !ve and 150 
minutes. In relation to the excellent 5yOS rates the 
nine PCC’s, their infrastructure and cooperations guar-
antee good outcome combined with a chance for ad-
equate quality of life through treatment close to home 
and family.
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Table 2. Percentage of specialist positions in the PCC’s, separated for haematopoietic stem cell transplantation duties and 





number of diagnoses (a),




stem cell transplant pts. < 18 ys,
sum of 2010, 2011, 2012
and (in bracket s)
number of 
transplantations/specialist/year
transplant excluded transplant only allogenic autologous
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E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  
%HOOLQ]RQD    37
*HQHYD   F 107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   
/DXVDQQH  201    G
/XFHUQH    90 
6W*DOOHQ    62 H H
=XULFK   276   6
Table 3. Overall Survival !gures as reported by Gatta et al (3) in EUROCARE-5 in comparison to !gures from the Swiss Childhood 
Cancer Registry (SCCR) (in italic) as reported in 2012 (2). The !gures from the SCCR represent partially other cohorts: (a) = 
all CNS tumors, (b) = all renal cancers, (c) = all soft tissue sarcoma. (d) = (except Burkitt’s lymphoma). The !gures are not 
completely comparable due to differences in the reported disease categories, and due to different methods of data catchment. 
Published 5yOS rates for all paediatric cancers in Switzerland are above the all European and the Central European rates. The 
European rates have been reported by Gatta to be signi!cantly above the Eastern European rates. The Swiss 5yOS !gures for 
the disease subgroups do !t well into the Central European EUROCARE-5 data. EUROCARE-5 evaluated the OS in 28 European 
countries. 5yOS in Switzerland was in the upper 25% for acute lymphoblastic leukemia, and second for 5yOS for all cancers 
combined (CNS tumors excluded). 
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  
DOO&16FDQFHUV   71.7D 
QHXUREODVWRPD   63.4 
:LOPVWXPRU 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E 
RVWHRVDUFRPD   85.6 
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 
UKDEGRP\RVDUFRPD   74.0F 
UHWLQREODVWRPD 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 96.1 
SPOG 
a.  all !rst diagnoses, relapses, secondary tumours, including HLH and 
aplastic anemia, stem cell transplant patients excluded
b. increased to 250% in 2014
c. increased to 150% in 2014
d. HLH and aplastic anemia not reported
e. performed at adult site
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Measuring, maintaining and improving the quality and 
structure of healthcare for rare diseases is an important, 
complex and scienti!cally challenging task.
The excellent 5yOS rates for all paediatric cancers in Swit-
zerland re#ect the high quality of the health care for chil-
dren with cancer in Switzerland. The evidence for out-
come improvement by further patient concentration in 
paediatric oncology, especially for surgical procedures  is 
not conclusive, apart from the accepted necessity to in-
clude as many patients as possible in therapy optimization 
studies, and the need for a to be de!ned minimum stan-
dard of available ressources (6,7,8,9).
We therefor conclude, that the existing structures to care 
for paediatric oncologic patients in Switzerland should be 
modi!ed  with great care and in a strictly evidence based 
process in order not to compromise the good OS  results 
(especially within the context of the intercantonal agree-
ment for HSM [IV-HSM]) (4,5)). Continuous improve-
ment and intensi!cation of collaborations between the 
centers is certainly in the interest of our patients. SPOG 
therefor decided to intensify the existing networking be-
tween the PCC’s e.g. by common tumour boards within 
three network regions, instead of concentrating patients 
on fewer centres. This strategy strengthens the quality 
of management (every individual patient is reviewed by 
several specialists) without compromising a close to home 
patient management.
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Introduction
Oesophageal carcinoma is a relatively rare disease with a 
dismal prognosis. During 2007-2011 about 11 in 100’000 
men (or 392 in total) and about 4 in 100’000 women (128 
in total) were diagnosed each year with oesophageal can-
cer, while the yearly death toll due to the disease was 9 
in 100’000 men (327 in total) and 3 in 100’000 women 
(106 in total) [1]. Age-adjusted incidences rates for cancer 
of the oesophagus have been increasing in Switzerland for 
both sexes since the beginning of cancer registration in 
the late Seventies and early Eighties of the 20th Century, 
with recent signs of levelling off, while mortality rates are 
steadily declining in men, but remaining stable in women 
[1]. Disease risk is considerably higher in men and mod-
erately higher in the French- or Italian-speaking part of 
Switzerland. Both, the sex-speci!c and the region-speci!c 
age-adjusted risk ratios have declined over time from ini-
tially 5.0 to 3.8 for men versus women and from 2.0 to 
1.4 for French-/Italian- versus German-speaking region, 
respectively. 
In the present descriptive study, epidemiological informa-
tion from tumour registries of seventeen Swiss cantons 
have been collapsed to examine the survival patterns of 
patients diagnosed with malignant primary cancer of the 
oesophagus during the last 30 years. 
Methods
This study is based on the National Core Dataset (NCD) 
managed by the National Institute for Cancer Epidemiol-
ogy and Registration (NICER) for the purpose of national 
cancer monitoring in Switzerland. Twenty of 26 Swiss 
cantons have transmitted population-based cancer data to 
the NCD up to diagnosis date 31.12.2011. Cancer cases 
from 17 cantons were collapsed for this report: Appenzell 
Ausserrhoden (AR) and Appenzell Innerrhoden (AI), Ba-
sel-Landschaft (BL) and Basel-Stadt (BS), Fribourg (FR), 
Geneva (GE), Glarus (GL), Graubünden (GR), Lucerne 
(LU), Nidwalden (NW), Obwalden (OW), St. Gallen 
(SG), Ticino (TI), Uri (UR), Valais (VS), Zug (ZG) and 
Zurich (ZH). The cantons of Neuchâtel, Jura and Vaud 
could not be included, because they do not provide infor-
mation on patient survival to the NCD.
Cancer registries recorded all incident cancer cases diag-
nosed in their resident population and assessed cases’ sur-
vival by active and/or passive follow-up until 31.12.2011. 
We extracted 5’519 malignant primary cancer diagnoses 
for oesophagus (ICD-10 C15) from 1980 to 2011. For 
the cantons BL and BS the latest available year of diag-
nosis was 2009. We excluded all cases diagnosed at death 
(N=86) or with a death certi!cate as the only source of 
information (N=107). Case !nding via death certi!cates 
was infrequent (3%-7%, depending on cancer registry). 
Patients with multiple primary tumours (22%) were in-
cluded [2]. Excluded were 78 cases because no active fol-
low-up has been performed. Recent active follow-up was 
lacking for 133 cases (i.e. follow-up <2011). The vital 
status of these cases was set lost to follow-up using the 
date of last contact. A total of 5’248 cases (95%) remained 
for analysis, with 86% of observations uncensored (i.e. pa-
tients who have died). 
Because we did not assume survival up to 31.12.2011 in 
the absence of reported death (i.e. based on passive follow-
up alone), our survival estimates will be conservative. Us-
ing the assumption of survival in the absence of reported 
death could overestimate survival because two large regis-
tries did not utilize death certi!cates for several diagnosis 
years: ZH (1980-1996) and BS/BL (1981-2001, 2008-9). 
Completeness of case ascertainment for oesophageal cancer 
was estimated with the mortality-incidence ratio (MIR). 
A ratio above unity is suggestive of under-registration of 
diagnoses. MIRs were determined for consecutive 5-year 
intervals from 1987 to 2011 for each cancer registry and 
provided no evidence for systematic under-registration 
[1]. MIRs ranged usually between 0.7 and 0.9 and were 
above or close to unity only for ZH and SG in time inter-
val 1987-1996 and for BL/BS in time interval 1992-1996. 
Observed survival (OS) and relative survival (RS) were de-
rived for consecutive time intervals of increasing length 
after diagnosis during which the hazards were assumed 
to remain constant. Temporal divisions were 0.05, 0.1, 
0.2, 0.4, 0.6, 1, 2, 3, 4, 5, and 6 years. RS was calculated 
as the ratio of the observed survival of cancer cases and 
the expected survival of persons in the general population 
matching in age, sex, calendar year of death and cantonal 
pool [3]. Expected cancer survival was estimated using the 
Ederer II method applied to all-cause mortality tables for 
the cantons combined [4]. All-cause death probabilities, 
transformed from age-, sex- and calendar year-speci!c 
death rates, were interpolated and smoothed using the 
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Elandt-Johnson formula [5]. RS ratios were estimated us-
ing the strs command (version 1.3.7) [6] written for the 
Stata Statistical Software [7]. Partially complete survival 
analysis was used for the comparison in Table 2. Since di-
agnoses from 2011 were excluded from this analysis, only 
13 of 17 cantons were eligible. Period survival analysis [8] 
was used for the analysis of time trends in Table 3. Since it 
included diagnoses from 2011, all 17 cantons contributed 
to this analysis. In brief, partially complete analysis de-
scribes the survival of cases de!ned by dates of diagnosis, 
and period analysis de!nes cases by follow-up dates. RS 
estimates were age-standardized using weights speci!c for 
cancer of the oesophagus from the International Cancer 
Survival Standards (ICSS) [9]. Ninety-!ve percent con!-
dence intervals (95% CI) were estimated using Green-
wood’s method [10] in partially complete analysis and in 
period analysis by applying the delta method to a trans-
formation of the cumulative hazard. For age-standardized 
RS, 95% CI were estimated as described in [9].
To test for linear time trends of RS, the annual percentage 
change and its 95% CI was estimated with the Joinpoint 
Regression Program v4.0.4 [11].
Results
This report combines more than 8’500 person-years of 
survival experience for patients diagnosed with primary 
malignant cancer of the oesophagus (Tab. 1). The data 
pool contains increasing numbers of cancer registries over 
time. Until 1995, only the cantons AR, AI, BL, BS, GE, 
SG, and ZH contributed to the pool, whereas canton TI 
joined in 1996, canton FR in 2006, canton LU in 2010, 
and cantons OW, NW, UR and ZG in 2011. The cantons 
TI, VS, GR, GL, FR, LU, OW, NW, UR and ZG contrib-
uted less than 25% of the total cases. 
Age at diagnosis ranged from 29 to 101 years. The me-
dian age at diagnosis was 66 years in men (interquartile 
range IQR 58-74) and 71 years in women (IQR 61-80). 
Neoplasms are more frequent at deeper anatomic sub-
sites within the oesophagus, and overall, the most com-
mon primary malignancy was squamous cell carcinoma 
(61%), followed by adenocarcinoma (31%), other type 
(5%), and unspeci!ed type (3%). Adenocarcinoma inci-
dence increased in relative frequency from 29% to 39% 
if 1991-2000 is compared with 2001-2010, while squa-
mous cell carcinoma incidence decreased from 62% to 
53%, and proportions of other or unspeci!ed histologic 
types remained constant. Information regarding tumour 
detection was available from the cantons GE, VS and FR 
and revealed that symptoms were responsible for detec-
tion in 88% of the cases. 
The survival experience of men and women diagnosed 
with cancer of the oesophagus is shown in Tab. 2 for 
survival proportions at one and !ve years after diagnosis, 
and by survival curves in Fig. 1. The age-standardized 
relative survival (RS) proportions in men, diagnosed be-
tween 1991 and 2000, were 41.2% and 11.5% for one 
and !ve years after diagnosis, respectively. A decade 
later (2001-2010), the age-standardized RS had im-
proved substantially to 51.1% and 18.5%, respectively. 
Age-standardized and age-speci!c relative survival (RS) 
proportions in women were slightly higher as compared 
with men, an advantage which declined with time of 
diagnosis. For diagnoses between 1991 and 2000, age-
standardized RS in women were 44.2% and 17.9% for 
one and !ve years after diagnosis, respectively. A decade 
later (2001-2010), the improvement was somewhat less 
as compared with men, to 51.1% and 21.5%, respec-
tively. 
Temporal survival trends were analysed at higher resolu-
tion using !ve consecutive time periods of four year dura-
tion, starting in 1992 and ending in 2011 (Tab. 3). The 
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zero for short term (one year after diagnosis) as well as 
for long term survival (!ve years after diagnosis). Persons 
above 60 years of age at diagnosis seemed to have gained 
less than younger patients if !ve-year RS is compared with 
one-year RS: the gap in RS at !ve year after diagnosis be-
tween age 75+ and <60 has widened from 8% to 22%, 
and between age 60-74 and <60 from -3 to 11%, while 
the one-year RS gaps by age remained the same.  
Discussion
The main strength of our study is the large number of 
malignant primary oesophageal cancer cases that could be 
combined from seventeen Swiss cantons. The data spans 
30 calendar years, thus allowing the analysis of changes 
over time. There are, however, important limitations to 
our study. We did not stratify survival by histological type 
of the primary tumour nor by progression stage of the 
disease due to limited data. In Switzerland we observed 
the same trend as in the Western world towards more ad-
enocarcinoma compared to the squamous cell carcinoma. 
Because of slight survival advantages for cases of adeno-
carcinoma over squamous cell carcinoma [12], different 
case mix might have contributed to the observed positive 
trend in survival. 
While age-standardized !ve year RS for men and women 
combined in Switzerland was close to the European mean 
for diagnoses during the Nineties of the 20th century, the 
RS moved to a position clearly above the European mean 
for diagnoses during the 1st decade of the 21st century. The 
4th round of the European cancer registry-based study of 
cancer patients’ survival and care, or EUROCARE-4 [13], 
estimated age-standardized !ve year RS for patients diag-
Table 2: Relative 
survival estimates 
after diagnosis of 
malignant cancer of the 
oesophagus, with 95% 
con!dence intervals, by 
10-year calendar period, 
age at diagnosis, years 
since diagnosis and sex. 
Data pooled from 13 
Swiss cantons (AR, AI, 
BL, BS, FR, GE, GL, GR, 
LU, SG, TI, VS, and ZH).
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Table 3: Trends in relative survival for 
cancer of the oesophagus, expressed 
as the annual percentage change 
(APC). Cases for men and women were 
pooled from 17 Swiss cantons (AR, AI, 
BL, BS, FR, GE, GL, GR, LU, NW, OW, SG, 
TI, UR, VS, ZG, and ZH) for successive 
four-year calendar periods of follow-up.
Figure 1: Age-speci!c relative survival 
curves for two calendar periods of 
diagnosis (1991-2000 and 2001-
2010). 95% con!dence intervals are 
shown for survival proportions at one 
and !ve years after diagnosis. Cases 
of oesophageal cancer in men and 
women were pooled from 13 Swiss 
cantons (AR, AI, BL, BS, FR, GE, GL, GR, 
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nosed with oesophageal cancer in 1995-1999 with 11.1%, 
which is close to the Swiss estimate of 12.5% for diagnoses 
in 1991-2000 (Tab. 2) or 1996-1999 (Tab. 3). While the 
updated EUROCARE-5 estimates of the European mean 
survival for patients diagnosed 2000-2007 remained 
low at 12.4% [14], estimates for Switzerland improved 
to 19.1% for patients diagnosed 2001-2010 (Tab. 2), or 
19.0% for 2004-2007 (Tab. 3). There could be several rea-
sons for this observation. Before 2001, patients in Switzer-
land were treated very heterogeneously. In 2002, the Swiss 
Group of Clinical Cancer Research (SAKK) started a se-
ries of clinical trials in the !eld of oe sophageal carcinoma. 
Since then almost all clinical centers in Switzerland treat-
ing this type of cancer have participat ed in these SAKK 
activities. This has certainly led to better standardization 
of diagnosis and therapy in Switzerland and can explain 
some increase in quality of care. Other reasons for the in-
creased survival over time are better patient selection and 
improved perioperative management. Most patients with 
newly diagnosed oesophageal carcinoma present with lo-
cally advanced disease. It remains a challenge to clinically 
stage these patients. For T-staging endosonography is re-
garded as the most accurate tool, whereas for N- and M-
stage determination the combination of endosonography 
and PET-CT scan should be used. PET-CT scan detects 
about 10-20% distant metastasis not seen with conven-
tional staging and is able to prevent this kind of surgery 
for some patients. In most European countries PET-CT 
is not registered for oesophageal cancer diagnostics. In 
Switzerland those diagnostic tools has been widespread 
and increased the accuracy of staging compared to some 
other European countries.  Similar differences were seen 
in the peri- and postoperative management keeping in 
mind that oesophageal surgery is linked with a high peri-
operative risk for patients and full equipped, highly expe-
rienced intensive care unit is key. 
In spite of some improvement in survival over time we 
have to recognize that survival with oesophageal carci-
noma is still poor. The main reason is that most of the 
tumours already have systemic metastases at diagno-
sis. Progress over the last decade has been modest, and 
primarily re#ects better patient selection and improved 
perioperative management. To accelerate progress, more 
research in this !eld is needed. In addition, public health 
interventions working towards changes in lifestyle factors 
associated with increased risk and worse survival, espe-
cially tobacco smoking [15, 16], might be bene!cial. 
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Ricerca svizzera contro il cancro / Swiss Cancer Research KFS
Krebsforscherin Nancy 
Hynes ab 2015 neue
WiKo-Präsidentin
Kurt Bodenmüller, Krebsliga Schweiz
Ende 2014 endet die Amtszeit des Präsidenten der Wis-
senschaftlichen Kom mision (WiKo), Prof. Dr. med. 
Martin F. Fey. Eine externe, unabhängige Eva luation 
hat der Arbeit des Fachgremiums, die während neun 
Jahren unter der Ägide des Direktors und Chefarztes 
der Universitätsklinik für Medizinische Onkologie am 
Ber ner Inselspital stand, kürzlich sehr gute Noten be-
scheinigt. In seine Fussstapfen tritt die renommierte 
Krebsforscherin Prof. Dr. Nancy Hynes, Forschungs-
gruppenleiterin am Friedrich Miescher Institut und 
Titularprofessorin für Molekularbiologie an der Uni-
versität Basel.
Im Juni bzw. Juli haben der Stiftungsrat der Krebsfor-
schung Schweiz und der Vorstand der Krebsliga Schweiz 
Prof. Dr. Nancy Hynes einstimmig zur Präsidentin der 
Wissenschaftlichen Kommission (WiKo) gewählt. Das 
17-köp!ge Fachgremium evaluiert pro Jahr rund 170 
Forschungs- und Stipendiengesuche aus allen Krebsfor-
schungsbereichen nach klar de!nierten, wissenschaftli-
chen Kriterien. Basierend auf ihren Empfehlungen !nan-
zieren die Vorstände von Krebsforschung und Krebsliga 
Schweiz jährlich gut 70 Projekte und Stipendiaten mit 
14–15 Millionen Franken.
Überzeugende Nachfolgerin
Aus einer Liste mit 13 potenziellen Kandidatinnen und 
Kandidaten überzeugte Nancy Hynes die Vorstände in je-
der Hinsicht. Von 1994 bis 2001 war sie bereits Mitglied 
der WiKo sowie 27 weiteren Gremien, Review Panels, 
Advisory und Editorial Boards, die sie zum Teil auch prä-
sidierte. Ihr wissenschaftlicher Leistungsausweis ist tadel-
los: Hynes wies den höchsten h-Index von 67 aus, hat 183 
Publikationen als Erst- bzw. Letztautorin veröffentlicht 
und die durchschnittliche Anzahl Zitierungen pro Publi-
kation liegt bei 85 – ein Spitzenresultat. Die Biochemike-
rin ist eine weltweit anerkannte Expertin im Bereich der 
Signalübertragung bei Brustkrebs und im Speziellen des 
Her2-Rezeptors, der bei der Diagnose und Therapie des 
Mammakarzinoms eine wichtige Rolle spielt.
Für ihre wissenschaftliche 
Leistung wurde Nancy Hy-
nes mehrfach mit hochdo-
tierten Forschungspreisen 
ausgezeichnet, darunter auch 
der Robert Wenner-Preis 
der Krebsliga Schweiz. 
Die US-Amerikanerin lebt 
seit ihrer Zeit als Post-Doc 
Ende der 70er-Jahre in der 
Schweiz. Obwohl sie selber 
keine Medizinerin ist, ar-
beitete sie aufgrund ihres 
Forschungsthemas lange 
und intensiv mit Klinikern 
zusammen. Die Förderung 
der translatio nalen Krebsforschung – die Verbindung von 
Laborforschung und Patientenbehandlung – war stets ein 
zentraler Schwerpunkt ihrer Arbeit. Nancy Hynes, die im 
Frühjahr 2015 pensioniert wird, ist somit eine Idealbeset-
zung für das Amt als WiKo-Präsidentin.
Eindrücklicher Leistungsausweis
Sie übernimmt den Stab von Martin F. Fey, der die WiKo 
von 2006 bis 2014 präsidiert hat. Sowohl seine Arbeit 
wie auch seine Art wurden von den Vorstands- und Kom-
Prof. Dr. med. Martin F. Fey
Prof. Dr. Nancy Hynes





missionsmitgliedern rundum geschätzt. Kompromisslose 
«scienti!c excellence» war stets sein Massstab für die fach-
liche Begutachtung der Forschungsarbeiten. Engagiert 
hat sich der Onkologe aber nicht bloss für die Förderung 
der klinischen Forschung, sondern – neben der kompeti-
tiven Grundlagenforschung – auch für epidemiologische 
und psychosoziale Forschungsarbeiten. Mit seinen klaren 
und mit spitzem Humor vorgetragenen Voten schaffte es 
Martin F. Fey, die WiKo-Mitglieder während den jeweils 
ganztätigen Sitzungen bei guter Laune zu halten. 
Ende 2013 wurde eine umfangreiche Evaluation nach 
internationalen Standards der Forschungsförderung von 
Krebsforschung und Krebsliga Schweiz für den Zeitraum 
1998-2012 veröffentlicht. Die international zusammen-
gesetzte Expertengruppe würdigte in ihrem Bericht ins-
besondere die exzellente Arbeit der WiKo im Rahmen des 
Peer-Review-Verfahrens (siehe Artikel auf Seite 53-55 im 
Krebsbulletin vom März 2014). Gute Noten gab es auch 
seitens der Forschenden: Die überwiegende Mehrheit be-
zeichnete den Evaluationsprozess als transparent, fair und 
qualitativ gut. Die bibliometrische Analyse ergab ebenfalls 
erfreuliche Resultate: Ein Grossteil der unterstützten Pro-
jekte waren von ausgezeichneter Qualität und resultierten 
in vielen bedeutenden Publikationen – mit Topwerten im 
internationalen Vergleich. Für seine hervorragende Arbeit 
gebührt ihm seitens der Krebsforschung und der Krebsli-
ga Schweiz ein herzliches Dankeschön.
KFS
   Schweizer Krebsbulletin  Nr. 3/2014 235
KLSKrebsliga Schweiz / Ligue Suisse contre le cancerLega svizzera contro il cancro / Swiss Cancer League
InfoMonat Brustkrebs: 
Neue Broschüre, neues 
Booklet, neue Aktion
Cordula Sanwald, Kommunikationsbeauftragte, 
Krebsliga Schweiz
Der Oktober ist weltweit dem Thema Brustkrebs 
gewidmet. Die Krebsliga hat anlässlich des «Info-
monats Brustkrebs» die neue, über 80 Seiten starke 
Broschüre «Brustkrebs - Mammakarzinom » heraus-
gebracht. Begleitet wird sie von einem kleinen Book-
let mit Übungen für Frauen nach einer Brustkrebs-
operation. 
In der Schweiz erhalten jedes Jahr rund 5500 Frauen die 
Diagnose Brustkrebs. Die neue Broschüre der Krebsliga 
«Brustkrebs – Mammakarzinom» möchte diesen Frauen 
und ihren Angehörigen eine erste Orientierung geben 
in einer Situation, in der das Leben ausser Balance gerät. 
Entsprechend umfassend ist die Publikation angelegt. Sie 
beschreibt eingangs grundlegend die weibliche Brust und 
ihre Funktion, geht auf gutartige Veränderungen und 
Knoten ein, um schliesslich die unterschiedlichen Formen 
von Brustkrebs darzulegen.
Die Frage nach der Ursache für und Anzeichen von Brust-
krebs beschäftigt viele Frauen. Weil bislang jedoch keine 
eindeutigen Ursachen für Brustkrebs bekannt sind und es 
daher keine Methode gibt, um Brustkrebs zu verhindern, 
geht die Broschüre in diesem Zusammenhang vor allem 
auf  jene Faktoren ein, die das Erkrankungsrisiko erhöhen 
und skizziert mögliche Beschwerden und Symptome.
Informationen und Hilfestellungen
Die Krebsliga hat grosse Erfahrung in der Beratung von 
Krebsbetroffenen und ihren Nächsten. Viel Raum nehmen 
in den Begleitungsgesprächen stets Erläuterungen ein, wel-
che die Untersuchung, die Diagnose und den Therapiepro-
zess bei Krebserkrankungen genauer erklären. Auch in der 
neuen Broschüre wurde diesen Fragen sorgfältig nachge-
gangen. So erhalten Lesende Informationen zu den ersten 
Abklärungen und den verschiedenen Untersuchungen, 
die zur genauen Diagnose führen. Erklärt werden auch die 
TNM-Klassi!zierungen, die UICC-Krankheitsstadien so-
wie die weiteren Präzisierungen der Diagnosen. 
Oft fällt es Betroffenen und ihren Nächsten schwer, in 
einer belastenden, akuten Phase die für sie wichtigen 
Fragen zu stellen. Die Broschüre gibt auch hier Hilfestel-
lung, thematisiert den Umgang mit unerwünschten Wir-
kungen der Therapie und greift Themen auf wie Sexua-
lität, Kinderwunsch oder Körperbild. Sie ermutigt zum 
Gespräch mit medizinischen wie psychoonkologischen 
Fachpersonen und unterstützt Betroffene bei der Vorbe-
reitung auf solche Gespräche. 
Behandlungsmöglichkeiten und Behandlungsablauf
Die Erkenntnisse der Forschung zu Brustkrebs in den 
letzten Jahren haben dazu geführt, dass Diagnosen im-
mer präziser und die Therapien immer gezielter auf jede 
betroffene Frau abgestimmt werden. Die Vielzahl der 
heutigen Behandlungsmöglichkeiten stellen Betroffene 
allerdings oft vor Entscheidungsprobleme. Die Krebsli-
ga-Broschüre zeigt die unterschiedlichen Behandlungs-
möglichkeiten bei Brustkrebs auf und erklärt die Wir-
kungsweise der einzelnen Therapien. Sie skizziert, welche 
Therapie bei welcher Diagnose und in welchem Stadium 
in Frage kommt  und stellt sachlich mögliche Folgen und 
Nebenwirkungen dar. Weitere Kapitel widmen sich einer-
seits den Behandlungsabläufen in verschiedenen Stadien, 
andererseits weiterführenden Behandlungen, welche zum 
Beispiel die Rekonstruktion der Brust oder eine Brustpro-
these ebenso im Fokus haben wie ein Lymphödem.
Ein ausführliches Verzeichnis mit Adressen von Bera-
tungs- und Informationsstellen, mit Literatur-, Broschü-
ren- und Internet-Hinweisen zu Brustkrebs bei Frauen 
und bei Männern runden die Publikation ab.
Bestellung
«Brustkrebs- Mammakarzinom» sowie das Booklet «Bewe-
gung tut gut» liegen derzeit erst in deutscher Sprache vor. 
Sie sind  kostenlos erhältlich. Beides kann bei der Krebsliga 
bestellt werden. Sie erhalten die Publikationen auch bei den 
kantonalen und regionalen Krebsligen. www.krebsliga.ch
Bestellungen unter Tel. 0844 85 00 00, shop@krebsliga.ch 
oder im Internet unter www.krebsliga.ch/broschueren
Bewegung tut gut 
Bewegung spielt für krebsbetrof-
fene Frauen eine wichtige Rolle. Es 
ist wissenschaftlich belegt, dass der 
Krankheitsverlauf bei Brustkrebsbe-
troffenen, die regelmässig körperlich 
aktiv sind, positiv beein#usst werden 
kann. Darum liegt jeder Brustkrebs-
Broschüre ein kleines Büchlein mit 
Übungen bei, die speziell nach einer 
Brustkrebsoperation sinnvoll sind. 
Das Büchlein «Bewegung tut gut» 
ist auch separat erhältlich. 
3
Bewegung tut gut 
Übungen nach einer Brustoperation
Ein Angebot der Krebsliga
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Radon entsteht beim 
Zerfall von Uran im 
Erdreich. Dieses na-
türliche, radioaktive 
Edelgas, verursacht in 
der Schweiz jährlich 
200 bis 300 Todesfälle 
durch Lungenkrebs. 
Mit baulichen Mass-
nahmen bei Neu- und 
Umbauten kann die 
Radonbelastung in 
Innenräumen stark 
gesenkt werden. Die 
Krebstagung 2014 be-
leuchtet dieses wich-
tige Thema aus un-
terschiedlichen Blickwinkeln und gibt Fachpersonen 
aus Medizin, Public Health, Wissenschaft und aus 
dem Bauwesen die Möglichkeit, sich zu vernetzen. 
Das natürliche, radioaktive Edelgas Radon gelangt vom 
Boden her in die Luft und ist unsichtbar, geruch- und 
geschmacklos. In der freien Umgebungsluft ist es unbe-
denklich für die Gesundheit. Es kann jedoch durch un-
dichte Stellen in Bodenplatten und Kellerwänden in Häu-
ser eindringen und sich dort anreichern. 
Radonatome können weiter zerfallen. Werden diese radio-
aktiven Zerfallsprodukte eingeatmet, setzen sie sich in 
der Lunge fest und bestrahlen das Lungengewebe. Mit 
steigender Radonkonzentration erhöht sich das Risiko, an 
Lungenkrebs zu erkranken. 
Lungenkrebs durch Radon
Die Ergebnisse von epidemiologischen Studien, die nach 
1994 durchgeführt wurden, zeigen, dass das Risiko im 
Zusammenhang mit einer langfristigen Radonexposition 
in Wohnräumen grösser ist, als frühere Studien mit Berg-
arbeitern vermuten liessen. Aufgrund dieser Erkenntnisse 
empfahl die Weltgesundheitsorganisation 2009 eine ma-
ximale Konzentration von 300 Bq/m3, um das gesund-
heitliche Risiko infolge der Radonbelastung in Innenräu-
men zu verringern. 
Den neuen Risikoeinschätzungen zufolge treten erhöhte 
Radonkonzentrationen in Innenräumen nicht nur in den 
bis anhin bekannten Risikogebieten der Alpen und der 
Jurakette, sondern in allen Regionen der Schweiz auf. Ra-
don verursacht 8 bis 10 Prozent der Lungenkrebstodesfäl-
le in der Schweiz, dies entspricht 200 bis 300 Todesfällen 
pro Jahr. Diese Anzahl ist vergleichbar mit der Anzahl 
an Todesfällen durch Melanome. Nach dem Rauchen ist 
Radon die häu!gste Ursache für Lungenkrebs, für Nicht-
raucher stellt Radon gar den grössten Risikofaktor für 
Lungenkrebs dar.
Radonschutz in der Schweiz 
Das Bundesamt für Gesundheit lancierte 2011 den natio-
nalen Radonaktionsplan 2012–2020, mit dem Ziel, den 
Schutz der Schweizer Bevölkerung vor Radon sicherzu-
stellen. Schlüsselelement des Aktionsplans ist die Revi-
sion der Strahlenschutzgesetzgebung, bei der die Grenz-
werte angepasst werden sollen. Auch die Förderung des 
Radonschutzes im Bausektor stellt ein zentrales Element 
dar: durch geeignete Massnahmen bei Neu- und Um-
bauten lässt sich die Radonbelastung in Innenräumen mit 
wenig Aufwand erheblich senken. 
Die Radonkonzentration kann sich beispielsweise auch als 
Folge einer energetischen Sanierung erhöhen, da das Edel-
gas durch die verbesserte Gebäudeabdichtung bzw. Isola-
tion nur noch ungenügend aus dem Gebäude entweichen 
kann. Eine Abstimmung von Energie- und Radonsanie-
rung ist somit unerlässlich. In Zukunft wird Radon auch 
in den Baunormen verankert werden.
Krebstagung 2014: Radon – unterschätztes Risiko 
im Wohnraum
Alle Bewohnerinnen und Bewohner der Schweiz können 
durch erhöhte Radonkonzentrationen belastet werden, 
Krebstagung 2014: 
Radon –  
unterschätztes Risiko  
im Wohnraum
Donnerstag, 4. Dezember 2014
Hotel National, Bern
Radon – unterschätztes Risiko im Wohnraum
Patrizia Frei, Projektleiterin Umwelt und Tabak, Krebsliga Schweiz
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mente ainsi le risque 
de contracter un can-
cer du poumon.
Cancer du poumon 
engendré par le ra-
don
Les résultats de nou-
velles études épidémio-
logiques réalisées dans 
l’habitat montrent que 
le risque, extrapolé à 
partir de données sur les 
travailleurs de mines, a 
jusqu’ici été sous-éva-
lué. Sur la base de ces conclusions, l’Organisation mondiale 
de la santé a recommandé en 2009 une concentration maxi-
Le radon provient de la désintégration de l’uranium 
dans le sol. Ce gaz naturel radioactif provoque chaque 
année en Suisse 200 à 300 décès par cancer du pou-
mon. Des techniques de construction permettent de 
réduire considérablement la concentration de radon 
dans les bâtiments neufs et rénovés. La Journée du 
cancer 2014 éclaire ce thème important sous diffé-
rents angles et offre aux professionnels de la méde-
cine, de la santé publique, de la science et du secteur 
du bâtiment la possibilité de se rencontrer.
Le gaz radioactif radon est naturellement présent dans le 
sol; ses émanations dans l’air sont invisibles, inodores et 
insipides. À l’air libre, il ne présente aucun risque pour la 
santé. Il peut cependant s’in!ltrer par les défauts d’étan-
chéité de l’enveloppe des bâtiments et s’accumuler dans 
l’air ambiant. Lors de la respiration, les produits de désin-
tégration du radon se déposent sur le tissu pulmonaire et 
l’irradient. Une concentration croissante de radon aug-
KLS/LSC
Radonschutz ist deswegen eine Notwendigkeit. Aus die-
sem Grund organisiert die Krebsliga Schweiz gemeinsam 
mit dem Bundesamt für Gesundheit und in Partnerschaft 
mit dem Schweizerischen Ingenieur- und Architektenver-
ein (SIA) am 4. Dezember 2014 im Hotel National in 
Bern eine Tagung zum Thema Radon. 
Fachreferenten aus Medizin, Wissenschaft und Bauwe-
sen beleuchten Radon und dessen Risiken aus unter-
schiedlichen Blickwinkeln. Die Tagung wendet sich an 
Fachleute und Interessierte aus Medizin, Public Health, 
Bauwesen und Wissenschaft sowie an Behördenvertreter, 
Hauseigentümer und Notare. Die Tagung wird mit ei-
ner Podiumsdiskussion abgeschlossen, an welcher u. a. 
Dr. Roland Charrière, Stv. Direktor des Bundesamtes für 
Gesundheit, und Prof. Dr. Jakob Passweg, Präsident der 
Krebsliga Schweiz teilnehmen.
Das Programm der Krebstagung 2014 sowie die Anmel-
demodalitäten und weitere Informationen !nden sich un-
ter www.krebsliga.ch/krebstagung. 
Krebstagung 2014: «Radon – unterschätztes 
Risiko im Wohnraum»
Donnerstag, 4. Dezember 2014, 9.15–16.30 Uhr
Hotel National in Bern
www.krebsliga.ch/krebstagung 
Ein Anlass der Krebsliga Schweiz und des Bun-
desamtes für Gesundheit. Der Schweizerische In-
genieur- und Architektenverband (SIA) ist Part-
ner der Tagung.  
Korrespondenz:
Dr. Patrizia Frei
Projektleiterin Umwelt und Tabak
Krebsliga Schweiz
krebstagung@krebsliga.ch
Journée du cancer 2014 : 
Radon –  
un risque sous-estimé 
dans l’habitat
Jeudi 4 décembre 2014
Hôtel National, Berne
Radon – un risque sous-estimé dans l’habitat
Patrizia Frei, responsable de projet Environnement et tabac, Ligue suisse contre le cancer
 238 Schweizer Krebsbulletin  Nr. 3/2014
male de 300 Bq/m3, a!n de réduire les risques sanitaires liés 
au radon dans l’habitat.
Selon cette évaluation récente du risque, toutes les régions 
de Suisse sont désormais concernées par la problématique 
du radon, et plus seulement les régions à risque élevé des 
Alpes et de l’Arc jurassien dé!nies jusqu’ici. Le radon gé-
nère 8 à 10 pourcent des décès par cancer du poumon, soit 
200 à 300 cas par année en Suisse. Ce chiffre est comparable 
à celui des décès suite à des mélanomes. Le radon est la cause 
la plus fréquente de cancer du poumon après le tabagisme. 
Protection contre le radon en Suisse
En 2011, l’Of!ce fédéral de la santé publique a lancé le 
Plan d’action radon 2012–2020, dans le but d’assurer la 
protection de la population. L’élément-clé de ce plan d’ac-
tion est la révision de la législation sur la radioprotection, 
dont les valeurs légales doivent être ajustées. Promou-
voir la protection contre le radon dans le secteur du bâti-
ment est également un élément central: des techniques 
appropriées lors de la construction et des transformations 
permettent de réduire considérablement et facilement la 
concentration de radon dans les bâtiments.
Cette concentration peut également augmenter, par 
exemple suite à un assainissement énergétique, étant don-
né que la ventilation naturelle du bâtiment sera entravée. 
Un compromis entre l’assainissement énergétique et le 
radon est donc indispensable. À l’avenir, le radon sera éga-
lement intégré dans les normes de construction.
Journée du cancer 2014: Radon – Un risque 
sous-estimé dans l’habitat
Toute la population suisse peut être exposée à des concen-
trations accrues de radon. La protection contre ce gaz est 
par conséquent nécessaire. Dans ce cadre, la Ligue suisse 
contre le cancer organisera une journée sur le thème du 
radon le 4 décembre 2014 à l’Hôtel National de Berne, 
LSC
en collaboration avec l’Of!ce fédéral de la santé publique 
et en partenariat avec la Société suisse des ingénieurs et 
des architectes (SIA). 
Des intervenants spécialisés dans les domaines de la mé-
decine, de la science et du bâtiment apporteront chacun 
leur éclairage sur les risques liés au radon. Cette journée 
s’adresse aux professionnels de la médecine, de la santé 
publique et de la construction, aux scienti!ques, aux per-
sonnes intéressées, ainsi qu’aux représentants des autori-
tés, aux propriétaires immobiliers et aux notaires. Elle se 
terminera par un débat public auquel participeront, entre 
autres, le Dr Roland Charrière, directeur suppléant de 
l’Of!ce fédéral de la santé publique et le Prof. Jakob Pass-
weg, président de la Ligue suisse contre le cancer.
Vous trouverez le programme de la Journée du cancer 
2014, les modalités d’inscription et des informations com-
plémentaires sous www.liguecancer.ch/journeeducancer. 
Correspondance:
Dr Patrizia Frei
Responsable de projet Environnement et tabac
Ligue suisse contre le cancer
journeecancer@liguecancer.ch
Journée du cancer 2014: «Radon – Un risque 
sous-estimé dans l’habitat»
Jeudi 4 décembre 2014, 09.15-16.30 h
Hôtel National, Berne
www.liguecancer.ch/journeeducancer
Un événement de la Ligue suisse contre le cancer 
et de l’Of"ce fédéral de la santé publique, en par-
tenariat avec la Société suisse des ingénieurs et 
des architectes (SIA). 
   Schweizer Krebsbulletin  Nr. 3/2014 239
LSC
Im Oktober sieht 
die Schweiz Pink!
Im Oktober 2014 mobilisiert die Krebsliga die ganze 
Schweiz zur Solidarität mit Brustkrebsbetroffenen. 
Mit der Aktion «Die Schweiz sieht Pink – bekenne 
Farbe» baut die Krebsliga eine neue Community-
Plattform auf, um den von Brustkrebs betroffenen 
Frauen und ihren Angehörigen und Freunden 
einen Raum des Austauschs zu bieten. Gleichzeitig 
ermöglicht diese Plattform allen Interessierten, ihre 
Solidarität durch eigene Aktionen oder durch die 
Teilnahme an Veranstaltungen konkret kundzutun. 
Eine neue pink-farbige Community-Plattform, 
… um Emotionen zu teilen!
Unter dem Motto «Die Schweiz sieht Pink – bekenne 
Farbe» lädt die Krebsliga Brustkrebsbetroffene, ihre An-
gehörigen und alle Interessierten ein, ihre Hoffnungen, 
ihre Wünsche und ihre Trauer auf der neuen Commu-
nity-Plattform zu teilen: www.krebsliga.ch/brustkrebs 
(ab 1. Oktober 2014). 
… um private-Solidaritätsaktionen anzukünden!
Im Oktober sind alle Interessierten aufgerufen, eine per-
sönliche Aktion zur Solidarität mit Brustkrebsbetroffenen 
durchzuführen und diese auf der Community-Plattform 
bekanntzumachen: Pink-farbige Muf!ns backen und ver-
kaufen, Haare pink färben, die persönliche Facebook-Seite 
pink einfärben, ein Konzert zugunsten der Krebsliga ge-
ben – dem Einfallsreichtum sind keine Grenzen gesetzt. 
… um sich solidarisch zu zeigen! 
Weiter kann die Bevölkerung an verschiedenen Aktionen 
oder Aktivitäten teilnehmen, die von der Krebsliga und 
ihren kantonalen und regionalen Ligen, von Partnern oder 
von Privatpersonen auf der Plattform angeboten werden. 
Die Aktionen !nden alle im Oktober statt. Ihren Hö-
hepunkt erreichen sie am 23. Oktober, an dem sich die 
Schweiz aufgrund der zahlreichen Aktionen ganz in pink 
präsentieren wird. 
Alle diese Aktionen werden auf der Community-Platt-
form beworben und dokumentiert.
www.krebsliga.ch/brustkrebs
Im Oktober sieht die Schweiz Pink. 
En octobre, 
la Suisse voit rose!
En octobre, la Ligue contre le cancer invite toute la 
Suisse à se mobiliser pour témoigner sa solidarité aux 
personnes touchées par le cancer du sein. A travers 
l’action «La Suisse voit rose», elle met en place une 
nouvelle plateforme communautaire qui poursuit 
un double objectif: offrir aux femmes concernées et 
à leurs proches et amis un espace de partage, mais 
aussi permettre à tous les intéressés de faire connaître 
leur soutien en organisant des actions ou en partici-
pant à des activités. 
Une nouvelle plateforme communautaire en rose pour… 
… partager ses émotions 
Sous le slogan «La Suisse voit rose», la Ligue contre le 
cancer invite les femmes touchées par le cancer du sein, 
leurs proches et tous les intéressés à partager leurs es-
poirs, leurs souhaits et leur tristesse sur la nouvelle plate-
forme communautaire: www.liguecancer.ch/cancerdusein 
(dès le 1er octobre). 
… annoncer des actions personnelles de solidarité 
En octobre, toutes les personnes intéressées sont invitées à 
mettre sur pied une action personnelle en signe de solida-
rité avec les femmes touchées par le cancer du sein et à le 
faire savoir sur la plateforme communautaire: confection-
ner et vendre des muf!ns roses, se teindre les cheveux en 
rose, af!cher sa page facebook en rose, donner un concert 
au pro!t de la Ligue contre le cancer… il n’y a pas de 
limite à l’expression de la solidarité! 
… participer au mouvement de solidarité 
La population pourra par ailleurs participer à différentes 
actions ou activités organisées par la Ligue suisse et les 
ligues cantonales et régionales contre le cancer, par des 
partenaires ou des particuliers. Toutes les actions se dérou-
leront en octobre et trouveront leur point culminant le 
jeudi 23: ce jour-là, grâce aux nombreuses actions mises 
en place, toute la Suisse se présentera en rose. 
Toutes ces actions seront annoncées et documentées sur la 
plateforme communautaire.
www.liguecancer.ch/cancerdusein
En octobre, la Suisse voit rose!
Correspondance:
Nicole Bulliard, chargée de communication
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Fort- und Weiterbildungen der Krebsliga Schweiz
Formation continue de la Ligue suisse contre le cancer
 «INTERPROFESSIONELLE WEITERBILDUNG IN PSYCHOONKOLOGIE»
In folgenden Einzel-Workshops hat es freie Plätze:
23.10.2014 Inselspital, Wirtschaftsgebäude, Bern
 Ganzer Tag: Einführung in die Psychoonkologie: Konzepte und Onkogenese
20.11.2014 Haus der Krebsliga, Bern
 Nachmittag: Brustkrebs / Hoden CA / Melanom
11.12.2014 Haus der Krebsliga, Bern
 Nachmittag: Allgemeine Tumoreinteilung und Staging, Lungenkrebs, HNO-Krebs
19.03.2015 Inselspital, Wirtschaftsgebäude, Bern
 Vormittag: Onkologische Behandlung (Prostata CA / Lymphome, Nieren CA)
 Nachmittag: Männerbetreuung
23.04.2015 Haus der Krebsliga, Bern
 Nachmittag: Genetische Prädisposition: Wie beraten?
21.05.2015 Inselspital, Wirtschaftsgebäude, Bern
 Vormittag: Hämatologie / Nachmittag: Folgen der Isolation
18.06.2015 Inselspital, Wirtschaftsgebäude, Bern
 Vormittag: Coping, Lebensqualität (kognitive Störungen, Umgang mit Persönlichkeitsveränderungen)
 Nachmittag: Hirntumoren
Information und Anmeldung für Lehrgang und Einzel-Workshops: Loredana Palandrani, Krebsliga Schweiz, 
Kursadministration, Tel. 031 389 93 27, kurse-cst@krebsliga.ch
 «KOMMUNIKATIONSTRAINING»
Seminar für Ärztinnen, Ärzte und P!egefachleute von Krebskranken
Teilnehmende sind onkologisch erfahrene Fachkräfte, die ihre Kommunikationstechniken verbessern 
möchten. 
Nr. 146  30.–31.10.2014  Sorell Hotel Aarauerhof, Aarau
Das Seminar wird von der SGMO für den FMH-Titel Onkologie gemäss Weiterbildungsstatut akzeptiert. 
Diverse medizinische Fachgesellschaften vergeben Fortbildungspunkte/Credits.
Information und Anmeldung: Loredana Palandrani, Krebsliga Schweiz, Kursadministration 
Tel. 031 389 93 27, kurse-cst@krebsliga.ch
Kommunikation mit krebskranken Jugendlichen und deren Eltern
Trainingsseminar für pädiatrische Onkologen und Onkologiep!egende
 21.-22.11.2014 Hotel Bildungszentrum 21, Basel
Angefragt wurde die Schweizerische Gesellschaft für Pädiatrie, die das Seminar bisher mit 12.5 Credits als 
fachspezi"sche Kernfortbildung anerkannt hat.
Information und Anmeldung: kurse-cst@krebsliga.ch, www.krebsliga.ch/cst_d
 «MIEUX COMMUNIQUER»
Séminaire pour médecins et personnel in"rmier en oncologie
Ce cours est destiné à des personnes expérimentées travaillant en oncologie, et souhaitant perfectionner 
leurs connaissances en techniques de communication. 
No 229  27.–28.11.2014 Hôtel Préalpina, Chexbres
Ce séminaire est reconnu par la SSOM pour le titre FMH en oncologie, en accord avec les statuts régissant 
la formation continue. Différentes sociétés médicales reconnaissent ce séminaire et lui octroient des crédits 
de formation continue.
Information et inscription: Loredana Palandrani, Krebsliga Schweiz, Kursadministration 
Tel. 031 389 93 27, kurse-cst@krebsliga.ch
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SGPOSchweizerische Gesellschaft für Psychoonkologie
Tagungsbericht zur 
11. Schweizer Fachtagung 
Psychoonkologie vom 
10. April 2014 in Olten
Theresa Tondorf, Unispital Basel, Onkologie
Das Thema der diesjährigen Fachtagung «Der Angst den 
Schrecken nehmen» stiess auf reges Interesse. Die Tagung 
war lange vor Anmeldeschluss ausgebucht und mit 150 
Teilnehmern sehr gut besucht. Der Tag begann mit der 
Mitgliederversammlung der SGPO, bei der die drei lang-
jährigen Vorstandsmitglieder Urs Stillhard, Christine Beer 
und Regula Ursprung mit einem grossen Dankeschön für 
ihr grosses Engagement und ihre Arbeit verabschiedet wur-
den. Dem Vorschlag des Vorstandes, Ruedi Schweizer und 
Lucia Stäubli neu in den Vorstand aufzunehmen, stimmten 
die anwesenden Mitglieder ohne Gegenstimme zu. 
Als erstes referierte Judith Alder, die Präsidentin der 
SGPO und psychologische Psychotherapeutin in eigener 
Praxis, zum Thema «Krebskrank – Angstkrank?». Sie be-
tonte darin, dass Angst eine der wichtigsten Emotionen 
unserer Existenz sei und sich vielfältig ausdrücke. Bei ei-
ner Krebserkrankung würden Ängste genährt durch eine 
existentielle Komponente: die Möglichkeit, dass diese 
Krankheit das Ende des eigenen Lebens bedeuten könnte. 
Es sei für Betroffene und Angehörige, aber auch für Be-
handelnde wichtig, die biologischen Grundlagen dieser 
existentiellen Angst zu verstehen. Frau Alder präsentierte 
einige der wichtigsten und neusten Erkenntnisse zu den 
biologischen Grundlagen der Angst und ermöglichte den 
Teilnehmenden, ihr Wissen zu erweitern. 
Im zweiten Referat des Morgens 
wies Bärbel Gründobler, Ärztin 
für Psychosomatische Medizin 
und Psychotherapie an der Tech-
nischen Universität München, auf 
eine besondere Form der Angst 
hin, der Angst vor dem Fort-
schreiten oder der Rückkehr der 
Erkrankung, auch Progredienz-
angst genannt. Frau Gründobler gewährte in ihrem Vortrag 
sowohl einen Einblick in die aktuelle Forschung der Progre-
dienzangst als auch in die Behandlung dieser spezi!schen 
Angst in Form eines gruppentherapeutischen Angebotes.
Am Nachmittag folgte ein vielfältiges Angebot an Paral-
lelworkshops, die eine vertiefte Auseinandersetzung boten. 
Folgend die Auswahl an Themen: Hilf mir zu verstehen – 
systemisch-psychotherapeutisches Verständnis der Angst 
in einem komplexen Behandlungssystem; Freiräume in 
der Angst schaffen durch Meditation; musiktherapeutische 
und psychologische Interventionen in der pädiatrischen 
Onkologie; Progredienzangst bei onkologischen Erkran-
kungen – ein gruppen-therapeutischer Ansatz; Angst am 
Lebensende: Die Angst vor dem Tod, dem Nicht mehr Sein 
und die vielfältigen Aspekte der Furcht im Sterbeprozess. 
Inspiriert und ausgestattet mit Ideen zu Behandlungsansät-
zen, fanden sich die Teilnehmenden nach den Workshops 
zum Abschlussvortrag von Frau Christa Diegelmann, psy-
chologische Psychotherapeutin in eigener Praxis und Fort-
bildungsleiterin am Institut für Innovative Gesundheits-
konzepte in Kassel. Sie berichtete «Vom kreativen Umgang 
mit der Angst in der Psychoonkologie». Sie hob darin die 
Relevanz von Ressourcen und der Kreativität bei der Be-
handlung von Krebserkrankungen hervor. Die Aktivierung 
von Ressourcen könne als eine Form der «Entängstigung» 
wirken und Kreativität fördern. Reduzierter Stress, sowie 
höhere kognitive und emotionale Flexibilität sei die Folge 
und eine damit einhergehend gestärkte Resilienz. 
Das Organisationskomitee dieser Fachtagung kann auf ei-
nen durch und durch gelungenen Tag zurückblicken mit 
einem vielfältigen Programm und der Möglichkeit eines 
regen Austauschs unter Fachpersonen. Die nächste Fach-
tagung der SGPO wird am 16. April 2015 statt!nden und 
sich mit dem Thema «Würde» im Umgang mit und in der 
Behandlung von Krebserkrankungen auseinandersetzen.
Mitglieder des Organisationsteams und Helferinnen
Korrespondenz:
Theresa Tondorf, MSc Psychologin, Doktorandin
Universitätsspital Basel, Onkologie
Petersgraben 4, CH-4031 Basel
theresa.tondorf@usb.ch
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SGMOSchweizerische Gesellschaft für Medizinische Onkologie
Die moderne Behandlung von Krebskrankheiten ist 
durch eine zunehmende Spezialisierung geprägt. Aber 
kennt jeder Leistungserbringer die Möglichkeiten des 
anderen Spezialisten wirklich? Wohl kaum, weshalb die 
meisten Kolleginnen und Kollegen interdisziplinäre 
Fallbesprechungen wie Tumorboards nicht in Frage stel-
len1. An Tumorboards bringen die verschiedenen Spe-
zialisten breit gefächertes Wissen und Erfahrung in die 
Diskussion ein. Die gemeinsame Besprechung ermög-
licht zudem eine individuell abgestimmte Koordination 
zur Abklärung und Behandlung des Patienten. Während 
der Nutzen des Tumorboards auf das Outcome des Pati-
enten schwierig zu belegen ist, führt die Befolgung von 
Guidelines nachgewiesenermassen zu besseren Behand-
lungsergebnissen2,3,4.
Im Schweizerischen Umfeld sind die Medizinischen On-
kologen in der freien Praxis wie auch in allen Spitälern 
sehr häu!g diejenige Spezialisten, welche die Rolle des 
«Disease Managers» für den Patienten übernehmen. Es 
erstaunt deshalb wenig, dass gerade aus dem Umfeld der 
Medizinischen Onkologie die Initiative zur Gründung 
des Swiss Cancer Network entstanden ist.  
Swiss Cancer Network
Das Swiss Cancer Network (SCN) ist 2012 aus einer 
Initiative der Schweizerischen Gesellschaft für Medizi-
nische Onkologie (SGMO) entstanden und hat sich ver-
schiedene Ziele für die Förderung des interdisziplinären 
Austauschs, der Zusammenarbeit sowie der Qualitäts-
kontrolle gesetzt. So will das SCN unter anderem dazu 
beitragen, ausgewählte Ziele des Nationalen Krebspro-
gramms 2014-2017 zu erreichen. Das SCN bezweckt, 
dass eine Evidenz- und Guideline-basierte Behandlung 
über die ganze Behandlungskette koordiniert und ge-
währleistet wird und die Behandlungsqualität gefördert 
wird, bei gleichzeitig wohnortsnaher Versorgung des Pa-
tienten5. 
Mit dem Quality Oncology Practice Initiative Certi!-
cation Program der ASCO wird in den USA bereits seit 
einigen Jahren ein sehr ähnliches Projekt erfolgreich vo-
rangetrieben6. 
Zerti"kat Swiss Cancer Network
Das Zerti!kat Swiss Cancer Network bezweckt, die 
Behandlungs- und Betreuungsqualität für Tumorpati-
enten zu fördern. Interdisziplinäre, Prozess-orientierte 
Entscheidungs!ndung sowie Respektierung aner-
kannter Guidelines sind die Basis der Qualitätskrite-
rien. Diese fanden bei der Urabstimmung der SGMO 
am 15. Januar 2014 eine 87%-ige Zustimmung (40% 
Stimmbeteiligung).
Das Zerti!kat wird an Einrichtungen vergeben, die 
Krebspatienten behandeln und diagnostische und thera-
peutische Entscheide in einem Tumorboard erarbeiten. 
Mitglieder, die das Zerti!kat erwerben, dokumentieren 
unter anderem
• dass sie ihre Tumorpatienten gemäss international an-
erkannten Richtlinien behandeln und betreuen,
• ihre Patienten in interdisziplinären Tumorboards be-
sprechen,
• eine strukturierte Zusammenarbeit mit Querschnitts-
fächern betreiben,
• ihre Bereitschaft, ihre Behandlungsdaten im Rahmen 
eines Qualitätsregisters offenzulegen. 
Das SCN ist für die Umsetzung des Zerti!kats zuständig. 
Die zerti!zierten Institutionen müssen sich einem Au-
dit unterziehen, das von einer unabhängigen Auditstelle 
(SanaCERT Suisse) unter Beizug von Peers (Onkologen 
mit mindestens 5 Jahren Berufserfahrung) stichproben-
weise geführt wird. 
Ab dem 1. Juli 2014 kann das Zerti!kat beantragt wer-
den. Die initiale Vergabe erfolgt aufgrund einer Selbst-
deklaration, die in jährlichem Abstand erneuert werden 
muss. 
Zerti!zierungsprozess «Swiss Cancer Network» 
ist gestartet
Walter Mingrone, Kantonsspital Olten
Vorstandsmitglied Swiss Cancer Network
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SGMO
Korrespondenz:
Dr. med. Walter Mingrone, Kantonsspital Olten
Vorstandsmitglied Swiss Cancer Network
walter.mingrone@spital.so.ch
Ausblick
Nach vielen internen Diskussionen, Gesprächen mit Fach-
leuten von Akkreditierungs- und Zerti!zierungsstellen, 
dem Studium von ausländischen Modellen und organspe-
zi!schen Zerti!zierungen sind wir überzeugt, mit dem 
Zerti!kat ein Instrument geschaffen zu haben, welches 
die Schlüsselelemente einer hochstehenden onkologischen 
Versorgung widerspiegelt. 
So wie die SAKK ein Netzwerk für die klinische For-
schung ist, so soll das SCN eine Plattform für die hoch-
stehende onkologische Versorgung aller Tumorpatienten 
sein. Unsere Ziele können nur durch gegenseitigen Re-
spekt und unter Einbezug aller Disziplinen erreicht wer-
den. Dafür setzt sich das SCN ein. Alle, die an Krebs 
erkrankte Menschen behandeln und betreuen, sind herz-
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Kursleitung: • Prof. Dr. med. T. Cerny, CH-St. Gallen
 • Prof. Dr. med. M. Fey, CH-Bern
 • Prof. Dr. med. U. Güller, CH-St. Gallen
 • Prof. Dr. med. S. Gillessen, CH-St. Gallen
 • Prof. Dr. med. H. Ludwig, AT-Wien
 • Prof. Dr. med. J. Beyer, CH-Zürich
 • Prof. Dr. med. A. Neubauer, DE-Marburg
 • PD Dr. L. Plasswilm, CH-St. Gallen
Informationen/ Deutschsprachig-Europäische Schule für Onkologie (deso) 
Anmeldung: Rorschacherstr. 150, CH-9006 St. Gallen
 Tel. +41 (0)71 243 00 32 Fax +41 (0)71 245 68 05
 deso@oncoconferences.ch – www.oncoconferences.ch (Rubrik deso) 
 oder www.kssg.ch (Rubrik Veranstaltungen) 
deso Deutschsprachig-Europäische Schule für Onkologie
25. Ärzte-Fortbildungskurs in Klinischer Onkologie
19. - 21. Februar 2015, Kantonsspital, CH-St. Gallen
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Rudolf Maibach, IBCSG Coordinating Center, Berne
Keywords: metastatic breast cancer, chemotherapy, 
endocrine treatment, quality of life, pregnancy
The TEXT and SOFT trials are phase III, randomized 
clinical trials that enrolled 2,672 and 3,066 premeno-
pausal women with hormone receptor-positive early 
breast cancer, respectively, between November 2003 
and April 2011. Over 500 medical institutions from 27 
countries enrolled women in the trials. Fourteen SAKK 
centers and private practices included 114 patients in 
SOFT and 165 patient in TEXT. In the two trials, 4,690 
women were randomized to 5 years adjuvant treatment 
with exemestane+ovarian function suppression or with 
tamoxifen+ovarian function suppression.
Treatment with an aromatase inhibitor has previously 
been demonstrated to be bene!cial to postmenopausal 
breast cancer patients compared with tamoxifen. TEXT 
(Tamoxifen and Exemestane Trial) and SOFT (Sup-
pression of Ovarian Function Trial) were conducted to 
determine whether this bene!t could be extended to 
premenopausal women by combining exemestane with 
ovarian function suppression.
 
After a huge effort to update the clinical documentation 
of the patients, the two trials were !nally ready for analy-
sis earlier this year. They were designed to be complemen-
tary and were conducted over the same time period, in the 
same general population, and have these two treatments 
in common. IBCSG decided to merge the data of the two 
trials which address the aromatase inhibitor question in 
order to analyze the data earlier than would have been pos-
sible by separate analyses, and submitted a late-breaking 
abstract to ASCO. 
On Sunday June 1, Olivia Pagani from Istituto Onco-
logico della Svizzera Italiana presented the results in the 
plenary session. Treatment with exemestane plus ovarian 
function suppression reduced the risk of developing any 
invasive cancer by 28%, and reduced the risk of develop-
ing invasive breast cancer recurrence by 34%, compared 
to treatment with tamoxifen plus ovarian function sup-
pression. At 5 years from 
study entry, 92.8% of wom-
en remained free from breast 
cancer after treatment with 
exemestane plus ovar-
ian function suppression; 
88.8% after tamoxifen plus 
ovarian function suppres-
sion. Olivia concluded that 
exemestane+OFS, as com-
pared with tamoxifen+OFS, 
signi!cantly improves dis-
ease-free survival, breast 
cancer free interval and distant relapse free interval and 
is therefore a new treatment option for premenopausal 
women with hormone-receptor positive early breast can-
cer. The publication of the results was e-published on the 
same day by New England Journal of Medicine.
Both trials also included a Quality of Life part. Jürg Bern-
hard and colleagues presented !rst results of the substudy 
in a poster. Patients on tamoxifen+OFS were signi! - 
cantly more affected by hot #ushes than exemestane+OFS, 
a difference which persisted over time. Throughout treat-
ment, patients on exemestane+OFS reported more vagi-
nal dryness and greater loss of sexual interest, while 
tamoxifen+OFS resulted in more vaginal discharge. The 
difference between treatments in bone/joint pain was 
most pronounced in the short-term in favor of T+OFS, 
but a difference persisted over time. Changes of global 
QoL indicators (mood, physical wellbeing, and coping ef-
fort) from baseline were similar between treatments over 
the whole treatment period. Jürg concluded that there is 
no strong indication to favor either treatment option from 
a quality of life perspective, and that the ef!cacy bene!t 
of the aromatase treatment is achieved without an overall 
impact on quality of life. The differential effects of the 
two treatments on endocrine symptoms burden need to be 
addressed with patients individually.
The SOFT-EST substudy was conducted to describe es-
tradiol (E2), estrone (E1) and estrone sulphate (E1S) 
levels during the !rst 4 years of trial treatments 
triptorelin+exemestane and triptorelin+tamoxifen, and 
to possibly identify a group of patients on trip+exe with 
suboptimal estrogen suppression. The substudy was con-
ducted in collaboration with the SOLTI group (Spain) and 
Meritxell Bellet from Hospital Vall d’Hebron, Barcelona, 
presented in a poster the results of the !rst 12 months 
of observation. Under triptorelin+exemestane, the me-
dian reductions from baseline in E2, E1 & E1S levels were 
>95% at 3, 6 and 12 months after start of treatment, 
and signi!cantly lower than in triptorelin+tamoxifen. A 
group of 27 out of 79 trip+exe patients with ≥1 post-
Olivia Pagani, IOSI
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baseline sample had E2 levels >2.72 pg/mL at least once, 
and 2 had vaginal bleeding for longer than 3 months be-
yond start of treatment, 1 with suboptimal estrogen sup-
pression (SES). Baseline factors related to SES in trip+exe 
were no prior chemo, high BMI, low FSH & LH, but not 
age. The conclusion was that most pts on trip+exe reached 
an E2 level below the de!ned threshold, consistent with 
postmenopausal pts on an AI, but some may be subopti-
mally suppressed. The clinical relevance of this !nding 
will be further explored with the full 4 years of estrogen 
results and outcome data. 
CLINICAL TRIALS
IBCSG 38-09/ BIG 3-07/ TROG DCIS
This randomized phase III study of radiation doses and 
fractionation schedules for ductal carcinoma in situ (DCIS) 
of the breast is conducted by IBCSG in Switzerland and 
Italy on behalf of the Trans Tasman Radiation Oncology 
Group TROG. Women with completely excised non-low 
risk ductal carcinoma in situ (DCIS) treated by breast 
conserving surgery suitable for adjuvant whole breast ra-
diation therapy (RT) are eligible for the study. The trial 
explores the value of adding a tumor bed boost to whole 
breast RT, and compares a shorter vs a standard dose frac-
tionation schedule in a two by two design. 
The recruitment rate was well above expectations and in 
July 2014 the recruitment was closed after 1608 patients. 
Eight Swiss radio-oncology units have recruited a total of 
55 patients. Treatment of the last patients continues and 
every patient will be followed up for 10 years after ran-
domisation. One interim analysis of the trial endpoints is 
planned to take place after 50% of the expected local recur-
rences have occurred, estimated to occur at approximately 
one year after the end of accrual. The main analysis of end-
points time to local recurrence, time to disease recurrence, 
cosmetic outcome, toxicity, quality of life, but not yet over-
all survival will take place in 2019. Patients will then be 
followed yearly for a further 5 years, at the end of which the 
analysis of overall survival will take place together with an 
updated analysis of the other study endpoints.
IBCSG 42-12 SNAP
The trial evaluates in a randomized phase II fashion three 
different schedules of nab-Paclitaxel in patients with his-
tologically or cytologically con!rmed HER2-negative 
metastatic (stage IV) breast cancer who have not received 
any prior chemotherapy. The acrynom stands for Sched-
ules of NAb-Paclitaxel. It is planned to recruit 240 pa-
tients within about 30 months.
SNAP evaluates three schedules of nab-Paclitaxel as pro-
longed chemotherapy administration strategy. All three 
arms start with a common induction treatment during the 
!rst 3 cycles, and then continue with different schedules 
of reduced dose intensity until progressive disease or lack 
of tolerability. Each of the three arms will be compared to 
a historical reference of seven-month median PFS based 
on the most recent trial with docetaxel as control arm to 
determine whether any of the three arms are worthy of 
further investigation.
The trial is being conducted in several European coun-
tries. The !rst patient was randomized in April 2013, and 
by June 30, 2014, 121 patients have been recruited. Nine 
SAKK sites participate, and recruited 29 patients until 
June. 
Based on recommendations from the IBCSG Data and 
Safety Monitoring Committee (DSMC), IBCSG has de-
cided to adapt the dose of nab-Paclitaxel in the induc-
tion phase, and asks to carefully consider comorbidities 
when screening new patients. The corresponding amend-
ment has been issued and will be activated in the next few 
months. 
IBCSG 43-09 HOHO 
IBCSG 43-09 is the Young Women’s Breast Cancer Study, 
and HOHO stands for «Helping Ourselves Helping Oth-
ers». It is a longitudinal cohort study of 300 young women 
with breast cancer (early or advanced) in selected institu-
tions in Europe. All eligible patients treated at each center 
are invited to join the cohort. Patient surveys and medical 
record review are utilized. Women are surveyed every 6 
months for the !rst 3 years after diagnosis, then yearly 
thereafter for an additional 7 years (for a total follow-up 
of 10 years following diagnosis). The study has two main 
objectives:
1. To identify in selected institutions in Europe a co-
hort of young women (age 18-40) newly diagnosed 
with breast cancer (early or advanced) to assess a broad 
range of variables at baseline and over the course of 
the ensuing 10 years.
2. To characterize this population at diagnosis and in fol-
low-up regarding disease and psychosocial outcomes 
(e.g., presentation and disease characteristics, fertility 
and menopausal issues, and long term outcome).
At present 11 centers in Italy and 4 centers in Switzerland 
are participating in the trial and have accrued 213 pa-
tients up to end of June 2014, 54 of them by Swiss sites.
COOPERATIVE GROUPS IBCSG
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IBCSG 48-14/BIG 8-13 POSITIVE 
The best available evidence suggests that pregnancy after 
breast cancer does not negatively impact disease outcome 
and is safe for the offspring but no de!nitive information 
is available to recommend a safe interval from BC diagno-
sis to pregnancy. The POSITIVE trial will investigate en-
docrine therapy (ET) interruption to enable conception for 
young women between 18 and 42 years of age with endo-
crine responsive early breast cancer who received adjuvant 
ET for 18 to 30 months and wish to attempt pregnancy. 
The main objectives are: 
• To assess the risk of breast cancer relapse associated 
with temporary interruption of endocrine therapy to 
permit pregnancy
• To evaluate factors associated with pregnancy success 
after interruption of endocrine therapy. 
The trial will also allow for the testing of biologic corre-




Ef!ngerstrasse 40, CH-3008 Berne
Tel. +41 (0)31 389 91 96
rudolf.maibach@ibcsg.org
www.ibcsg.org
A psycho-oncological companion study evaluating psy-
chological distress, fertility concerns and decisional con-
#ict in young women who participate in POSITIVE has 
been developed and will be activated in sites interested 
and capable to conduct it. The participation of the US-
American Alliance Group is anticipated and will be nego-
tiated in the months to come.
A total of 500 patients are planned to be recruited into 
the trial from centers worldwide in approximately 4 
years. The trial activation package has been sent to more 
than 60 interested sites and all IBCSG centers on July 3. 
IBCSG COOPERATIVE GROUPS
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COOPERATIVE GROUPS ETOP
ETOP: Five years  
of successful growth
Solange Peters, ETOP Communication Chair  
and Scienti!c Coordinator
Keywords: Non small cell lung cancer, small cell lung can-
cer, translational research, chemotherapy, radiotherapy
The interest in promoting and improving collaboration in 
clinical and translational research in lung cancer and me-
sothelioma in Europe prompted investigators represent-
ing collaborative study groups and institutions concerned 
with thoracic malignancies to explore new ways of work-
ing together. Out of this discussion the European Tho - 
racic Oncology Platform was founded in 2009. This was 
the !nal step after two years of consultation between 
friends and leaders in the !eld of thoracic oncology 
throughout Europe. While Rolf Stahel as President of the 
Foundation Council and chair of the Scienti!c Committee 
and Solange Peters as Scienti!c Coordinator are the driv-
ing forces behind this effort, it is important to note that 
without the contribution of a large number of investiga-
tors, the Statistical Of!ce lead by Urania Dafni and the 
staff at the Coordinating Of!ce in Bern it would have not 
have been possible to get where we are. 
Since 2009 ETOP has continuously enlarged its mem-
bership and now comprises more than 50 collaborative 
groups and institutions from all over Europe, as well as 
two large and eminent institutions outside Europe, one 
in the United States (Roswell Park) and one in China 
(Shanghai Chest Hospital).
In these pioneer years ETOP has evolved greatly in sev - 
eral ways. The !rst major undertaking which was started 
is Lungscape, a project to study the molecular epidemiol-
ogy of lung cancer in Europe. Seventeen major cancer cen-
ters have created a decentralised biobank of tumor samples 
from over 2700 patients who are fully documented with 
comprehensive demographic and clinical data. A succession 
of so-called Lungscape Modules is being implemented to 
study a variety of biomolecular markers with the ultimate 
goal of identifying targets for latest-generation substances. 
The innovative approach of combining local sample collec-
tions into one virtual biobank with a centralised database of 
clinical parameters collected uniformly by all participants 
has generated a lot of enthusiasm not only among oncolo-
gists but also their colleagues in the pathology departments 
by providing them with an excellent opportunity to take 
part in highly competitive translational research.
From the start, ETOP also strived to present a platform 
for the exchange of knowledge and for dissipation of 
latest insight on thoracic malignancies. First of all, 
www.etop-eu.org is the place where ETOP members 
!nd a valuable collection of scienti!c evidence. Slide 
sets summarising the most important presentations 
from major cancer conferences like ASCO, ESMO, 
WLCC and ELCC are compiled by a series of editors 
within a few days of these events. Moreover, the edi-
tors select the most important publications and present 
them brie#y on the ETOP website. In addition, ETOP 
members have free access to the Lung Cancer Journal.
The ETOP Residential Workshop brings together young 
investigators and experienced faculty and allows in an in-
formal setting to develop and discuss with peers new ideas 
for clinical research. This format is a great opportunity for 
the next generation of researchers to improve their skills 
and to network.
Early on ETOP has also decided to advance clinical re-
search by conducting therapeutic trials in collaboration 
with its members. Several approaches have been taken 
which all have their merits. ETOP conducts its own trials 
and sponsors them; examples are EMPHASIS and STIM-
ULI, the latter being performed in collaboration with 
IFCT (Intergroupe Francophone de Cancérologie Thoraci-
que) as the potential largest contributor. The BELIEF trial 
is sponsored by ETOP, but coordinated by the Spanish 
Lung Cancer Group (SLCG). EORTC is in charge of the 
conduct and evaluation of the SPLENDOUR trial, where-
as ETOP still sponsors this trial. Each trial is !nancially 
supported by a pharmaceutical company, and ETOP and 
its partners vouch for the academic independency in the 
conduct, evaluation and publication of the results. The 
safety of the patients participating in these trials is as-
sessed semi-annually by ETOP’s Independent Data Moni-
toring Committee. 
The members of ETOP are either single academic hos-
pitals and clinics or collaborative groups like EORTC, 
SAKK, SLCG, IFCT, the All Ireland Co-operative On-
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cology Research Group ICORG or the Central European 
Collaborative Oncology Group CECOG. Such groups take 
over some of the responsibilities in the projects and often 
act as intermediary between ETOP and their own sites. 
This provides the necessary #exibility to take into account 
local requirements and traditions and allows conducting 
research in a way which is familiar for the respective inves-
tigators and their staff.
In order to complete the various tasks entailed by all these 
projects, ETOP has undergone a strategic collaboration 
with IBCSG and its Coordinating Center in Bern. The 
ETOP Coordinating Of!ce is able to support all activities 
in the above projects. In addition, Frontier Science Hel-
las, a non-pro!t organisation based in Athens, Greece, is 
providing statistical expertise for all the projects. 
ETOP is a foundation with the purpose to promote and 
exchange research in the !eld of thoracic malignancies in 
Europe. ETOP still expands and consolidates its activities. 
During its !rst !ve years it has already become one of the 
leading organisations conducting research in the !eld of 
thoracic malignancies and certainly continues to grow in 
expertise, recognition and leadership. At the basis of this 
success is the determination of the ETOP investigators to 
collaborate in research and to openly exchange informa-
tion.  
ETOP projects and trials
Lungscape
Lungscape was initiated in 2011 as a result of discus-
sion on how to foster translational collaborative research 
within ETOP.  Its objective was to develop a decentralised 
biobank of tumor samples with centrally collected exten-
sive annotated clinical data as a resource for the descrip-
tion of the landscape of molecular changes in non-small 
cell lung cancer, the generation of hypotheses regarding 
the prognostic impact of speci!c markers in patients with 
complete resection of non-small cell lung cancer and the 
generation for future diagnostic platforms and biomarker 
driven clinical trials.
The aim was to perform biomarker testing where feasible 
at the participating site after external quality assurance. 
Biomarkers are to be tested sequentially as funding be-
comes available. An unrestricted grant from Roche and a 
grant restricted to testing ALK in adenocarcinoma were 
obtained by the end of 2011 and the Lungscape master 
protocol and Lungscape 001-ALK substudy were distrib-
uted in May 2011 and activated in the individual sites 
over the following 12 months. In its initiation, Lungscape 
ETOP COOPERATIVE GROUPS
included 14 sites from Europe, subsequently a site from 
China and from the USA and in 2013 one additional site 
from Europe have joined the effort. Data on more than 
2700 patients have been included in the database. 
ETOP 2-11 BELIEF 
BELIEF, the !rst therapeutic trial sponsored by ETOP 
is chaired by Rafael Rosell and Rolf Stahel and is being 
coordinated by the Spanish Lung Cancer Group (SLCG). 
Oliver Gautschi is co-chair of this trial. BELIEF aims at 
determining the long-term outcome of patients with ad-
vanced NSCLC and activating EGFR mutations (deletion 
of exon 19 and L858R) treated with erlotinib and bevaci-
zumab. Notably, one of the objectives of the trial is to as-
sess the clinical relevance of the EGFR T790M mutation 
in a prospective way. 
Until 30 June 2014, 92 of the planned 102 patients have 
been recruited from 6 countries; SAKK sites have enrolled 
34 patients. The accrual goal will be reached this summer.
ETOP 3-12 EMPHASIS-lung 
The predictive value of a proteomic signature, called 
Veristrat, regarding erlotinib ef!cacy is being assessed in 
this trial in pretreated advanced squamous cell lung car-
cinoma. Over 50 centers from several European countries 
were activated. Until the end of January 2014, 81 patients 
were randomised, 14 from SAKK sites. Recruitment was 
terminated prematurely due to an accrual rate. No safety 
concerns led to the decision to close accrual. Treatment 
and follow-up of all included patients continue as speci-
!ed in the protocol. The trial results will be evaluated and 
published.
ETOP 4-12 STIMULI 
Thirty percent of patients with small cell carcinoma 
(SCLC) will have limited stage disease, with a median sur-
vival of 16 to 24 months with current forms of treatment 
and only 15-25% long term survivors.
The primary objective of the randomised multicenter 
open-label STIMULI trial is to evaluate if limited-disease 
SCLC patients treated with standard chemo-radiotherapy 
and prophylactic cranial irradiation followed by ipilim-
umab consolidation have a better overall survival com-
pared to patients treated with chemo-radiotherapy and 
prophylactic cranial irradiation alone. Overall survival is 
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the primary endpoint, the hypothesis of interest being an 
absolute increase of 12.3% in OS rate at 2 years with ipi-
limumab consolidation treatment. 
A large immune-based and immunomonitoring transla-
tional research program is planned within ETOP special-
ised centers and in collaboration with the Ludwig Insti-
tute in Lausanne. 
The protocol has been sent out to the two SAKK sites who 
will participate, as well as to sites in Spain, France, Ger-
many, Belgium, Poland and the UK. The activation pro-
cess is ongoing and the !rst patient was enrolled in July.
ETOP 5-12 SPLENDOUR
In a pivotal phase III trial in patients with NSCLC and 
bone metastasis, the effect of denosumab on time to !rst 
on-study skeletal-related event relative to zoledronic acid 
by tumour strati!cation factors resulted in a hazard ratio 
(HR) of 0.84 for NSCLC (95% CI, 0.64 to 1.10; P=0.20). 
Interestingly, an ad hoc analysis examining overall surviv-
al for speci!c distinct strata, demonstrated a signi!cantly 
improved overall survival in NSCLC patients treated with 
denosumab compared to reated with zoledronic acid with 
a HR of 0.79 (9.5 vs. 8.1 mos., 95% CI, 0.65 to 0.95). 
SPLENDOUR is an ETOP-sponsored open-labeled multi - 
centre randomised phase III prospective trial to evaluate 
the potential of denosumab – as an antitumor agent – to 
increase survival of advanced NSCLC with or without 
bone metastasis, when combined with platinum-based 
!rst line standard chemotherapy. The trial will be con-
ducted in the context of a strong and unique European 
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collaboration between ETOP and the EORTC, which will 
act as the coordinating group. 1000 patients will be en-
rolled within about 3 years.
The protocol plans the systematic collection of tissue and 
serum samples from all enrolled patients. Tissue blocks 
will be stored centrally at the ISREC in Lausanne and will 
be evaluated for biomarkers on the ef!cacy of denosumab 
and will constitute a unique source for further exploratory 
analyses. Sequential serum samples will be sent to the 
biorepository of the Northern General Hospital Shef!eld 
and will undergo an array of biomarkers like CTX, osteo-
protegerin (OPG), bone sialoprotein (BSP), osteopontin 
(OPN), free RANKL and RANKL-OPG. These may be 
changed and the panel of serum biomarkers will include 
best candidates at the time of analysis.
The protocol will be activated soon across Europe. The 
survey conducted at the end of last year has raised a 
lot of interest and about 150 sites and several coopera-
tive groups, especially CECOG, GFPC and SLCG, have 
applied for participation. The total number of sites is 
limited; the good news is that nine SAKK sites will be 
able to participate. An investigator meeting speci!cally 
for SAKK sites was held during the SAKK semi-annual 
meeting on June 26.
COOPERATIVE GROUPS ETOP
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«Is there a Future for 
Swiss Academic Clinical 
Research?»
5th Symposium of the 
Swiss Clinical Trial 
Organisation (SCTO)
Bern, June 18, 2014 
Tatiana Terrot, Project Manager, Clinical Trial Unit,  
Ente Ospedaliero Cantonale, Bellinzona
On June 18th, 2014 the 5th Symposium of the Swiss Clin-
ical Trial Organisation (SCTO) was held at the University 
Hospital of Bern. 
The SCTO is a non-pro!t organisation that aims at sup-
porting patient oriented clinical research in Switzerland. 
The organisation, which has been active in this !eld since 
2009, coordinates and harmonises the activities of the 6 
Swiss Clinical Trial Units (CTU). As central cooperation 
platform, the SCTO strives to promote a high-quality 
and nationally harmonised study culture to attractively 
and competitively position Swiss clinical research in in-
ternational competition. Furthermore, the SCTO aims at 
building bridges between academia, industry and public 
authorities, while facilitating the communication among 
all stakeholders. 
Members of the SCTO are the !ve Swiss University Hos-
pitals, the St. Gallen Cantonal Hospital, the Swiss Acad-
emy of Medical Sciences (SAMW) and the representatives 
of the medical school faculties (Collège des Doyens) at the 
Swiss universities. 
«Is there a Future for Swiss Academic Clinical Re-
search?» was the topic of the 5th Symposium of the 
SCTO, a topic always in discussion and which involves 
not only researchers but also politicians and pharmaceuti-
cal companies.
Clinical research is very active in Switzerland and most 
of it is supported by the pharmaceutical industry. In the 
last years, thanks to the support of the CTUs, academic 
clinical research has become more and more active and has 
been able to provide high quality and expertise to the trial 
design, implementation and data analysis.
Academic clinical research in Switzerland is supported 
mostly by national and private funding. One of the aims 
of this Symposium was to discuss the conditions created 
by the new regulation (Human Research Act, HRA), in-
troduced in January 2014, in terms of improvements and 
drawbacks of the academic clinical research in Switzerland.
During the Symposium several speakers discussed this topic 
from different points of view: Dr. François Jaquet, Head of 
Division Clinical Trials, Swissmedic, gave a short summary 
on the new Swiss law and ordinances related to the human 
research; Prof. Christiane Pauli-Magnus and Prof. Mirjam 
Christ-Crain, Dep. Clinical Research University Hospital 
Basel, presented the positive effects of the new law by a case 
study; Prof. Stephan Windecker, Department of Cardiol-
ogy, University Hospital Inselspital Bern, showed, on the 
contrary, the negative aspects of the implementation of the 
Swiss Ethics Committee’s new organisation in a provocative 
talk; Hansruedi Völkle, a patient, presented the expecta-
tions from a patient perspective.
The new law on research involving human beings (Hu-
man Research Act, HRA) aims mainly to shorten time 
until Regulatory Authorities approval introducing the 
parallel submission of a new clinical trial to Swissmedic 
and the Ethics Committee. This is now possible as the 
responsibilities of the Regulatory Authorities have been 
clari!ed and redundancies were eliminated. To maintain 
high quality of the clinical research, Swissmedic increased 
the number and the scope of inspection visits. As men-
tioned, the main advantage of the new law consists in the 
parallel submission process, whereby the Ethics Commit-
tees are still in the preparation phase and establishment of 
a better organisation among them. From the researcher’s 
point of view, it seems that the communication among 
these committees is not ef!cient yet. Templates are con-
tinuously updated and, after 6 months, they need further 
updating. In this sense, the new law intends to create fa-
vourable conditions for research involving human beings; 
however, the current bureaucracy so far reduces this !rst 
principle and compromises a competitive trials approvals 
procedure with other countries.
What do patients think about clinical research? Clini-
cal research brought huge progress in patients’ treatment 
over the past 30 years and dif!cult diseases like HIV can 
today be easily controlled allowing the patients to lead an 
almost normal life. Patients’ expectations regarding clini-
cal research include an improvement of the quality of life 
with fewer side effects of the treatments as well as a longer 
life expectancy. But patients also want to be more involved 
in clinical research, for example by being more considered 
and more informed of the results. Furthermore, patients 
demand greater collaboration between clinical and social 
research to receive better care.
The second part of the 5th Symposium started with a nice 
entertainment by Thomas Fraps, a magician who amused 
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the audience in the role of a fake expert. After a smooth 
restart, the second part of this event dealt with funding 
strategies for clinical research of other countries. The fund-
ing schemes of the German Research Foundation (DFG) 
and the Research Council of Norway were presented and 
the experiences of a reorganisation of the Italian clinical 
research funding, carried out 10 years ago, were shared. 
Researchers highlighted their experience in the funding 
of their clinical studies in Switzerland.
Clinical research in Germany is very complex because of dif-
ferent stakeholders with different interests. Because of this 
complex organisation the quality of clinical research is often 
not as expected and is lower than international standards. 
Only few studies are published. DFG is an independent pri-
vate organisation, which aims to provide funding to selected 
research projects. There is not a speci!c !eld of interest: a 
project must have a scienti!c and non-marketed interest 
and must be a multicentre study in order to be selected. 
The economic situation in Germany discourages clinical re-
searchers because of the pressure due to the high costs and 
limited time to dedicate to this activity. The DFG’s strat-
egy is «where they fund and not how much is invested». In 
contrast, Norway has four health regions with state-owned 
Regional Health Authorities, responsible for ensuring spe-
cialised health services for the public and for funding clinical 
research projects. Among the Norway University Hospitals, 
clinical research is supported by a network and a long term 
program has been established focusing on multiregional, 
national and international intervention studies, as well as 
research in the !eld of general practice and primary health 
care services. The collaboration of the four regions is impor-
tant also to maintain national competition. In Italy, instead, 
there wasn’t an independent research funding program until 
2003. The research was driven and !nanced mainly by phar-
maceutical companies and public funding was very poor. In 
2003 the «Agenzia Italiana del Farmaco» (AIFA) was estab-
lished to force the pharmaceutical companies to support the 
public funding by providing 5% of their annual income. 
Unfortunately the research program was frozen for political 
reasons in 2008 and since then public funding has been dif-
!cult to obtain. An interesting funding experience was done 
in a multicentre study, involving Switzerland, France and 
Germany, on deep brain stimulation in the early phase of 
Parkinson’s Disease. Two independent groups, one in France 
and one in Germany, designed a similar clinical trial and 
being aware of this, decided to start a collaboration. Because 
of the different languages and cultures of the groups, and 
different countries’ regulations and requirements, many ob-
stacles had to be overcome. Not only the administrative as-
pects of study implementation were demanding; the search 
for funding was also a long path. The clinical trial costs’ 
coverage was possible thanks to public and pharmaceutical 
company funding. 
Prof. Peter Jüni, ISPM and CTU Bern, concluded the 
presentations of this Symposium by highlighting the 
problem of the cost coverage of academic clinical research 
in Switzerland. In the latter country, clinical research 
receives public funding through the Swiss National Sci-
ence Foundation (SNSF). This is generally not enough to 
support all independent research projects. To cover the 
costs of a clinical trial more sources of funding need to be 
considered. This type of funding is however dif!cult to 
manage, as pharmaceutical companies are not interested 
in independent research. A new scheme of funding should 
be evaluated possibly in conjunction with public health 
insurances and pharmaceutical companies. 
The 5th Symposium closed with a round table discussion 
on different perspectives of academic clinical research and 
funding schemes with the participation of David Nadal 
(SwissPedNet), Dr. Peter Brauchli (Swiss Group for Clini-
cal Cancer Research, SAKK), Dr. Yvonne Gilli (National 
Council, Grüne), Dr. Andreas Schiesser (santésuisse), Dr. 
Aysim Yilmaz and Prof. Urs Frey (both Swiss National 
Science Foundation, SNSF). The discussion raised several 
problems, from the dif!culties in getting funding inde-
pendent research to the poor coordination among research-
ers. Furthermore, the political landscape is not suf!ciently 
sensitised on this topic and, therefore, more efforts should 
be done in order to increase awareness in the Parliament. 
Pharmaceutical companies would be interested in funding 
the research but, in return, they would probably like to 
have something and at the moment politics is not inter-
ested in starting a discussion on this issue. With the new 
law, more favourable conditions have been implemented 
but more can yet be done. For example, the !nancing sys-
tem of off-label drugs should be revised by encouraging 
and facilitating their use especially in some critical !elds 
like paediatrics and oncology. 
All participants agreed that a different funding scheme 
should be considered. Health insurances should be more 
involved by actively contributing to the academic clinical 
research. Collaboration and better communication among 
all stakeholders (politicians, pharmaceutical companies, 
health insurances, organisations, researchers and public) 
are of outmost importance as academic research is a vital 
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The advent of Next-Generation Sequencing (NGS) technol-
ogies has revolutionized the way genomic study is progress-
ing. The Next Generation Sequencing Conference 2014 
(NGS 2014) has been a dedicated meeting on cutting-edge 
approaches to the processing and analysis of NGS data. It 
has been hosted by the International Society for Computa-
tional Biology (ISCB) and the Centre for Genomic Regu-
lation (CRG), in the wonderful city of Barcelona (Spain). 
The conference brought together bioinformatics research-
ers and biologists facing new high-throughput sequencing 
challenges, showed how current platforms can be used to 
address key biological questions, what is the current state of 
the art for data analysis, the emerging and future trends in 
high-throughput sequencing and their associated computa-
tional challenges. Here, we review some of the key presen-
tations from the conference.
The meeting kicked off with Thomas Gingeras (Cold 
Spring Harbor Lab.) discussing how the use of NGS has 
resulted in new insights of Non-Coding RNAs. Dr Gin-
geras, highlighted some of his own experiences with next 
generation sequencing and the transition from Sanger se-
quencing; The use of NGS technology in projects like the 
human ENCODE (Encyclopedia of DNA Elements) un-
derscores several under-appreciated lessons concerning the 
conservation and novel functions of long and short non-
coding RNAs (ncRNAs). These lessons include: a) speci!c 
short ncRNA classes are enriched in micro-vesicles and 
used for inter-cellular communication b) the conservation 
of long ncRNAs between mouse and human of several 
transcriptional features that appear to be independent of 
the degree of sequence similarity and c) a multiplicity of 
cap modi!cations present on short ncRNAs. Dr. Gingeras 
also called out that these and other insights drawn from 
data sets produced with NGS platform assist in beginning 
to understand what is often seen as dauntingly complex 
but elegantly organized genomes and continue to prompt 
a reconsideration of the de!nition of a gene.
We then moved on to discuss new strategies for achiev-
ing better de novo genome assemblies from NGS, pre-
sented by Tyler Alioto. When sequencing long strands 
of DNA, the molecules are broken randomly into small-
er fragments from which reads of the DNA sequence 
can be experimentally produced. Algorithms can use 
this information to infer the original sequence through 
the process of «de novo assembly». Dr. Alioto began 
by reiterating the dif!cult of this task due to experi-
mental sequencing errors and the repeated sequence 
regions that are present in most genomes. His team 
developed a «divide and conquer» strategy where all 
paired-end reads are re-aligned to the assembly to de-
tect regions where mappings are inconsistent, at which 
they subsequently break the assembly. They join the 
pieces through a re-scaffolding step increasing the !nal 
contiguity. He ended his talk presenting data showing 
how the «divide and conquer» strategy really pays off in 
terms of time and ef!ciency.
Following Alioto was Rory Stark from the University 
of Cambridge to present his new algorithm ChIPQC 
for computing and reporting quality metrics for ChIP-
Seq experiments. He reiterated the need for quality 
control at multiple steps of an NGS work#ow, includ-
ing run quality, sample quality, peak calling and inter-
pretation. 
ChIPQC offers a straightforward way to generate an inter-
active QC report for a sample or a set of samples associ-
ated with an experiment which can be examined to assess 
the absolute and relative quality of individual ChIP-seq 
samples as well as overall quality of the experimental data. 
In a later session, Kristin Ardlie (The Broad Institute of 
Harvard and MIT) discussed clinical reporting based on 
the The Genotype-Tissue Expression (GTEx) Program, a 
very interesting project launched by the US National In-
stitutes of Health (NIH) in September 2010 that aims to 
study human gene expression and regulation in multiple 
tissues. It is an NGS-Seq «tour-de-force»: RNA extract-
ed from multiple tissues (an average of 28 tissues per 
person) from more than 900 individuals has been quan-
ti!ed with RNA-Seq experiments and blood DNA from 
each donor was genotyped. The data produced by the 2.5 
year pilot study, have been enable studies of expression 
quantitative trait loci (eQTLs), alternative splicing, and 
the tissue speci!city of gene regulatory mechanisms, and 
aid in the interpretation of Genome-Wide Association 
Studies (GWAS). GTEx is a pioneering project that uses 
state-of-the-art protocols for obtaining, storing and test-
ing diverse human tissue types. The results of this study 
will provide valuable insights into the mechanisms of 
gene regulation and, in the future, its disease-related 
perturbations.
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Day 2 was underway with an interesting talk about em-
bryonic !eld of the single-cell transcriptomics by John 
Marioni from the Sanger-EBI Single Cell Genomic Cen-
tre. The ampli!cation steps into the NGS protocols intro-
duce technical noise, and Dr. Marioni proofed it through 
a dilution series experiments that clearly show that the 
degree of noise gets progressively worse as the amount of 
starting material gets lower. The problem is exacerbated 
for lowly-expressed genes. He suggested using spike-ins 
to quantify the variability. The strong correlation to cell 
cycle is another issue the single-cell sequencing has to face 
to. John’s team demonstrated that is possible to «normal-
ize» expression relative to the stage of the cell cycle. They 
examined T-cells and estimated that 27% of the variance 
in gene expression (GEX) is due to technical noise, and 
that for 42% of genes 30% variance can be attributed to 
the «cell cycle effect». By correcting for both two T-cell 
sub-populations become apparent, at different stages of 
differentiation. He identi!ed cell sub-types in an elegant 
way using single-cell transcriptomics with the caveat that 
the technical noise/cell cycle effect must be taken into 
consideration.
After a quick break, Beatriz Bellosillo (Hospital del 
Mar-IMIM) presented her studies aiming to elucidate 
the molecular mechanisms of resistance to cetuximab-
based therapy acquired by patients affected by metastat-
ic colorectal cancer (mCRC). She collected paired tumor 
samples (prior and progression to treatment) from 37 
patients with acquired resistance to this speci!c type of 
therapy, and analyzed them using next-generation pyro-
sequencing. Dr. Bellosillo and colleagues identi!ed mu-
tations in EGFR, KRAS, NRAS, BRAF and PIK3CA. 
RAS mutations were the most frequent event (40% of 
patients) and mostly affected exons 3 and 4, followed 
by mutations in PIK3CA (19%), BRAF (11%), EGFR 
S492R (8%) and novel mutations in EGFR ectodomain 
(5%). In conclusions multiple mechanism are respon-
sible for acquired resistance to cetuzimab-base therapy 
in mCRC. This data established the need to routine mo-
lecular studies at disease progression to individualize 
further therapeutic decisions. 
We then moved on to discuss the landscape of RNA 
splicing alterations in human cancers, wonderfully 
presented by Angela Brooks from the Broad Institute. 
She has developed a computational pipeline called 
JuncBASE to identify and quantify alternative splicing 
in cancer RNA-Seq data. Through this algorithm it has 
been possible to identi!ed 470 altered splicing events 
signi!cantly associated with mutations in the splicing 
factor U2AF1, including an altered splicing event in 
CTNNB1. In addiction, her research group has detected 
splice site mutations that are associated with expression 
of oncogenic isoforms, including isoforms of MET and 
ERBB2. To distinguish between cancer-speci!c splic-
ing alterations and normal transcriptome variation, they 
have utilized RNA-Seq data from healthy individuals 
from the Genotype-Tissue Expression (GTEx) project. 
To identify splicing events that may be novel somatic 
driver alterations, these events have been pro!led using 
RNA-Seq data from the Cancer Cell Line Encyclopedia 
and are being used as biomarkers to identify genetic 
vulnerabilities in high-throughput shRNA screens. Her 
work has a signi!cant impact on our understanding of 
the role of splicing in cancer pathogenesis.
Cornelia M. Van Duijn (Erasmus MC) ended the meet-
ing talking about the Erasmus Rucphen Family (ERF) 
study, a program aims to identify genetic risk factors in 
the development of complex disorders. She began her 
presentation with a brief overview of the project: 22 
families that had at least !ve children baptized in the 
community church between 1850-1900 were identi!ed 
with the help of genealogical records. She announced 
that she had recruited the living descendants of these 
couples getting an impressive data collection started in 
June 2002 and !nished in February 2005 (n=2065). Dr. 
Van Duijn went on to detail how she is now moving over 
to exome-sequencing using HiSeq. In doing so, she !nd 
thousands of variants per exome, then !lter these down 
using various approaches, and developing a new pipeline 
that combines the successful bioinformatics approach 
followed for rare disease analyses and classical genetic 
epidemiological analyses. The schematic of this pipeline 
is certainly a useful resource for researcher looking for 
genetic risk factors.
All in all, NGS 2014 was a fantastic and enriching 2-day 
conference with excellent scienti!c sessions. The meeting 
highlighted the near complete absence of bioinformatic 
best-practice guidelines and standardized pipelines for 
NGS data analysis. Despite this issue, the !nal statement 
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Parallel zum wichtigen internationalen Krebskon-
gress ASCO fand auch dieses Jahr wieder das «Chica-
go in the Mountains» statt. Nach dem erfolgreichen 
Start des Projekts im 2013 hatten die Onkologen aus 
der ganzen Schweiz wiederum die Gelegenheit, vom 
1. bis 4. Juni 2014 die wichtigsten Präsentationen des 
grössten Krebskongresses in einem ruhigen Bergho-
tel in der Innerschweiz zu verfolgen und direkt vor 
Ort zu diskutieren. Ein Konzept, das einem echten 
Bedürfnis entspricht und bei den Teilnehmern auf 
grossen Anklang stösst. 
Für Onkologen ist der ASCO einer der wichtigsten inter-
nationalen Krebskongresse, um sich über neue Entwick-
lungen in der Onkologie zu informieren. Der Kosten-
Nutzen-Effekt einer Reise nach Chicago ist jedoch für 
die Ärzte nicht wirklich befriedigend. Mit jeweils über 
30‘000 Teilnehmern und mehreren parallelen Sessions ist 
der Kongress so gross, dass vor Ort nie alle wichtigen Prä-
sentationen besucht werden können. Genau hier setzt das 
«Chicago in the Mountains» an.  
Technik sei Dank - Flüeli-Ranft rückt ganz
nahe zu Chicago 
Mit modernster Technik wurden die Vorträge und Dis-
kussionen in Chicago den Kollegen im Heimatland si-
multan zugänglich gemacht. Neben der Übertragung 
der Präsentationen vom ASCO in sogenannten «Virtual 
Meetings» gab es tägliche Live-Schaltungen zu einem in 
Chicago aufgebauten Interviewstudio. Am Kongress prä-
sentierte Daten konnten so nicht nur verfolgt, sondern 
direkt mit Experten in Chicago und den eigenen Kolle-
gen am Event bewertet, diskutiert werden. Die übertra-
genen Vorträge beinhalteten ASCO-Highlights, die von 
einem unabhängigen schweizerischen wissenschaftlichen 
Gremium (Steering Committee) im Vorfeld ausgesucht 
und dann durch in Chicago vor Ort anwesende Kollegen 
(Scouts) nach Qualität und Neuigkeitswert der Vorträge 
adaptiert wurden: die Scouts meldeten nach Besuch der 
wissenschaftlichen oder Educational Sessions in Chicago 
die Highlights der Vorträge an das Steering Committee 
in Flüeli-Ranft. Dieses sichtete die entsprechenden Vor-
träge dann oft noch spätabends oder am Morgen vor Pro-
grammbeginn, damit die Sessions noch am selben Tag den 
Teilnehmern präsentiert werden konnten.
Hochkarätiges Committee sorgt für unabhängige 
Programmgestaltung
Die fünf Ärzte des Steering Committees Dr. Daniel 
Helbling vom Onkozentrum Zürich, PD Dr. Thomas 
Ruhstaller vom Kantonsspital St. Gallen, Prof. Roger 
Stupp vom Universitätsspital Zürich, PD Dr. Roger 
von Moos vom Kantonsspital Graubünden und Dr. Ste-
fan Zimmermann vom Hôpital de Fribourg waren alle-
samt bereits im 2013 mit von der Partie und zeigten 
sich erneut angetan von Konzept und Organisation der 
Veranstaltung. Stellvertretend für seine Kollegen Dr. 
Zimmermann: «Der Event ist rundum gelungen. Toll 
auch, dass so viele Ärztinnen und Ärzte den Weg hier-
hin gefunden haben. Ohne Zweifel entspricht die Veran-
staltung einem Bedürfnis und bietet eine willkommene 
Alternative zur Teilnahme in Chicago. Extrem geschätzt 
wird von den Teilnehmern die Möglichkeit, das Beste 
vom ASCO mitzuerleben. Da die Sessions in Chicago oft 
Das wissenschaftliche Steering Committee (von links nach 
rechts): Dr. Daniel Helbling, PD Dr. Thomas Ruhstaller, Prof. 
Roger Stupp, Dr. Stefan Zimmermann, PD Dr. Roger von Moos 
fehlt auf dem Bild  (er weilt am ASCO in Chicago)
Innovatives Konzept holt internationalen  
Krebskongress in die Innerschweiz
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parallel laufen, ist ‘cherry-picking’ dort nicht machbar. 
Besonders staune ich dieses Jahr über die sehr differen-
zierten Fragen der Teilnehmer zu den Präsentationen 
und Diskussionen in Chicago - sie sind auf einem hohen 
Niveau, was die Sache für uns als Steering Committee 
noch interessanter macht.» 
Global interagieren, dabei aber Umwelt schonen 
und Zeit sparen 
Die Veranstaltung entspricht einem echten Bedürfnis, 
mussten die Ärzte doch nicht nach Amerika reisen, um 
sich über die neuen Entwicklungen in der Onkologie zu 
informieren. So fanden über 50 Onkologen aus Privatpra-
xen und Spitälern den Weg nach Flüeli-Ranft. Während 
drei Tagen konnten sie bequem, ganz ohne Reisestress und 
Jetlag, in einer entspannten und  inspirierenden Umge-
bung den Präsentationen folgen und sie anschliessend un-
tereinander diskutieren - ein echter Mehrwert, den auch 
Frau Dr. Sylvia Baumann Kurer von der Onkologiepraxis 
Winterthur bestätigt: «Das Chicago in the Mountains ge-
fällt mir sehr gut. Als Mutter schätze ich es, nicht allzu 
lange von meinen Kindern weg zu sein. Das Programm 
ist vom Steering Committee sehr gut zusammengestellt 
und erleichtert es, sich auf eine Selektion an Themen zu 
konzentrieren. Daneben !nde ich es grossartig, mich an 
diesem tollen Ort mit meinen Kollegen auszutauschen. 
Ein solch intensiver Austausch ist in Chicago wegen der 
Grösse des Kongresses nicht möglich.» 
Chicago in the Mountains – Entstehung
und Grundsätze
Beim «Chicago in the Mountains» wurde die Tren-
nung von Finanzierung / Organisation und Veran-
staltungsinhalten von Anfang an gross geschrieben. 
Die Programmgestaltung, Auswahl der Experten, 
Sessions und die Moderation wird vollkommen un-
abhängig durch das wissenschaftliche Steering Com-
mittee bestimmt. Dieses investiert jedes Jahr viel 
Zeit, um internationale und nationale Experten aus-
zuwählen und zu kontaktieren, Sessions zu sichten 
und mit Hilfe seiner Kollegen in Chicago die High-
lights auszuwählen. Eine Arbeit, die Monate vor der 
Veranstaltung beginnt und erst mit der Übertragung 
und Diskussion der letzten Session in Flüeli-Ranft be-
endet ist. Initiiert wurde die Veranstaltung von der 
Roche Pharma (Schweiz) AG im 2013. Die Roche 
Pharma (Schweiz) AG hat auch dieses Jahr die logi-
stische Unterstützung der Veranstaltung koordiniert 
und einen namhaften !nanziellen Beitrag geleistet. 
Um die langfristige Realisierung und Unabhängig-
keit von «Chicago in the Mountains» sicherzustellen, 
wird ein Multisponsoring-Konzept gewählt. In die-
sem Jahr wurde die Veranstaltung neben Roche von 
Amgen und Astra Zeneca !nanziell unterstützt.
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F-18-DOPA PET/CT revealed 
a neuroendocrine tumor 
located in an unusual site
Giorgio Treglia, Luca Ceriani, Luca Giovanella
Department of Nuclear Medicine, Oncology Institute 
of Southern Switzerland, Bellinzona
Introduction
Neuroendocrine tumors (NETs) are a heterogeneous 
group of neoplasms with increasing incidence, various 
clinical presentations, growth rates and responses to avail-
able therapies. They arise from the neuroendocrine cells 
which are located in different organs through the body, 
although most frequently NETs arise from abdominal and 
thoracic organs [1].
Chromogranin A is still the best available marker used for 
the biochemical con!rmation of these tumors [2], but new 
more sensitive markers are urgently required. Although 
scintigraphy with Indium-111-octreotide has widely been 
applied for the localization and staging of NETs [3], newer 
imaging modalities based on the functional characteristics 
of these tumors are evolving aiming not only to facilitate 
the diagnosis but also prognosis and evaluation of treat-
ment [4].
Here we report the case of a rare NET located in an unusu-
al site detected by #uorine-18-dihydroxyphenylalanine 
positron emission tomography/computed tomography 
(F-18-DOPA PET/CT).
Case report
A 33-year-old man with progressive hearing impair-
ment underwent a CT scan which showed an abnormal 
tissue in the right middle ear (Fig. 1). The patient re-
fused the biopsy. Based on the increased serum chromo-
granin A value (280 U/L), the presence of a NET was 
suspected.
The patient underwent a F-18-DOPA PET/CT to look 
for a possible NET. F-18-DOPA PET/CT was performed 
without carbidopa premedication. Images were acquired 
60 minutes after the i.v. injection of 4 MBq/Kg of F-
18-DOPA.
Three-dimensional PET/CT reconstruction (Fig. 2), PET 
and fused PET/CT images in axial, sagittal and coronal 
projection (Fig. 3) showed the presence of a focal area of 
increased radiopharmaceutical uptake corresponding to 
the abnormal tissue in the right middle ear. No other ar-
eas of abnormal F-18-DOPA uptake were detected in the 













showing a focal 
area of increased 
tracer uptake in 
the right middle 
ear (arrow).
Figure 3: PET (upper row) and PET/CT images (lower row) 
showing a focal area of increased F-18-DOPA uptake in the 
right middle ear (arrow).
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with paraganglioma or pheochromocytoma [8] and re-
current medullary thyroid carcinoma [9]. About NETs 
of the thoracic and abdominal regions, F-18-DOPA 
PET/CT shows a higher diagnostic accuracy in patients 
with carcinoid tumors from the distal duodenum to 
proximal colon (midgut carcinoids) compared to other 
sites [6].
In our case F-18-DOPA PET/CT has been very useful in 
revealing and staging a primary NET of the middle ear, 
demonstrating that this functional imaging method may 
be useful to detect NETs located in unusual sites.
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DER SELTENE FALL
Based on this PET/CT !nding the patient underwent sur-
gery. Histological examination of the tissue in the right 
ear revealed tumor cells forming gland-like and cribri-
form structures at hematoxylin and eosin staining (Fig. 
4A). No cellular atypia nor signi!cant mitotic activity 
were found. On immunohistochemical staining, tumor 
cells were positive for epithelial markers such as cytokera-
tins (Fig. 4B), and neuroendocrine markers such as synap-
tophysin (Fig. 4C) and chromogranin (Fig. 4D). Based on 
these histological !ndings a diagnosis of well-differentiat-
ed NET of the middle ear was performed and the patient 
was addressed to follow-up.
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Figure 4: Histological examination of the tissue in the right 
ear revealed tumor cells forming gland-like and cribriform 
structures at hematoxylin and eosin staining (A). Tumour cells 
were positive for cytokeratins (B), synaptophysin (C) and 
chromogranin (D).
Discussion
Abdominal and thoracic regions represent the most fre-
quent location of primary NETs. Less often patients de-
velop NETs in the head and neck region [1]. An uncom-
mon site of origin of NETs in the head and neck area is 
the middle ear. NETs of the middle ear are usually benign 
entities and the most frequent symptom is hearing im-
pairment; nevertheless, in a small number of cases they 
may metastasize to cervical lymph nodes [5].
A speci!c feature of NETs is amine precursor uptake and 
decarboxylation; this is the rationale for using F-18-DO-
PA, a catecholamine precursor, as PET radiopharmaceuti-
cal for the detection of NETs [6].
Literature !ndings suggest that F-18-DOPA PET/CT 
is an accurate functional imaging method in patients 
with NETs [7] and in particular in evaluating patients 
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  Kontakt/Organisation: DGHO Service GmbH, Alexanderplatz 1, D-10178 Berlin 
  jahrestagung2014@dgho-service.de, www.haematologie-onkologie-2014.com
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12.-13.12. 2 Module, jeweils Freitag 14.00 Uhr bis Samstag 17.00 Uhr, Kantonsspital St. Gallen, Palliativzentrum, Haus 33
St. Gallen Info + Anmeldung: Herr Benjamin Rhyner, benjamin.rhyner@kssg.ch, Tel. +41 (0)71 494 35 50
20.-21.11. SAKK Halbjahresversammlung
St. Gallen www.sakk.ch
27.-29.11. 17. Zentraleuropäisches Seminar «Methodik klinischer Prüfung in der Onkologie»
Wien, AT DESO – Veranstalter: ACR-ITR VIEnna / LBI-ACR VIEnna – LB-CTO, Univ.-Prof.Dr. Christian Dittrich (Wien, A)
 Auskunft: Angewandte Krebsforschung – Institution für Translationale Forschung Wien (ACR-ITR VIEnna),  
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28.-29.11.  Molecular Diagnostics, Genomics and Epigenetics in Clinical Oncology
Rom, IT European School of Oncology, Via Turati 29, I-20121 Milan, rventura@eso.net, www.eso.net
04.12. Krebstagung 2014: Radon – unterschätztes Risiko im Wohnraum
Bern Journée du cancer 2014: Radon – un risque sous-estimé dans l’habitat
 Krebsliga Schweiz und Bundesamt für Gesundheit, Ligue suisse contre le cancer et Of!ce fédéral de la santé publique
 www.krebsliga.ch/krebstagung, www.liguecancer.ch/journeeducancer
2015
19.-21.02. 25. Ärzte-Fortbildungskurs in Klinischer Onkologie
St. Gallen  Deutschsprachig-Europäische Schule für Onkologie (deso), Rorschacherstr. 150, CH-9006 St. Gallen 
 deso@oncoconferences.ch, www.oncoconferences.ch (Rubrik deso) oder www.kssg.ch (Rubrik Veranstaltungen) 
07.-12.03. 14th ESO-ESMO Masterclass in Clinical Oncology
Ermatingen European School of Oncology, Via Turati 29, I-20121 Milan, fmarangoni@eso.net, www.eso.net 
12.-14.03. Advanced Prostate Cancer Consensus Conference
St. Gallen Contact: prostatecancerconsensus@kssg.ch, www.prostatecancerconsensus.org
18.-21.03.  14th St.Gallen International Breast Cancer Conference 2015
Vienna, AT  St.Gallen Oncology Conferences (SONK), c/o Tumor und Brustzentrum ZeTuP, Rorschacherstr. 150, CH-9006 St.Gallen
  info@oncoconferences.ch, www.oncoconferences.ch
26.03. 17. Schweizer Onkologiep!ege Kongress - 17ème Congrès Suisse des soins en oncologie
Bern info.onkologiep!ege.ch, www.onkologiep!ege.ch, www.soinsoncologiesuisse.ch
30.04.-02.05. 19. Internationales Seminar «Palliativbetreuung von Tumorkranken»
Warth Deutschsprachig-Europäische Schule für Onkologie (deso), c/o Tumor- und Brustzentrum ZeTuP, Frau Gabi Laesser
b. Frauenfeld Rorschacherstr. 150, CH-9006 St. Gallen, deso@oncoconferences.ch, www.oncoconferences.ch 
17.-20.06. ICML - International Conference on Malignant Lymphoma
Lugano www.lymphcon.ch
03.-04.09. 18. Internationales Seminar «Onkologische P!ege – Fortgeschrittene Praxis»
St. Gallen  Deutschsprachig-Europäische Schule für Onkologie (deso), c/o Tumor- und Brustzentrum ZeTuP, Frau Gabi Laesser 
 Rorschacherstr. 150, CH-9006 St. Gallen, deso@oncoconferences.ch, www.oncoconferences.ch
